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Abstract 
Rationale  
 
Cognitive deficits are now recognised as a major symptom of 
schizophrenia with a number of studies reporting profound deficits in 
cognitive function in both chronic and first episode patients.  Recent 
advances in cognitive remediation therapy have provided the opportunity 
for patients to improve their cognitive function and therefore improve their 
functional outcome. 
 
Aim 
  
The aim of the present study was to investigate cognitive deficits using the 
Cambridge Neuropsychological Test Automated Battery (CANTAB®) in 
first episode psychosis and chronic schizophrenia patients.  In the first 
episode population the effect of ethnicity on cognition was also examined.  
In the chronic schizophrenia study comparisons between severity of 
deficits with first episode psychosis patients were also made.  The effects 
of cognitive remediation therapy were also examined in a sample of first 
episode patients.   
 
Methods 
 
A total of 35 patients and 30 healthy controls were recruited into the first 
episode study, 17 patients and 17 controls into the chronic schizophrenia 
study and 11 patients into the cognitive remediation study.  The first 
episode psychosis patients were recruited from the Bradford and Airedale 
Early Intervention Service and the chronic patients from the Leeds 
Partnership NHS Foundation Trust.  The control subjects were matched as 
closely as possible in terms of intelligence and demographics to the 
patient groups.  The Wechsler Test of Adult Reading (WTAR) was used to 
estimate subjects pre-morbid IQ.  The severity of symptoms was assessed 
using the Positive and Negative Syndrome Scale (PANSS).  All subjects 
who took part in the study completed a comprehensive battery of 
neuropsychological tests from the CANTAB®.  Patients in the cognitive 
remediation study participated in group therapy sessions using X-cog®.  
 
Results 
  
There were no significant differences found between patients and controls 
in relation to intelligence or demographics in all studies.  The effect of 
ethnicity was shown to be not significant in the first episode study.  Results 
show that patients performed significantly worse than controls across all 
iv 
 
cognitive domains tested in all studies.  A correlation between negative 
symptoms and executive function was found in both first episode and 
chronic schizophrenia patients.  Comparisons between first episode 
psychosis and chronic schizophrenia patients in cognition showed no 
significant differences, however significant differences were found in levels 
of negative symptoms and age between the two groups with chronic 
patients scoring higher on negative symptoms and being older.  In the 
cognitive remediation study a significant improvement was observed in 
patients in the domain of executive function and a reduction in negative 
symptoms following completion of the intervention.       
   
Conclusion 
    
First episode and chronic schizophrenia patients display significant 
cognitive deficits across all domains when tested using the CANTAB®. 
Some of these deficits appear to be independent of the length of the 
illness but dependent on negative symptoms.  This study demonstrates 
that cognitive deficits exist across all patient groups regardless of age, 
gender, pre-morbid IQ, years in education and ethnicity.  Cognitive 
remediation therapy has also been shown to be effective in improving 
cognitive functioning in patients.  
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1.1 Schizophrenia  
 
Emil Kraepelin (1883) used the term ‘dementia praecox’ to refer to various 
kinds of progressive, irreversible mental deterioration that began early in 
life and involved thought disorders and departures from reality (Meltzer et 
al., 1999).  Following on from his work Eugen Bleuler (1911) introduced 
the term ‘schizophrenia’ to refer to disorders that he believed reflected a 
split ‘schism’ of the mind ‘phrenos’ (Fusar-Poli and Politi, 2008).  Both 
Bleuler and Kraepelin agreed that the predominant feature of this 
psychological abnormality was thought disorder and that it was a physical 
disease.  In the modern age schizophrenia is a term used to define a 
specific type of psychosis marked by disturbances of thought, language, 
and behaviour not due to a primary mood disorder or medical condition 
(Bleuler, 1984).   
Schizophrenia is a major psychological disorder that affects approximately 
1 – 2 percent of the world’s population and like many other major 
psychological disorders it can have different forms with somewhat different 
features and causes (Goldner et al., 2002).  It can be associated with 
other psychiatric conditions such as, depression (Maurino et al., 2011; 
Hasan et al., 2011; Cotton et al., 2011), anxiety (Bayle et al., 2011; 
Lysaker et al., 2011; Achim et al., 2011), post traumatic stress disorder 
(Strauss et al., 2011; Newman et al., 2010;  Lommen and Restifo, 2009), 
personality disorder (Yu et al., 2011);  and substance misuse (Bennett et 
al., 2011; Donoguhe et al., 2010; Turkington et al., 2009).  It can be 
divided into a cluster of disorders, characterised by psychotic symptoms 
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which lead to a breakdown in a person’s perceptions, thoughts, mood and 
behaviour (Nice Guidelines, 2009).  Patients suffering from schizophrenia 
will all display a unique set of symptoms and behaviours which can be put 
into four different categories – positive, negative, cognitive and general 
(Kay et al., 1987).  Although there is a common course of the illness, 
progression can vary significantly with most people reporting symptoms at 
early adulthood.  Recently there has been as emphasis on the early 
detection and intervention in schizophrenia with importance being placed 
on patient choice in the management of their condition (Weiser, 2011; Le 
Galudec et al., 2011).   
There is strong evidence to suggest that there are a number of factors 
which may contribute to somebody developing schizophrenia (table 1.1); 
with the two most significant being genetic and environmental causes 
(Harrison, 2003).  Research has shown that patients diagnosed with 
schizophrenia often have a family history of psychiatric disorders and that 
onset is usually preceded by some form of social or environmental 
stressor (Day, 1987).  Social factors such as, living in urban areas, poverty, 
migration, family dysfunction, unemployment, bad housing and 
experiences of childhood trauma and abuse have all been suggested as 
risk factors for developing some form of schizophrenia (Van Os, 2004; 
Swinnen et al., 2007; Schenkel, 2005).      
The genetic component involved in the development of schizophrenia has 
been thoroughly investigated.  Twin and adoption studies have suggested 
that schizophrenia is a disorder of complex inheritance with many potential 
genes of effect (O’Donovan, 2003).  There is evidence to suggest that 
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candidate genes can also be found in other psychiatric disorders such as 
bipolar disorder (Craddock et al., 2006).  However there is no conclusive 
evidence to suggest that schizophrenia is solely caused by genetic 
abnormalities.   
There is a growing research base focusing on the dual diagnosis of 
schizophrenia and substance abuse disorder.  It has been difficult for 
researchers to prove any direct casual relationship between the two 
however it is widely recognised that around 50 percent of patients with 
schizophrenia use some kind of drugs or alcohol, with the vast majority 
also smoking tobacco (Drake et al., 2006).  The most commonly abused 
illegal substance appears to be cannabis, with patients reporting self 
medication to help alleviate some of their symptoms.  However some 
research has shown that increased use of cannabis may heighten the risk 
of developing a psychotic disorder rather than help alleviate any of the 
symptoms (Casadio et al., 2011; Manrique-Garcia et al., 2011; Dragt et al., 
2011; Moore et al., 2007).   
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Causes of Schizophrenia 
Genetic abnormalities  Family studies - Erlenmeyer-Kimling et 
al., 1995; Kendler et al 1993; Parnas et 
al., 1991 
Twin studies -  Gottesman and 
Bertelsen 1989; Gottesman and 
Wolfgram 1991; O’Donovan, 2003 
Adoption studies - Petersen and 
Sorensen 2011; Leo 2006; Kety et al., 
1994 
Genetic marker studies - Cannon et al., 
1995; Park et al., 1995; Lee and 
Williams, 2000 
 
Brain abnormalities  Neuro-imaging studies -  Flaum et al., 
1995; Cannon et al., 1994; Breier et al., 
1992; Raz and Raz, 1990 
 
Neuro-cognitive abnormalities  Executive function – Bozikas and 
Andreou 2011; Penades et al., 2010; 
Barrett et al., 2009 
Working memory – Anticevic et al., 
2011; Zanello et al., 2009; Brebion et 
al.,2009  
Attention – Backes et al., 2011; de Jong 
et al., 2010; Pukrop et al., 2006  
 
Neuro-developmental abnormalities  Neuro-developmental – Owen et al., 
2011; Powell 2010; Olie et al., 2009 
 
Bio-chemical abnormalities  Neuro-biology – Pearlson 2000; 
Wolfarth and Ossowska 1995; Davis et 
al., 1991 
 
Psychological abnormalities  Families - Singer and Wynne 1963; 
Liem, 1980 
Expressed emotion - Leff and Vaughn, 
1981; Nuechterlein et al., 1992; 
  
Diathesis-Stress  Stress – Tessner et al., 2011; 
Nuechterlein et al., 1992 
 
Table 1.1 – showing the different risk factors associated with developing 
schizophrenia/psychosis. 
 
1.2 Schizophrenia Spectrum     
 
To warrant a diagnosis of schizophrenia, a person must show at least two 
of the following behaviours or experiences for a minimum duration of one 
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month: delusions, hallucinations, disorganized speech, disorganized 
behaviour, catatonic behaviour, flat affect or lack of motivation (DSM-IV-
TR).  Only one of these symptoms is required if bizarre delusions are 
present or if auditory hallucinations consist of a running commentary on 
the person’s behaviour or two voices conversing with each other.  Finally, 
to be diagnosed with schizophrenia, the person must display major 
impairment in functioning.     
According to the diagnostic criteria set out in the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR) there are five sub-classifications 
of schizophrenia and two further sub-classifications in the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10) 
(fig1.1). 
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1.3 Gender differences in Schizophrenia 
 
Researchers have found important sex differences in the experience, 
course and possible origins of the disorder (table 1.2).  Precise reasons for 
these gender differences are as yet unknown, but speculation points to 
superior social skills and support among women as well as to protective 
effects associated with the hormone oestrogen (Abel et al., 2010; Hafner, 
2003; Kulkarni et al., 2001).   
 
Males vs. Females 
Course of the disorder tends to be less severe among women (Grossman 
et al., 2006) 
 
Females have fewer re-hospitalisations and shorter stays (Goldstein, 
1988) 
 
Females exhibit better response to overall treatment (Szymanski et al., 
1995) 
 
Males show an increased pattern of poor adjustment before diagnosis 
(Messias et al., 2007) 
 
Males display increased chronic symptoms, negative symptoms and have 
poorer functional outcome (Moriarty et al., 2001) 
 
Males are less likely to have graduated, married or worked (Tamminga, 
1997) 
 
Females have a significantly later age of onset (Salokangas et al., 2003) 
 
Table 1.2 - table showing the common differences between men and 
women in schizophrenia 
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1.4 Course of Schizophrenia  
 
There is considerable unpredictability in terms of how quickly 
schizophrenia develops, how long an episode might last, the quality of life 
a person has when the symptoms subside and the rate of recurrence of 
symptoms.  Some people have relatively good functional outcome, 
whereas others live in and out of hospitals unable to maintain a functional 
life (Bellack et al., 2007) see figure (1.2).   
Schizophrenia may have a slow and gradual onset with mounting 
maladjustments over time before symptoms are apparent or it may have a 
rapid or acute onset (Ramirez et al., 2010).  Schizophrenia with a gradual 
onset is typified by poor functioning throughout childhood, such as; 
disruptive behaviour, social withdrawal, and lack of good peer relations 
(Hassan and Taha, 2011).  However not all people who suffer from 
schizophrenia display noticeable signs at an early age, some may develop 
relatively normally (Harrop and Trower, 2001).   
Bleuler (1978) characterised several patterns of symptoms in his clinical 
population which he labelled as ‘common’ and ‘rare’.  He reported that 
common patterns included; acute onset with recovery and periodic 
episodes, varying in completeness of recovery over-time; and gradual 
onset with relatively sustained symptoms with different levels of recovery 
over time.  Rare patterns included; acute onset with continuing symptoms 
and no recovery; and gradual onset with periodic episodes and good 
overall recovery.   
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Research has shown that schizophrenia is usually a lifelong disorder with 
increasing deterioration and little chance of complete recovery.  A study by 
Hegarty et al., (1994) looking at 100 years of research between the years 
1895 – 1992 has shown how only 40 percent of patients were considered 
improved after follow-ups averaging about 6 years.  According to other 
research around 60 percent of patients relapse within 2 years post 
discharge (Hui, 2011; Fitzgerald et al., 2009).  However there is research 
to suggest that poor functional outcome is not inevitable in schizophrenia.  
One of the longest follow-up studies ever conducted, after an average of 
32 years, found that 62 percent of patients had completely recovered or 
showed only mild impairment (Harding et al., 1987).   
One of the best predictors of the course of schizophrenia and its outcomes 
is pre-morbid adjustment (person’s level of functioning before the onset of 
the disorder).  A patient with schizophrenia with good pre-morbid 
adjustment has a normal early developmental history, good overall 
physical health, established relationships and usually satisfactory 
educational achievement (Shapiro et al., 2009).  In general after their 
acute episode, which usually involves an identifiable precipitating stressful 
life event, positive symptoms are mostly present.  Positive response to 
treatment is usually expected in these cases with fewer psychiatric 
symptoms and better functional outcome at a follow-up assessment of two 
years (Goldberg et al., 2011).   
In contrast, patients with poor pre-morbid adjustment function poorly, lack 
basic problem solving abilities, and display inadequacies in work, social 
and personal responsibilities.  The person often has poor academic 
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achievement and social skills.  Social isolation and a lack of emotional 
responsiveness are evident before the actual episode and there is less 
chance of being able to identify any precipitating event or experience 
(Shapiro et al., 2009).      
 
 
 
 
 
 
 
 
Figure 1.2 – course of schizophrenia according to Shepherd et al., (2010)   
 
1.5 Symptoms of Schizophrenia  
 
The core symptoms of schizophrenia typically fall into three categories, 
positive symptoms, negative symptoms and cognitive symptoms (Kay et 
al., 1987).  Symptom expression can manifest itself differently in patients 
and the progression of the illness can depend on this (Chang et al., 2011).     
Losses/upheaval 
 
Confusion 
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Improvement in 
symptoms 
Development of 
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management 
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Adaptations in 
social 
relationships
Optimism/ 
hope 
Acceptance
/resignation 
Despair 
 
Early 
course 
Middle 
Course 
Present/
future 
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From the point of view of observers, schizophrenia is marked by 
fundamental disturbances in thought, speech and perceptual processes as 
well as by disturbances in behaviour, mood and interpersonal relationships.  
See table (1.3)  
Symptoms and Experiences of Schizophrenia 
 
Disturbances of thought and language  
Loose associations (personal meanings, intrusions of associations, 
incoherence) 
Conceptual difficulties (concrete thinking)  
Peculiar word usage (clang associations, neologisms, word salad) 
Poverty of speech (vague, over-elaborated, overly abstract) 
Delusions (grandiose, paranoid, nihilistic)  
 
Perceptual disturbances  
Increased intensity of sensations and perceptions  
Perceptions of changes in the environment  
Hallucinations  
 
Affective disturbances  
Flat affect, apathy  
Inappropriate affect  
Lack of pleasure  
 
Behavioural disturbances  
Peculiar mannerisms, posture, facial expressions  
Reduced spontaneous movement  
Social withdrawal or inappropriate social behaviour  
Impairment in interpersonal relatedness  
Lack of motivation, lack of volition  
Lack of pleasure and motivation  
Table 1.3 – most characteristic symptoms of schizophrenia, although many of the symptoms may 
also occur in other psychiatric or cognitive impairment disorders. Adapted from Kendall and 
Hammen (1998) 
 
1.5.1 Positive symptoms  
 
The positive symptoms in schizophrenia can be grouped into the following 
four categories; hallucinations, delusions, thought disorders and 
movement disorders (Schneider, 1999).  These symptoms are usually 
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present at the acute phase of the illness and are regarded as a sign of 
psychosis.   
Hallucinations can affect the patient’s senses and cause them to hear, see 
and smell things that are not present.  They are usually present at the 
acute phase of the illness and patients report hearing voices and noises.  
They sometimes report having ‘visions’ or smelling things that others do 
not (Silbersweig et al., 1995).   
Delusions are considered to be false beliefs which are illogical.  The 
patient may believe that other people can read their mind or control their 
behaviours; they may believe that they are famous, wealthy and highly 
intelligent.  They can also believe that they are receiving personal 
communication through the television, radio or newspapers and can 
sometimes believe that they are a messenger, an angel or God himself 
(Maher et al., 2006).   
Thought disorders are regarded as an unusual way of thinking and effects 
patients in a number of different ways.  The most common manifestation is 
when patients speak in an incoherent way with no logical connections 
between statements and occasionally make up words which have no 
meaning (Harrow et al., 1983).   
Movement disorders are characterised by when a patient either 
continuously repeats a movement or when a patient becomes catatonic 
and they are unable to move or to respond to any kind of external stimuli 
(Owens et al., 1982).  
Chapter 1   General Introduction 
14 
 
Positive symptoms can be treated through the use of pharmacological 
treatments and are often controlled particularly well as long as a patient is 
medication compliant.  Once a patient’s positive symptoms are treated 
they may return to some relative form of ‘normal’ functioning (Geddes et 
al., 2000).   
 
1.5.2 Negative symptoms  
 
 The negative symptoms in schizophrenia can sometimes be confused 
with symptoms of other psychiatric conditions like depression and bipolar 
disorder (Toomey et al., 1998) and often patients are somewhat aware of 
these symptoms but do not fully understand the implications (Selten et al., 
1998).  Negative symptoms are characterised by a lack of speech, 
socialisation, motivation, emotional responsiveness and movement.  The 
symptoms can sometimes be a result of a psychotic episode, with patients 
becoming socially withdrawn as a result of their paranoia (Chang et al., 
2011).  Patients who exhibit significant negative symptoms have 
particularly poor functional outcome (Wegener et al., 2005; Lysaker et al., 
2004).  Although the progression of symptoms differs in patients it is quite 
common to develop negative symptoms during or after the initial psychotic 
episode and these symptoms can lead to a loss of an individual’s abilities 
to lead a functional life (Arango et al., 2004).   
The treatment of these symptoms is difficult and conventional 
pharmacological treatments for schizophrenia do not adequately address 
negative symptoms (Kirkpatrick et al., 2006) and there is evidence to 
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suggest that secondary negative symptoms may be exacerbated by 
antipsychotic medication (Carpenter et al., 1985).   
 
1.5.3 Cognitive symptoms   
 
Cognitive symptoms are similar in their nature to negative symptoms in 
that they are present before psychosis, subtle, can sometimes be difficult 
for the patient to recognize as part of the psychotic disorder and are often 
only detected through the use of cognitive testing (Keefe and Fenton, 
2007).  Research has shown that negative symptoms can be correlated 
with cognitive performance on tests of verbal learning and memory, verbal 
fluency, visual memory, and visual motor sequencing (Lincoln et al., 2011; 
Greenwood et al., 2005; O’Leary et al., 2000).  Furthermore, many 
patients who suffer from schizophrenia show a significant decline in 
intellectual ability from the initial diagnosis and display impaired 
performance in tasks which require differing types of information 
processing and mental flexibility (Leeson et al., 2009; Woodberry et al., 
2008; Rund, 1998).    
Previous studies have reported impaired performance on tasks assessing 
cognitive function in schizophrenia patients, despite significant 
improvements in psychotic symptoms following treatment compared to 
healthy controls (Yun da et al., 2011; Staring et al., 2011; Leeson et al., 
2010; Mitchell et al., 2001).  The understanding of the processes through 
which these neuropsychological deficits develop in patients with 
schizophrenia is still incomplete and is an area of controversy (Jahshan et 
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al., 2010; Hawkins et al., 2008; Addington et al., 2005; Bilder et al., 2000) 
however there is some evidence to suggest that these deficits may be a 
result of both early developmental abnormalities and subsequent 
deterioration following the onset of symptoms (Frommann et al., 2011; 
Owen et al 2011; Bilder et al., 1992).   
More specifically patients with schizophrenia have been shown to have 
impairments on neuropsychological summary measures of memory and 
learning, when tested on a battery of neuropsychological tests (Saykin et 
al., 1991).  Patients show deficits in executive function (Addington and 
Addington, 2002), in attention and information processing speed (Nestor et 
al., 1992) and psychomotor processing, which has been identified as one 
of the first affected cognitive domains in schizophrenia patients (Hoff et al., 
1992).   
The Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) initiative was set up by the National Institute of 
Mental Health (NIMH) and University of California Los Angeles (UCLA) 
(Green et al., 2008; Kern et al., 2008; Nuechterlein et al., 2008).  This 
initiative was formed in an attempt to identify areas of cognition that are 
affected in schizophrenia and furthering the development of new treatment 
strategies.  One of the aims of the MATRICS project was to further 
scientific discoveries in the development of pharmacological agents that 
may help to improve cognition and to develop suitable clinical and pre-
clinical cognitive tests for research - Matrics Consensus Cognitive Battery 
(MCCB) (www.matrics.ucla.edu).  The MATRICS initiative managed to 
identify seven primary domains of cognition that are affected in patients.  
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These domains are; speed of processing, attention/vigilance, working 
memory (verbal/no verbal), verbal learning and memory, visual learning 
and memory, reasoning and problem solving, and social cognition 
(Nuechterlein et al., 2004; Green et al., 2004).     
The MCCB battery consists of the following neuropsychological tests; Brief 
Assessment of Cognition in Schizophrenia (BACS), Category Fluency: 
Animal naming, Trail Making Test: Part A, Continuous Performance Test: 
Identical Pairs (CPT-IP), Wechsler Memory Scale – 3rd Edition (WMS III): 
Spatial Span, Letter Number Span, Hopkins Verbal Learning Test – 
Revised (HVLT-R), Brief Visuospatial Memory Test – Revised (BVMT-R), 
Neuropsychological Assessment Battery (NAB): Mazes and Mayer-
Salovey-Caruso Emotional Intelligence Test (MSCEIT): Managing 
Emotions.   
 
1.6 First Episode Psychosis and Cognition in Schizophrenia 
 
Early identification of schizophrenia in patients with a first episode of 
psychosis (FEP) could help to avoid inappropriate treatment and may 
enhance long-term outcome by addressing issues such as family network, 
treatment adherence and functional and symptomatic outcome (Ramirez 
et al., 2010).  Substantial cognitive deficits have been observed in all 
phases of schizophrenia, beginning in the pre-morbid period and 
continuing throughout life (Seidman et al., 2010).  Individuals experiencing 
their first episode of schizophrenia exhibit cognitive deficits that are often 
equivalent to those seen in patients with a more chronic course of illness 
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(Addington and Addington, 2002; Bilder et al., 2000; Mohammed et al., 
1999; Hutton et al., 1998; Hoff et al., 1992).    
Longitudinal studies of cognition in patients after a first episode of 
psychosis (FEP) provide extremely useful information, in that they include 
an adequate and realistic baseline measure of cognitive performance, 
while at the same time minimizing the effect of confounding variables 
associated with chronicity (Bozikas and Andreou, 2011).  The global 
tendency of the results suggests that significant and measurable cognitive 
symptoms are present at the onset of the disease and these remain stable 
in the subsequent period between 2 and 5 years. Their deterioration can 
increase with the course of the disease, especially in hospitalized patients 
(Ojeda et al, 2007).  Recently there has been a large emphasis placed on 
the link between cognitive deficits, functional outcome and risk prediction 
of psychosis/schizophrenia.  Table 1.4 summarises some of the most 
recent studies looking at cognitive deficits in first episode psychosis.   
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1.7 Cultural factors  
 
Odegard (1932) showed how Norwegians migrating to the USA had a 
higher chance of developing psychosis.  He theorized that the cultural and 
geographic changes resulted in paranoia and alienation (Selten et al., 
2002). This finding has been demonstrated amongst many migrant groups 
(Castle et al, 1991; Harrison et al, 1997; King et al, 1994; Selten et al, 
1998; van Os et al, 2001).  Even when controlling for urbanicity (since 
many migrants settle in urban areas), studies demonstrate an excess 
migration effect (van Os et al 2004).   
Psychotic disorders have also been attributed to factors such as racism 
(overt and institutionalized), social isolation, and reduced social networks.  
Boydell et al, (2001) demonstrated that incidence rates of schizophrenia 
increased in ethnic minorities as the proportion of ethnic minorities in the 
locality reduced in size, suggesting that social experience contributed to 
development of the illness.  Karlsen and Nazroo, (2002) studied the 
experience of discrimination among a UK representative sample of 5000 
persons from ethnic minorities. They demonstrated significantly increased 
odds ratio for a range of health problems and particularly psychosis.    
There are also studies demonstrating higher rates of schizophrenia in the 
children of migrants. This has been observed in Greenland (Mortensen et 
al 1999), in the USA (Malzberg, 1969), and in the UK with the Afro-
Caribbean population (Harrison et al 1988). Weingarten and Orren (1983) 
observed a high prevalence of schizophrenia among the children of the 
Yemenite Jewish population that migrated to Israel (Boydell et al., 2004).   
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Previous research has shown that certain black and minority ethnic (BME) 
migrant groups in the United Kingdom have an elevated chance of 
developing psychoses in comparison to other groups (McGrath et al., 2004; 
Coid et al., 2008; Bhugra et al, 1997).   Throughout recent research history, 
there have been many studies demonstrating that people of South Asian 
descent are rarely found using ‘mental health services’.  Beliefs concerning 
the causes of mental illness may help to explain why there are significant 
disparities in the rates of formal mental health service use among 
racial/ethnic minorities compared with their white counterparts (Jimenz et 
al., 2011; Sorkin et al., 2011; Sorkin et al., 2009; Raliegh et al., 2007; 
Singh et al., 2007; Bhui et al., 2003; Patel, 2003).   
 
1.8 Treatment  
 
Schizophrenia is treated using a combination of methods, such as 
antipsychotic medication, and psychological interventions.  Success rates 
of treatment vary with some people responding well to treatment while 
others are more challenging to treat.  Antipsychotic medication has been 
shown to successfully treat the positive symptoms, with psychological 
therapy such as Cognitive Behavioural Therapy (CBT) having success in 
treating behavioural problems.  However there is little evidence to suggest 
any form of effective therapy for treating negative symptoms and cognitive 
deficits which are considered the biggest obstacle to functional outcome.   
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1.8.1 Antipsychotics 
 
Antipsychotics are usually prescribed as the first line of action for the 
treatment of the acute symptoms of schizophrenia.  Antipsychotics can 
reduce the feelings of anxiety and aggression within a few days of use 
through sedation but take longer to have an effect on symptoms such as 
hallucinations or delusional thoughts.  The longer term use of 
antipsychotics is recommended to prevent further acute schizophrenic 
episodes occurring.  There are two main types of antipsychotics; typical 
and atypical.   
 
1.8.1.1 Typical antipsychotics 
 
Typical antipsychotics are the first generation of antipsychotics that were 
developed during the 1950s.  They can be classed as either ‘high potency’, 
for example haloperidol or ‘low potency’, for example chlorpromazine.  
High potency antipsychotics have more extra pyramidal side effects (EPS) 
and less histaminergic (e.g. sedation) and anti-cholinergic (e.g. dry mouth) 
effects.  Whereas low potency antipsychotics have fewer EPS but more 
adrenergic, muscarinic and histaminic blocking effects, (Stahl, 2002).  
Some of the high potency antipsychotics have been developed to be 
administered as an intramuscular injection (known as depot injections).  
This has an advantage for those patients who are not medication adherent, 
and is also used for involuntary community treatment to ensure medication 
compliance.    
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Typical antipsychotics act through the blockade of dopamine D2 receptors, 
muscarinic cholinergic receptors, α1-adrenergic receptors and histamine 
receptors (Stahl, 2002).  Typical antipsychotics have been shown to be 
effective in treating positive symptoms in patients with schizophrenia, 
however have limited success in treating the negative and cognitive 
symptoms of the illness.  Due to the extra pyramidal side effects and the 
apparent lack of efficacy against many of the symptoms of schizophrenia, 
there has been an increased amount of research focusing on the 
development of novel antipsychotics.   
 
1.8.1.2 Atypical antipsychotics  
 
Atypical antipsychotics (second generation) have been developed more 
recently, although the first atypical, clozapine, was discovered in the 
1950s but not used in the clinic until the 1970s due to concerns around its 
pronounced side effects.  Atypical antipsychotics are less likely to cause 
EPS in patients however they do not completely eliminate them.  Atypicals 
have been shown to be associated with a higher rate of response, 
efficiency in patients with refractory disease, lower risk of suicide, better 
functional capacity and improved quality of life (Melnik et al., 2010).  Other 
benefits of atypical antipsychotics include efficacy against positive and 
disorganised symptoms, lack of development of tardive dyskinesis and 
failure to increase serum prolactin.  There is also some evidence to 
suggest that they may help improve negative symptoms; however it 
remains unclear whether these agents treat core negative symptoms or 
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simply induce less secondary psychopathology (Javitt, 1999).  Although 
atypical antipsychotics have some benefit on cognitive function, further 
efforts to improve cognitive function are required (Sharma and Antonova, 
2003).  The side effects of atypical antipsychotics can vary and are very 
specific to the medication.  Some commonly reported ones are, weight 
gain, sexual dysfunction and dystonia (Lemon, 1998).   
Research by Geddes et al., (2000) concluded that there is no clear 
evidence to suggest that atypical antipsychotics are more effective or are 
better tolerated than conventional antipsychotics.  They recommended 
that typical antipsychotics should usually be used in the initial treatment of 
an episode of schizophrenia unless the patient has previously not 
responded to these drugs or have unacceptable EPS.   
Atypical antipsychotics have affinity for multiple receptors and some act as 
antagonists at 5-HT2A, 5-HT7, α1 and α2-adrenergic and histamine H1 
receptors (Stahl, 2002).  Atypical antipsychotics block 5-HT and dopamine 
receptors simultaneously.  The significance of 5-HT is that it can control 
the release of dopamine in four different pathways; the nigrostriatal 
pathway, the mesocortical pathway, the tuberoinfundibular pathway and 
the mesolimbic pathway (Libermann et al., 1998).   
 
1.8.2 Psychosocial interventions 
  
Even when some patients with schizophrenia are free of the positive 
symptoms, many still have difficulty with communication, motivation, self-
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care, and establishing and maintaining relationships with others.  Because 
patients with schizophrenia frequently develop the illness during the critical 
career-forming years of life (e.g., ages 18 to 35), they are less likely to 
complete the training required for skilled work. As a result, many patients 
with schizophrenia not only suffer thinking and emotional difficulties, but 
lack social and work skills as well as experience (Fett et al., 2011; 
Nuechterlein et al 2011; Ucok et al., 2011).   
It is with these problems that psychosocial treatments may help most. 
Although psychosocial approaches have little usefulness for acutely 
psychotic patients, they can be useful for patients with less severe positive 
symptoms or for patients whose positive symptoms are under control.  
There are different forms of psychosocial therapy available for people with 
schizophrenia, and most focus on improving the patient's social 
functioning.   
 
1.8.2.1 Cognitive Behavioural Therapy (CBT)  
 
CBT has been used to treat a variety of different psychiatric/psychological 
conditions.  Over the last few years it has gained credibility as being 
effective in helping patients with schizophrenia and psychosis (Kumari et 
al., 2011; Sarin et al., 2011; Addington et al., 2010).  It is frequently used 
in patients who have experienced their first psychotic episode, to help 
them with engagement, education, coping strategies and relapse 
prevention (Freedman et al., 2009; Velligen, 2009; Addington and Gleeson, 
2005; Turkington et al., 2003).       
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1.8.2.2 Family Interventions (FI) 
 
Family interventions in schizophrenia are most frequently used in differing 
combinations such as psycho-education, behavioural problem solving, 
family support, and crisis management.  Interventions can differ in whether 
they are conducted with individual families or groups of families and 
whether they are in the home, or out of the home.  They also differ in 
whether the patient is included or excluded, the length of the intervention, 
and the phase of illness of the patient at the time of the intervention, 
(Dixon and Lehman, 1995).   
 
1.8.2.3 Social Skills Therapy (SST) 
 
Social skills training methods are regarded as being one of the most 
important strategies for psychiatric rehabilitation in patients with 
schizophrenia.  Liberman and colleagues, (1986) were the first to develop 
a model to address this particular issue and they highlighted three major 
areas which they felt need most attention.  These three areas are; 
receiving skills (social perception), processing skills (social cognition) and 
response (behavioural responding).  Within this framework, social skills 
are a set of learned abilities and therefore provide opportunity for 
modification. 
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1.8.2.4 Cognitive Remediation Therapy (CRT) 
 
Cognitive remediation therapy is a psychological treatment designed to 
improve neuro-cognitive functioning in patients with schizophrenia.  This is 
achieved through targeting the cognitive domains of attention, working 
memory, executive functioning and planning for remediation (Wykes et al., 
2007).  Cognitive remediation of these neuro-cognitive domains has been 
linked to significant improvements in the quality of life, social functioning, 
response to traditional rehabilitation programmes and symptom 
expression in patients with schizophrenia (Vita et al., 2011; Wykes et al., 
2011; Kurzban et al., 2010).     
Cognitive remediation uses techniques which have been shown to be 
effective in modifying cognition in patients with schizophrenia such as, 
errorless learning, repetition (mass practice) and positive reinforcement 
(Reeder et al., 2006).  Errorless learning was first introduced by Baddeley 
and Wilson (1994), whilst working with amnesic patients, who show similar 
deficits in explicit memory as patients with schizophrenia.  Errorless 
learning appears to be effective because it avoids the implicit encoding of 
errors which cannot then be differentiated from correct information by 
explicit recall (Mullholland et al 2008; O’Carroll et al., 1999).  The use of 
errorless learning requires that the participant’s successes are high and 
that the possibility for mistakes are minimised. 
Typically all tasks within a cognitive remediation package are designed to 
be able to be repeatedly rehearsed.  In this way tasks and skills will be 
subject to massed practice which is helpful in allowing patients to learn 
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from previous experiences, encourage monitoring of their own 
performances, and maintain a therapeutic alliance (Wykes et al., 2007; 
Wexler, 2007; Kurtz et al., 2007).   
Cognitive remediation therapy is designed to ensure maximum success for 
patients.  Thus it is very important that all success should be reinforced 
frequently in order to encourage the desired behaviour, to maintain 
therapeutic alliance and to ensure that the therapy is a positive and 
enjoyable experience (Lindenmayer et al., 2008; Velligan et al., 2006; 
Wykes et al., 2003).  Cognitive remediation interventions should be 
tailored for individual needs according to strengths and weaknesses.  In 
addition, sessions should last for a ‘manageable’ length of time and they 
should be balanced in terms of level of difficulty of tasks.   
Meta-analyses on cognitive remediation report moderate range effect 
sizes on cognitive test performance, and daily functioning.  Reciprocal 
interactions between baseline ability levels, the type of instructional 
techniques used, and motivation may provide some explanatory power for 
the heterogeneity in patient response to cognitive remediation (Medalia 
and Choi. 2009).  However, research has shown that induced cognitive 
change does not necessarily need to be large to facilitate functional 
outcomes.  Instead, opportunities to apply newly acquired cognitive skills 
and strategies in the real world are vital (Wykes and Huddy, 2009).   The 
current overall opinion is that cognitive remediation provides a promising 
approach to helping patients achieve better outcomes far and beyond 
symptom stabilisation (Kern et al., 2009).    
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1.9 Pre-morbid Intelligence Quotient  
 
There appears to be some evidence to suggest that schizophrenia 
patients may have some mild cognitive deficits prior to a diagnosis that 
might predict a predisposition for the disease (Ismail et al, 2000; Davidson 
et al, 1999).  According to Green (2001) the degree of deterioration may 
be a better predictor of long term outcomes and response to treatment 
than positive and negative symptoms.  Estimates of pre-morbid IQ are 
attainable through several study designs, including follow-back studies of 
school, clinical based testing, longitudinal birth or conscript cohort studies 
and studies of samples at genetic risk for schizophrenia (Woodberry et al, 
2008).   
In previous studies where pre morbid intellectual ability has been 
controlled for through the use of the Wechsler Adult Intelligence Scale 
(WAIS) IQ (Wechsler, 1997), deficits in memory and executive function 
have still been apparent in the patients with schizophrenia compared to 
the healthy control group (Leeson et al., 2009), suggesting that deficits in 
these cognitive domains are a core feature of the illness (Weickert et al., 
2000; Kremen et al., 2008).   
Research by Wilk and colleagues (2005), has shown that when comparing 
cognitive function in working memory, processing speed, perceptual 
organisation and verbal comprehension in a group of medicated 
schizophrenia patients and control group, which has been matched for IQ 
performance on the WAIS–III, the patients scored lower across all 
domains relative to the group of matched controls (Wilk et al., 2005).  
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These findings suggest that patients with schizophrenia exhibit deficits in 
executive function, attention and memory compared to healthy control 
groups regardless of level of IQ (Riley et al., 2000).     
 
1.10 The MATRICS 
 
The Measurement and Treatment Research to Improve Cognition in 
Schizophrenia (MATRICS) Project produced a battery of tests, the 
MATRICS Consensus Cognitive Battery (MCCB), designed to assess 
cognitive treatment effects in clinical trials of patients with schizophrenia. 
In validation studies, the MCCB has demonstrated excellent reliability, 
minimal practice effects and significant correlations with measures of 
functional capacity (Keefe at al., 2011).   
The MCCB was designed to address the following purposes; as an 
outcome measure for clinical trials of cognition enhancing drugs, as an 
outcome measure for studies of cognitive remediation, as a measure of 
cognitive change in repeated tested applications and as a cognitive 
reference point for non-intervention studies of schizophrenia and related 
disorders (Keefe et al., 2011; Nuechterlein et al., 2008; Kern et al., 2008; 
Kirkpatrick et al., 2006; Marder et al., 2004).   
The MATRICS initiative managed to identify seven primary domains of 
cognition that are affected in patients.  These domains are; speed of 
processing, attention/vigilance, working memory (verbal/no verbal), verbal 
learning and memory, visual learning and memory, reasoning and problem 
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solving, and social cognition (Green et al., 2004).  The domains identified 
by the MATRICS initiative can be assessed through the use of a range of 
neuropsychological test batteries such as the CANTAB®.  The table 1.6 
illustrates the cognitive domains identified by the MATRICS initiative and 
the corresponding assessment tool for that domain.    
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1.10.1 Memory  
 
Memory can be defined as the ability to store, retain and recall information 
and experiences.  Cognitive psychologists have identified three memory 
stores, sensory memory, short-term memory and long-term memory.  
Sensory memory can be described as the earliest memory system and 
consists of information detected by ones senses after a glance at any 
stimuli.  Short term memory allows recall of information for a short period 
of time without rehearsal and long term memory can store pieces of 
information for potentially unlimited duration.   There have been various 
models of memory proposed by psychologists over the years with the two 
most influential being  Atkinson and Shiffrin’s (1968) – see figure (1.3) 
multi-store model of memory and Baddeley and Hitch’s (1974) working 
memory model – see figure 1.5 (p42).        
Atkinson and Shiffrin (1968) developed the multi-store model of memory, 
which is a classical model of memory and is sometimes referred to as the 
modal model or dual process model.  This model suggests that information 
enters the sensory memory, if attended to, this information then enters the 
short term memory and if rehearsed it transfers into the long term memory.   
  
 
 
 
Figure 1.3 –  Atkinson and Shiffrins (1968) multi-store model of memory 
taken from Eysenck and Keane, (2001)   
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1.10.2 Speed of processing 
 
Speed of processing or mental chronometry refers to the process of how 
quickly a person can perform the mental act needed by the task at hand.  
Behavioural expressions would be, pressing a button, eye movement, a 
vocal response or some other type of observable behaviour (Jensen, 
2006).  Mental chronometry methods have been used in the study of 
cognitive development, with a specific emphasis on the speed of 
processing.  There is research to suggest that speed of processing 
increases from early childhood to early adulthood (Kail, 1991).   
A link between slowing of processing speed and cognitive disorders, 
including memory, has repeatedly been found in research on aging and 
other cognitively impaired populations.  It has been suggested that 
memory deficits observed in schizophrenia may thus be partly accounted 
for by a slowing of processing speed (Brebion, 1997).  There is evidence 
to suggest that schizophrenia patients are affected by attentional and 
information processing deficits (Braff, 1981).  Research by Braff and 
Saccuzzo (1981) has shown that slow information processing is a 
relatively stable deficit of patients with schizophrenia who have a poor 
prognosis; however patients with a good prognosis have a similar deficit 
which is reversible.  They also suggested that it is unlikely that these 
deficits are due to medication effect or to gross psychopathology (Braff 
and Saccuzzo, 1981).   
More recent research has shown decreases in processing speed in 
patients with schizophrenia as being a significant predictor of deficits in 
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visual and verbal memory regardless of whether the task requires deep or 
superficial encoding (Brebion et al., 2011; McDowd et al., 2011; Brebion et 
al., 2006).   
 
1.10.3 Attention  
 
Attention can be described as the cognitive process of focusing on one 
particular stimulus whilst trying to block out other things.  It can be divided 
into three components; selective, divided and sustained (figure 1.4).  
Selective attention is also referred to as concentration and involves 
choosing to attend to a particular stimulus whilst ignoring others.  Divided 
attention refers to the ability to simultaneously respond to more than one 
task at any given time.  Sustained attention refers to the capacity to focus 
on a particular task over a period of time (Porter et al., 2007).   Historically 
there has been no single measure of attention and tasks generally 
measure global rather than specific types of attention (Porter et al., 2007).    
Attentional deficits are prominent in schizophrenia, affecting nearly all 
cognitive functions.  Human attention comprises three essential 
components: alerting, orienting and executive control (Backes et al., 2011).  
A review by Cornblatt and Keilp (1994) looked at 40 studies that used 
different versions of the Continuous Performance Test (CPT) as a primary 
measure of attention found that; impaired attention is evident in 
schizophrenia patients regardless of symptom severity, it is detectable 
before illness onset, it is inheritable, it is specific (in terms of distinct profile 
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patterns) to schizophrenia, and it can be predictive of later behavioural 
disturbances in susceptible individuals (Cornblatt and Kleip,1994).   
Other research looking at predictive factors of schizophrenia has shown 
that deficits in attention may be an indicator of the genetic liability to 
schizophrenia (Giakoumaki et al., 2011; Snitz et al., 2006; Erlenmeyer-
Kimling, 2000).    
 
  
 
 
 
   
Figure 1.4 – The ways in which different topics in attention are related to 
each other.  Taken from Eysenck and Keane, (2001) 
 
1.10.4 Working memory  
 
Working memory is the ability to hold information in the brain which is 
required to complete tasks of relative complexity, such as comprehension, 
learning and reasoning.  The cognitive processes involved include 
executive and attention control of short term memory (Baddeley and Hitch, 
1974).  
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Baddeley and Hitch (1974) proposed a working memory model in which 
working memory consists of three separate stores; the central executive, 
the phonological loop and the visuo-spatial sketchpad.  The role of the 
central executive is to direct information to the other component processes, 
with its essential role being to act as the controlling attentional system.  
The phonological loop stores acoustic information by silently rehearsing 
information in a continuous loop and it is also responsible for processing 
information from the written word to a phonological code.  The visuo-
spatial sketchpad stores visual and spatial information, receiving 
information from other memory stores.   
 Working memory impairment is well documented in schizophrenia and 
has been regarded as one of the major areas of cognitive deficit (Anticevic 
et al., 2011; Giakoumaki et al., 2011; Zanello et al., 2009; Brebion et al., 
2009; Conklin et al., 2007; Chua et al, 1995; Goldman-Rakic, 1994).  
Some studies suggest working memory impairment in schizophrenia to be 
common and disproportionate to the overall level of intellectual impairment 
(Gold et al, 1992; Rund, 1989).  It has been suggested that certain areas 
of  memory may be affected more than others, for example patients 
display a deficit in free recall from long term memory in comparison to 
recall from short term memory (Ragland et la 2011; Van Snellenberg, 
2009; Leeson et al., 2009; Herbener, 2009; ).   
Deficits in working memory in patients with schizophrenia have been 
linked with deficiencies in other areas of the illness. Research by 
Goldman-Rakic (1994) of cognitive function in normal, brain injured 
patients and patients with schizophrenia suggests that a defect in working 
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memory may be the fundamental impairment leading to thought disorder in 
patients with schizophrenia (Goldman-Rakic, 1994).     
 
 
 
 
 
 
  
Figure 1.5 – The working memory model (Baddeley and Hitch, 1974)   
 
1.10.5 Verbal learning and memory  
 
Verbal learning can be defined as the acquisition and retention of verbal 
information i.e. memorisation.  It can be characterised by serial learning 
and paired associate learning.  Serial learning is the ability to reproduce 
what you have learnt in its original order e.g. learning and reciting the 
letters of the alphabet.  Paired associate learning is the ability to make a 
verbal response when a specific stimulus is presented e.g. seeing a 
familiar picture and responding with its name/label (Baddeley and Hitch, 
1974).   
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Verbal memory is one of the most impaired cognitive domains in 
schizophrenia (Cirillo and Seidman, 2003; Aleman et al., 1999; Heinrichs 
and Zakzanis, 1998).  It is among the strongest predictors of functional 
outcome, can differentiate between antipsychotic responder and non-
responder and is associated with a greater emotional discomfort, poorer 
quality of life, worse clinical and community outcome, improvement in work 
performance, inefficient social problem solving and worse performance of 
daily life skills (Verdoux et al., 2002; Green et al., 2000; Lysaker et al., 
2000; Addington and Addington., 1999).         
Verbal learning deficits in schizophrenia are frequently reported however 
there is little agreement about which clinical symptoms are related to the 
deficit (Brebion et al., 2005; Muller et al., 2004; Heinrichs and Vaz, 2004).   
A meta-analysis by Bora et al., (2010) showed how the largest effect size 
was found in verbal learning along with other cognitive deficits when 
assessing schizophrenia patients compared to other psychiatric patients 
and healthy controls (Bora et al., 2010).        
 
1.10.6 Visual learning and memory 
 
Visual memory can be described as the relationship between perceptual 
processing and the encoding, storage and retrieval of the resulting neural 
representations (Baddeley and Hitch, 1974).  Visual memory occurs over a 
broad time range spanning from eye movements through to years in order 
to visually navigate to a previously visited location (Chi et al., 2010).  
Visual memory is a type of memory which preserves some features of our 
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senses pertaining to visual experience.  We are able to place in memory 
visual information which resembles objects, places, animals or people in a 
mental image so that we may return to it later.  The experience of visual 
memory can also be referred to as the ‘mind’s eye’ through which we can 
retrieve from our memory a mental image of original objects, places, 
animals or people (Hamame et al., 2011).    
Visual memory impairments are frequently reported in schizophrenia 
(Cocchi et al., 2009; Fuller et al., 2009; Brodeur et al., 2008; Tek et al., 
2002). Hallucinations have been found to be associated with false 
detection or false recognition of visual material in several studies (Brebion 
et al., 2008; Brebion et al., 2007).  Research suggests that schizophrenia 
patients have a visual memory disorder characterized by both 
organizational processing impairments and retention difficulties, and that 
there is a decline in visual memory functions with duration of illness 
(Fleming-Feick et al., 2006; Seidman 2003).   
 
1.10.7 Reasoning and problem solving  
 
Problem solving is a mental process and is part of the larger problem 
process that includes problem finding and problem shaping.  Problem 
solving is considered one of the most complex of all intellectual functions; 
it has been defined as a higher order cognitive process that requires the 
modulation and control of more routine or fundamental skills.  Problem 
solving occurs when a person needs to move from a given state to a 
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desired goal state (Sponheim et al., 2010; Vaskinn et al., 2009; Xia and Li, 
2007).       
People with schizophrenia have shown a lack of ability to solve problems 
involved in day to day living.  The shortage of these skills can affect their 
ability to live independently, contribute to a poor quality of life and in some 
cases can worsen the symptoms of schizophrenia, (Xia and Li, 2007).  
Research has shown that even high functioning patients with 
schizophrenia perform poorer than healthy controls on the Assessment of 
Interpersonal Problem Solving Skills (AIPSS) method (Vaskinn et al., 2009; 
Zanello et al., 2006; Toomey et al., 1997).   
Training patients in structured problem solving strategies is one of the 
oldest cognitive behavioural therapy methods.  Recent social, 
psychological and neuropsychiatric research provides a multi-factorial 
rationale for methods that strengthen patients' ability to carry out stepwise 
problem solving in their real life problems (Fallon et al., 2007; Mulholland 
et al., 2008; Kurtz et al., 2007; Wykes et al., 2007).   
 
1.10.8 Social cognition 
 
Social cognition is the encoding, storage, retrieval, and processing of 
information relating to social information in the brain.  The extent of our 
social abilities is unique and it leads to us developing relationships and 
taking part in social activities which add importance to our life (Adolphs, 
1999).  One of the most important sources of social information is faces; 
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humans are predominately visual animals and we spend a great deal of 
time looking at and analysing faces (Calder and Young, 2005).  Bruce and 
Young (1986) proposed an influential model of face recognition which 
involves structural encoding, expression analysis, facial speech analysis 
and directed visual processing (Bruce and Young, 1986).     
People with schizophrenia have difficulties in interpreting social 
information.  Patients have impairments in recognizing basic emotions and 
making social judgements from facial stimuli, they also have difficulties in 
interpreting social cues from faces (Demily et al., 2011; Komlosi et al., 
2010; Marwick and Hall, 2008).  A deficit in facial identification can 
potentially lead to social difficulties and can also negatively impact on the 
perception of other more complex information derived from faces and body 
language (Pomarol-Clotet et al., 2011; Silver et al., 2009; Addington and 
Addington, 2008). 
 
1.11 Cognitive Test Batteries  
 
A wide range of neuro-cognitive batteries have been developed to assess 
cognition in schizophrenia.  These batteries all differ across a number of 
factors, such as time requirements, repeatability, ease of administration, 
degree of face validity, availability of normative data and degree to which 
results can be put into separate domains of cognitive functioning.  The 
most appropriate battery to use depends on the setting and the nature of 
the questions being addressed.  The table below (1.7) illustrates the 
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different test batteries with their advantages and disadvantages (Kraus 
and Keefe, 2007).   
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1.12 Aims and Objectives  
 
The aim of the work presented within this thesis was firstly, to assess the 
cognitive function of first episode psychosis/schizophrenia patients using 
CANTAB® compared to healthy controls with a focus on the effect of 
ethnicity (South Asian versus Caucasian) in both groups.   
Secondly, a further study was conducted investigating the cognitive 
function of chronic schizophrenia patients compared to healthy controls 
using CANTAB®.  
Thirdly, a study of cognitive remediation therapy (CRT) was conducted in 
first episode psychosis/schizophrenia patients using X-cog® to investigate 
the impact of CRT on patient’s cognitive function.   
Patients and controls were matched as closely as possible in terms of 
demographics.  An objective neuropsychological assessment battery was 
used along with a validated symptom expression questionnaire and a pre-
morbid intellectual quotient assessment tool.   
The work within this thesis will increase our understanding and add to the 
data already reported in this field.   
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2.1 Ethical approval  
 
Ethical approval was required to protect the rights, safety, dignity and well-
being of research participants; and to facilitate and promote ethical 
research that is of potential benefit to participants, science and society 
(National Patient Safety Agency, 2011).   Before recruitment could 
commence ethics committee approval was obtained from three separate 
bodies (Appendix 1, 2 and 3) with any subsequent changes to the study 
protocol submitted as substantial amendments for ethical consideration 
(Appendix 4). 
The three bodies from which ethical approval was obtained are as follows:   
? NHS Research and Ethics Committee (REC) – which is responsible 
for the safeguarding of rights of people participating in research in 
the National Health Service (National Patient Safety Agency, 2011).    
? West Yorkshire Mental Health Research and Development 
Consortium (WYMHRDC) – which aims to facilitate high quality 
research in mental health and learning disabilities that will benefit 
local services and local people (West Yorkshire Mental Health and 
Learning Disabilities Research Partnership, 2010).    
? University of Bradford (UOB) – which has a responsibility to ensure 
that the research it supports is, carried out in conformity with the 
law and in accordance with the best current practices (University of 
Bradford, 2010).   
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Patients suffering from a psychiatric disorder are considered to be part of 
a vulnerable group (Llewellyn-Jones, 2001) and approaching them to take 
part in any form of research needs to be handled appropriately (Usher and 
Holmes, 1997).  It was of major importance that all participants in the 
current study completely understood what their involvement would entail, 
that they did not feel pressured in any way to take part and that they could 
withdraw from the study at any time without giving a reason and it would 
not affect their care in any way.  Additionally it was important that 
participants understood the value of the research and the potential 
benefits for them and other patients.     
Extreme care was taken when developing the patient information sheets 
and consent forms.  Patient information sheets were designed to be easily 
understood and to avoid any unnecessary jargon (Appendix 5).  Consent 
forms detailed all particulars of the study and participants were given the 
choice to opt out of any part of the research process which they did not 
feel comfortable with (Appendix 6).  The researcher Majid Saleem (MS) 
ensured that all potential participants had read and understood the patient 
information sheets and he answered any questions before the consent 
form was signed.     
Patient confidentiality was emphasised throughout the study, with patients 
being assured that all data would be anonymised and only the researcher 
(MS) would be able to link data to participants.  They were also informed 
that data would be stored in a secure place that only the research team 
would have access to.  The same process was carried out for control 
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subjects with separate information sheets and consent forms used 
(Appendix 7 and 8).     
Patients were informed at recruitment that if they so desired they could 
receive individual psychometric reports detailing their performance on the 
neuropsychological tests.  
 
2.2 Recruitment  
 
All patients included in the present study were recruited by the researcher 
(MS) between October 2009 and October 2011.  The recruitment was 
supported by the Bradford and Airedale Early Intervention in Psychosis 
Service (EIP), part of Bradford District Care Trust (BDCT) and staff at the 
Becklin Centre (Inpatient Unit) in Leeds, who belong to the Leeds 
Partnership NHS Foundation Trust (LPFT).  Patients were identified 
through the help of a Consultant Clinical Psychologist, Consultant 
Psychiatrist, Care Co-ordinators, Staff Nurses and Recovery Workers from 
both the EIP service and the Becklin Centre.   The research was promoted 
by (MS) at monthly team meetings at both the EIP service and the Becklin 
Centre.   
 Once patients had been identified as potential participants they were 
jointly approached by their Key Workers and a member of the research 
team (MS) to introduce the study.  These meetings took place either at the 
patient’s home or at an NHS premises.  Each patient was provided with an 
information sheet which they could keep and given the opportunity to ask 
the researcher any questions.  All patients were informed that they had a 
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minimum of 24 hours to think about participating before they would be 
asked to sign a consent form.        
Once patients had consented to taking part in the study, they were asked 
to sign a consent form and were allocated a patient number for reasons of 
confidentiality.  They only person who would be able to match the number 
to the patient was the researcher (MS).  Following this, an appointment 
was arranged at a convenient time for the patient so that the proposed 
research could begin.  Patients were given the choice of three locations to 
meet; their homes, the University of Bradford or an NHS premises either in 
Bradford or Leeds where the respective two services were based.  
Patients from the EIP service were recruited from three clusters around 
the Bradford District.  Initially recruitment started in the City cluster and 
was then expanded to the North and Airedale and South and West 
clusters.  Patients from LPFT were all recruited from the Becklin Centre in 
Leeds.    
Every effort was made to include people from all cultural backgrounds in 
the study.  All of the patients who took part were either of South Asian or 
Caucasian heritages.  For those patients who were unable to read from 
the South Asian community the researcher (MS) was able to translate into 
either Urdu or Punjabi.  For any other languages, translational services 
were available through the respective NHS teams however, no 
translational/interpretation services were required during any part of the 
study.     
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The control subjects for the first episode psychosis study and chronic 
schizophrenia study were recruited from the same catchment areas as the 
patients by advertising through local community and resource centres. 
Careful consideration was taken whilst recruiting to ensure that control 
subjects were matched as closely as possible across all demographic 
factors, such as; age, gender, ethnicity, years in education and level of IQ.  
This was done to ensure that any type of demographic bias was 
eliminated from the study.  
 
2.3 Participant demographics  
 
All participants who took part in the research were over the age of 18 and 
were able to consent for themselves.  Patients met the DSM-IV-TR and 
ICD-10 diagnostic criteria for schizophrenia spectrum disorders (see table 
2.1).  At the beginning of the studies all patients were on antipsychotic 
medication (see tables 2.2 and 2.3).   
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2.4 Exclusion criteria   
 
Exclusion criteria are used in clinical research to determine whether a 
particular person may or may not be allowed to participate in any given 
study.  The most important criteria routinely applied include, age, gender, 
treatment history and other significant medical conditions.   
For the purpose of the current research, patients were excluded from the 
first episode study if they were under the age of 18 or over the age of 40, 
had a history of more than one psychotic episode, had either a learning 
disability or difficulty, had suffered severe head injuries or other 
neurological illness and had an excessive history of drugs or alcohol 
abuse.   
For the chronic schizophrenia study patients were excluded if they were 
under the age of 18, had experienced less than two psychotic episodes, 
had either a learning disability or difficulty, had suffered severe head 
injuries or other neurological illness and had an excessive history of drug 
or alcohol abuse.   
The participants in the control group were excluded if they were under the 
age of 18, had any history of a psychotic illness, had either a learning 
disability or difficulty, had suffered severe head injuries or other 
neurological illness and had an excessive history of drugs or alcohol 
abuse. 
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2.5 Reliability  
 
The term reliability refers to the consistency of a measuring tool.  A test is 
considered to be reliable if it yields the same results on each occasion it is 
used (Golafshani, 2003, Higgins and Green, 2005).  
High reliability of a measuring tool is essential in clinical research however, 
unfortunately it is impossible to calculate reliability exactly, but there are 
several different ways to estimate reliability.  There are two forms of 
reliability which are pertinent to the current studies.  Test-retest reliability; 
which refers to the consistency of a test across time and inter-rater 
reliability; which is achieved by having two or more independent judges 
score a particular test and yield the same results.  The reliability of each 
tool used in the present study will be discussed later in this chapter.    
 
2.6 Validity  
 
Validity is considered to be the extent to which a test measures what it 
claims to measure.  It is essential for any kind of test to be valid in order 
for the results to be interpreted and applied correctly (Higgins and Green, 
2005).   The CANTAB® tests used in the current study have been validated 
in behavioural and psychopharmacological studies with animals and 
healthy human volunteers (Fineberg et al, 2009, Robbins, 2000, Majer et 
al, 2010, Quednow et al, 2008) in neuroimaging studies with healthy 
volunteers (Chamberlain et al, 2006, Conklin et al, 2007) and a wide 
variety of patient groups (de Rover et al, 2011, Benetti et al 2009, Vogels 
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et al 2008, Olley et al, 2005).  The validity for each tool used in the present 
study will be discussed later in this chapter.    
 
2.7 Assessment schedule  
 
Once participants had agreed to take part in the study a further 
appointment was made with them by the researcher (MS) to meet them in 
one of the following locations to undergo the research procedure; at their 
homes, the University of Bradford or an NHS premises (always the case 
for the chronic schizophrenia study as they were all inpatients).   
Assessment of patients at the drug naive stage would have been ideal as 
the data generated would have been very valuable, however due to the 
nature of the illness and the difficulty in gaining access to and testing 
patients who are floridly psychotic this was very difficult to achieve.  
Therefore all patients recruited into the First Episode study had been on 
some form of antipsychotic medication for a minimum of 6 months and 
those in the Chronic Schizophrenia study had a longer history of 
medication.  
All assessments were conducted by the researcher (MS).  Assessments 
were performed at times which were convenient for patients and controls 
and always took place in a quiet room with minimal distractions.  All efforts 
were made to ensure that the testing procedure was identical every time 
within a consistent time frame, therefore demands on participant’s time 
would be limited and boredom effects minimal.   For the patient groups, 
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they were allowed to take a break half-way through the testing procedure 
as they had to spend slightly longer than controls due to the administration 
of additional measurement tools i.e PANSS.   
For those participants who opted to undergo the assessments either at the 
University of Bradford or an NHS premises, they were provided with a 
means of transport to and from the locations.  For those who opted to 
make their own way there they were offered a reimbursement of any 
reasonable travel expenses.    
 
2.8 Assessment protocol  
 
All assessments were performed by the researcher (MS); the testing 
protocol was as follows:   
1. At the initial meeting the aims of the research were discussed and 
any questions answered by the researcher (MS).  The participant 
was asked to take a minimum of 24 hours to think about taking part.  
Following this if the participant was happy to take part then a 
consent form (Appendix 6 and 8) was completed and signed by 
them and the researcher (MS) with a copy being placed in their 
medical records (for patients only).  The participant was then 
allocated an ID/Code number by the researcher (MS) for reasons of 
confidentiality and another appointment was arranged so that the 
testing could begin.   
2. At the second meeting between the participant and the researcher 
(MS) basic demographic information was collected i.e. age, gender, 
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ethnicity, years in education, highest qualification achieved, 
medication types, duration of medication(s) (for patients only), 
height, weight, Body Mass Index (BMI) and Body Percentage Fat 
(BPF).    
3. Also at the second meeting an assessment of pre-morbid IQ was 
undertaken by the researcher (MS) through the use of a reading 
task; the Wechsler Test of Adult Reading (WTAR) – (Appendix 9).     
4.  The Positive and Negative Syndrome Scale (PANSS) 
questionnaire was conducted by the researcher (MS) to assess 
symptom expression in only the patient groups (PANSS) – 
(Appendix 10).   
5. A battery of neuropsychological assessments was carried out by 
the researcher (MS) using the Cambridge Neuropsychological Test 
Automated Battery (CANTAB®). 
6. A sample of saliva was obtained from each participant in the First 
Episode Psychosis study by the researcher (MS) using an Oragene 
DNA self collection kit.  This saliva was then stored in a secure 
human tissue bank which only the research team has access to at 
the University of Bradford for future genetic analysis. 
 
2.9 Data Collection for intelligence and symptom expression  
2.9.1 Wechsler Test of Adult Reading (WTAR) 
 
The Wechsler Test of Adult Reading (WTAR) (Appendix 9) is a measure of 
pre-morbid (pre-injury/illness) level of intellectual functioning for individuals 
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aged between 16 to 89 years.  The test was developed and co-normed 
with the Wechsler Adult Intelligence Scale - Third Edition (WAIS-III) 
(Wechsler, 1997a) and the Wechsler Memory Scale – Third Edition (WMS-
III) (Wechsler 1997b) for the United States and United Kingdom.  This has 
resulted in clinicians being able to directly compare between predicted and 
actual intelligence and memory function of large representative samples of 
healthy adults and a variety of patient groups.  The test can be 
administered as part of a comprehensive evaluation and used to predict a 
person’s cognitive functioning scores to develop appropriate treatment 
plans.  
Unlike many intellectual and memory abilities, reading recognition is 
relatively stable in the presence of cognitive decline associated with 
normal aging or brain injury.  This therefore makes the WTAR a good 
initial estimation of pre-morbid intellectual and memory abilities (assuming 
a normal development of reading skills prior to injury, illness or cognitive 
decline).     
The WTAR takes less than 5 minutes to complete and is a reading test 
that is made up of 50 words which have atypical grapheme to phoneme 
translations, so that it minimises the ability of the reader to apply standard 
pronunciation rules and assess previous learning of the word.   
The participant is asked to read aloud the list of words which are provided 
on a word card and all responses are then recorded by the administrator 
of the test scoring “1” for a correct response and “0” for an incorrect 
response.  Once the test is completed the raw scores obtained are then 
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converted into standard scores using the Wechsler Test of Adult Reading 
Manual.  There is also the opportunity to look at individual learning and 
memory domains.   
The reliability of the WTAR was estimated from the item scores obtained 
by the US and UK standardised samples on a single test administration.  
The WTAR displayed excellent internal consistency with co-efficients 
ranging from 0.90 to 0.97 for the US standardisation sample and from 0.87 
to 0.95 for the UK sample.  The high values indicate that WTAR 
measurement error is relatively small (The Psychological Corporation, 
2001).  The WTAR has displayed high positive correlations with other 
measures of reading ability.  Its correlations with the NART (Nelson, 
1982) .78, AMNART (Grober and Sliwinski, 1991) .90 and WRAT-R 
(Jastak and Wilkinson 1984) .73 were in the high range indicating good 
validity (The Psychological Corporation, 2001).   
The WTAR has been used previously to assess intelligence within 
research projects concerned with First Episode Psychosis (Hill et al 2009, 
Goldberg et al, 2009)   and Schizophrenia (Bowie et al, 2008, Huddy et al, 
2007).   
 
2.9.2 Positive and Negative Syndrome Sale (PANSS) 
 
The Positive and Negative Syndrome Scale (PANSS) (Kay et al, 1987) 
has been designed for the assessment of symptom severity in 
schizophrenia and other related clinical disorders.  It is also routinely used 
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to assess disorders such as bipolar disorder and affective psychoses.  
Different components of the PANSS have been used in studies of 
Alzheimer’s disease, anorexia nervosa, drug induced psychoses and 
many others.      
The PANSS is based on the premise that schizophrenia consists of at 
least two distinct syndromes, the positive symptoms and negative 
symptoms.  The positive symptoms consist of productive symptoms (e.g., 
hallucinations, delusions and notions of grandeur) which usually respond 
well to antipsychotic treatment and the negative symptoms consist of 
deficit features (e.g., blunted affect, social withdrawal and lack of rapport) 
which are indicative of poor pre-morbid status, medication resistance and 
poorer prognosis. There is also a third scale called general 
psychopathology which gauges the overall severity of schizophrenia.   
This distinction in symptoms is useful for clinicians and researchers as it 
allows the development of tailored treatment plans for patients.  It is also 
useful when studying the effects of medication because it allows clinicians 
and researchers to determine which type of symptoms are most prevalent.           
The PANSS has been widely researched and has been used in a variety 
of situations and settings.  The majority of clinical research use of the 
PANSS has been in clinical assessments, treatment response, predicting 
outcome and gauging impairment severity (Kolkebeck et al 2010, Galderisi 
et al 2009, Hill et al 2009, Ayers et al 2007, Saeedi et al 2007, Addington 
et al 2006).                                                                                                                               
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The PANSS is a questionnaire which is hand scored using a multi-health 
systems Quick Score form which makes it easy to rapidly and accurately 
score and profile the PANSS.  It is designed to be used for individuals 
aged 18 and over.  It takes around 30-40 minutes to administer and 15 
minutes to score by a trained professional.  Raters have the choice of 
using the standard dimensional scoring or the pentagonal scoring method.  
The pentagonal model is the result of recent research.  It uses 25 PANSS 
items organized into five scales: negative, positive, dysphoric mood, 
activation, and autistic preoccupation.  For the purposes of the current 
research we have used the standard dimensional scoring method.   
The reliabilities for the Positive 0.72, Negative 0.81 and General 0.77 
scales are all high (DeVellis, 1991).  The sequential stability of PANSS 
has been demonstrated with a number of psychiatric populations (Kay and 
Singh, 1989, Kay et al, 1987, Lindenmayer, 1984) and the inter-rater 
reliability has been shown to be highly concordant with average 
correlations ranging from 0.83-0.87 reported for the Positive, Negative and 
General Psychopathology scales (Kay et al, 1989).  Extensive research 
has shown that the PANSS is high in different types of validity and 
demonstrate support for the utility of the tool for it specified purposes (Kay 
et al, 1989, Kay and Singh 1989, Kay and Opler 1987, Kay et al, 1986, 
Lindenmayer et al 1984).    
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2.10 Neuropsychological testing   
2.10.1 Cambridge Neuropsychological Test Automated Battery 
(CANTAB®) 
 
The CANTAB® is a battery of computerised neuropsychological tests 
which have been developed by Cambridge Cognition.  These tests are an 
effective method of cognitive assessment, which are language 
independent and use touch screen technology to deliver rapid and non-
invasive cognitive assessment.  The tests have been extensively used in 
academic research and in clinical trials primarily focusing on schizophrenia, 
Alzheimer’s disease and attention deficit hyperactivity disorder.   The 
battery of tests examine a number of different cognitive domains; visual 
memory, spatial memory, executive function, working memory, planning, 
attention, semantic/verbal memory, decision making and response control.   
CANTAB® is designed in a game-like format, providing feedback after 
each individual trial thus helping to maintain participant motivation 
(Sahakian and Owen, 1992).  The main aim of developing CANTAB® was 
to measure cognitive dysfunction in clinical populations; however it has 
also been used to measure cognitive function in healthy populations and 
boasts a database of 3000 healthy controls (Robbins and Roberts, 2007).  
The advantages of using CANTAB® over more traditional pen and paper 
tools are that it is easier to administer and the precision and accuracy of 
the results are more reliable (Curtis-Prior, 1996).  CANTAB® provides 
comparable results to those found in more established methods of 
neuropsychological assessment such as the Wisconsin Card Sorting Test 
(WCST), Tower of London (TOL), Trail Making Test (TMT), Stroop Test 
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(ST), N-Back Test (NBT) and Grooved Pegboard (GP), thus confirming its 
reliability and validity as a measuring tool for cognitive assessment 
(Levaux et al, 2007, Lowe and Rabbitt, 1998, Fray and Robbins, 1996).   
The CANTABeclipse™ administration manual (CANTAB®, 2006) details 
how the task administrator should instruct the participant being tested 
before and during the test.  Careful attention was given to these 
instructions and they were followed consistently for all participant 
assessments that took place.   
For the purposes of the current research, five tests from the CANTAB® 
were chosen as the domains assessed by these tests have all been 
shown to be affected in patients with first episode psychosis (Rodriguez-
Sanchez et al, 2010, Gonzalez-Blanch et al 2010, Ngoma et al 2010) and 
schizophrenia (Jahshan et al 2010, Zanello et al 2009, Minatogawa-Chang 
et al 2009), (see table 2.3). 
 
CANTAB® TEST  MEMORY DOMAIN 
Pattern Recognition Memory 
(PRM) 
 
 
 
Visual memory 
Spatial Recognition Memory 
(SRM) 
 
 
 
 
Spatial Memory  
Stockings of Cambridge 
(SOC) 
 
 
 
 
Working memory and spatial 
planning 
Intra/Extra Dimensional Set 
Shift (IED) 
 
 
 
Executive function  
Choice Reaction Time (CRT)  Attention 
Table 2.4 – CANTAB® tests and memory domains assessed 
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2.10.1.1 Pattern Recognition Memory (PRM) 
 
PRM is a test of visual pattern recognition memory in a 2-choice forced 
discrimination paradigm.  This test is sensitive to dysfunction in medial 
temporal areas of the brain and relatively insensitive to dysfunction in the 
frontal lobe.  The test takes approximately 5 minutes to administer 
depending on level of impairment.    
The subject is presented with a series of 12 random visual patterns, one at 
a time, in the centre of the screen which they have to try and memorise.  
These patterns are designed so that they cannot easily be given verbal 
labels.  Once the subject has seen all 12 patterns the next phase of the 
assessment begins which is the recognition phase.   
In the recognition phase, the subject is required to choose between a 
pattern they have already seen and a novel pattern.   In this phase, the 
test patterns are presented in the reverse order to the original order of the 
presentation. The subjects must touch the pattern that has appeared 
before, whilst ignoring the new pattern.     
 At the end of this phase the subject is again presented with a new set of 
12 random visual patterns and they have to undergo the same procedure. 
 
Figure 2.1- Pattern Recognition Memory test screens from CANTAB® 
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 2.10.1.2 Spatial Recognition Memory (SRM) 
 
SRM is a test of visuo-spatial recognition memory in a forced-choice 
paradigm.  This test is primarily sensitive to dysfunction in the frontal lobe, 
and relatively insensitive to temporal lobe damage.  The test takes 
approximately 5 minutes to administer depending on level of impairment.   
In the presentation phase, a white square is shown on the screen in 5 
different locations.  Each appearance of a square marks a location on the 
screen which the subject must later remember.  Once the subject has 
seen all 5 squares the next phase of the assessment begins which is the 
recognition phase.   
In the recognition phase, the square reappears in the same 5 locations as 
in the presentation phase, however in reverse order.  On each appearance, 
it is paired with an identical distracter square in a location not used in the 
presentation phase.  The subjects must touch the square in the location 
that has appeared before, whilst ignoring the distracter.  This test is 
repeated three more times, each time with five new locations.   
 
Figure 2.2 - Spatial Recognition Memory test screens from CANTAB® 
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 2.10.1.3 Intra/extra dimensional set shift (IED) 
 
IED Set Shift is a test of rule acquisition and reversal.  It features; visual 
discrimination, attentional set formation, maintenance, shifting and 
flexibility of attention.  This test is primarily sensitive to changes in the 
fronto-striatal areas of the brain.  The test takes approximately 7 minutes 
to administer depending on level of impairment.   
Two artificial dimensions are used in the test; colour filled shapes and 
white lines.  Simple stimuli are made up of just one of these dimensions 
(coloured shapes); whereas compound stimuli are made up of both, 
namely white lines overlying colour filled shapes.  Subjects progress 
through the test by satisfying a set of criterion of learning at each stage 
(six consecutive correct responses).  If at any stage the subject fails to 
reach this criterion after fifty trials the test terminates.   
The test starts with block 1, the presentation of two coloured filled shapes.  
The subject must learn which of the shapes is correct by touching it and 
continue until the criterion is reached (as described above).  In block 2, the 
rule is reversed, so that the previously incorrect shape becomes the 
correct shape.   
In block 3, the second dimension (white line) is introduced, initially next to 
the shape and then in block 4 overlapping the shape.  The rule does not 
change at this stage until the criterion is reached and then in block 5 the 
rule is reversed within the original dimension.  It is important to note that 
the second dimension (white line) is redundant at this stage.   
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Once the subject has learned the compound discrimination, new shapes 
are introduced in block 6 still varying along the same two dimensions.  
Subjects are required to continue to attend to the previously relevant 
dimensions of shape and learn which of the two new shapes is correct – 
the intra dimensional shift.   
Once the subject has completed a successful intra-dimensional shift, 
followed by a reversal in block 7, again the compound shapes are 
changed.   For block 8 subjects are required to shift attention to the 
previously irrelevant dimension and learn which of the two exemplars in 
this dimension is now correct – the extra dimensional shift.  In block 9 the 
contingencies are again reversed.     
   
Figure 2.3 – Intra/extra Dimensional Set Shift test screens from CANTAB® 
 
2.10.1.4 Stocking of Cambridge (SOC) 
 
SOC is a test of working memory and spatial planning, which give a 
measure of frontal lobe function.  The test takes approximately 10 minutes 
to administer depending on level of impairment.   
The subject is shown two displays containing three coloured balls.  The 
displays are presented in such a way that they can easily be perceived as 
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stacks of coloured balls held in a stocking.  This arrangement makes the 
3D concepts involved apparent to the subject and fits with the verbal 
instructions given.   
The subject must copy the pattern shown in the upper display in the lower 
display.  The balls can be moved only one at a time by touching the 
required ball and then touching the position to which it should be moved.  
The time taken to complete the pattern and the number of moves required 
are taken as measures of the subject’s planning ability.   
In the early stages of the task, it is only necessary to move one ball and 
the number is gradually increased as the test progresses up to four moves.  
After the four move problems have been completed, a procedure 
controlling for motor performance is introduced.  The upper display moves 
one ball at a time, repeating the moves made by the subject in the 
previous planning phase.  The subject must follow the upper display by 
moving the balls in the lower display.  Again the number of moves 
increases from two to four. 
A second block of planning problems of two, four, and five moves follows 
and the test is completed with a second block of motor control problems.  
Should the subject make more than double the number of moves 
necessary the problem is terminated.  Should the computer terminate 
three problems in a row, the entire test ends.  The first problem is for 
demonstration by the tester.  After which the subject must make all the 
moves themselves.  There is no time limit.   
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This test has various outcome measures, including the number and 
percentage of correct trials and latency (speed of subject’s response).   
 
Figure 2.4 – Stockings of Cambridge test screens from CANTAB® 
 
 2.10.1.5 Choice Reaction Time (CRT) 
 
CRT is a 2-choice reaction time test which measures simple reaction time 
through the use of two possible stimuli and two possible responses.  It is 
useful for testing general alertness and motor speed and is often sensitive 
to medication effects.  The test takes approximately 7 minutes to 
administer depending on level of impairment.   
An arrow shaped stimulus is displayed on either the left or right side of the 
screen.  The subject must press the left hand button on the press pad if 
the stimulus is displayed on the left hand side of the screen and the right 
hand button on the press pad if the stimulus is displayed on the right hand 
side of the screen.  There is a practice stage of twenty four trials and two 
assessment stages each of fifty trials.   
This test has thirteen outcome measures, assessing correct and incorrect 
responses, errors of commission and emission (late and early response) 
and latency (response speed).   
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Figure 2.5 - Choice Reaction Time test screens from CABTAB® 
 
2.11 Cognitive Remediation  
 
2.11.1 X-Cog® 
 
X-Cog® is a computer based programme developed by EuroCog in 
Germany.  It was designed with the explicit aim of helping patients to 
remediate the following cognitive domains; memory (particularly working 
memory), problem solving skills (executive function), and various forms of 
attention and visuo-motor skills, including speed of responding.  Its current 
version contains 19 games which attempt to remediate the above 
mentioned domains.  Each game can be administered at five different 
levels of difficulty from ‘beginner’ to ‘super-professional’.    
In the current research all patients who took part in the X-Cog® study 
attended an 8 week Cognitive Remediation Therapy (CRT) course 
following their CANTAB® assessments, which was facilitated by a trained 
practitioner (MS).  The course was held at the University of Bradford and 
each session lasted approximately 90 minutes.  For the purpose of the 
course 6 games were chosen from the selection of 19, focusing on the 
following domains; memory, attention, executive function and visuo-motor 
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skills.    All patients were started on the beginner levels of each game and 
were only moved up to the next difficulty level upon successful completion.  
Easy to follow instruction sheets were provided to all participants at the 
beginning of the course (Appendix 11).   The facilitator and co-facilitators 
were available throughout each session to help answer any questions and 
to provide positive feedback to all participants.   
 
2.11.1.1 Magic Carpet  
 
The Magic Carpet is a game focusing on working memory and executive 
function.  A tile matrix can be seen in the centre of the screen in which 
eight of the nine fields are populated.  The fields display tiles of various 
colours (green, blue and red), shapes (triangles, circles and squares) and 
sizes (small, medium and large).  By examining the matrix the colour, 
shape and size of the missing tile must be logically deduced.   
Several possible solutions are presented to the player in the upper part of 
the screen.  The player has to click on their chosen tile (using the right key 
of the mouse) and fill the vacant position in the matrix.   If the matrix is 
solved successfully, the player receives positive feedback on the screen, 
and is presented with a new problem.  If it is not completed successfully, 
the tiles turn black and the correct answer is shown briefly and then the 
new problem is presented.        
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Figure 2.6 – Magic Carpet game screens from X-Cog®  
 
2.11.1.2 Maze 
 
The maze is a game focusing on executive function and visuo-motor skills.  
The game begins with the player’s character appearing at the 
entrance/exit of the maze on the left hand side of the screen.  On the right 
hand side of the screen there is another character that the player has to 
rescue.  Using the cursor keys on the keyboard the player must first reach 
this other character and then guide them back to the entrance/exit.  As 
soon as the task is complete the player is provided with a new maze 
assuming that the game time has not run out.   
 
2.11.1.3 Bridgework 
 
Bridgework is a game that focuses on working memory, executive function 
and visuo-motor skills.  The aim of the game is to get your character 
across the bridge.  In order for the player to achieve this they have to 
piece together the missing section of the bridge making sure that all 
contact points on the sections are of the same colour.   
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The first and last section of the bridge are always completed and 
connected to the river bank.  Depending on the difficulty level there are 
either two (beginner and advanced) or three (expert, professional and 
super professional) choices of pieces on the left hand side of the screen.  
Using the left key of the mouse, pieces can be selected, once chosen the 
centre of the piece turns red.  Any piece which has a yellow square in its 
centre can be rotated by being selected and then by pressing the right key 
of the mouse.       
By clicking the left key of the mouse on a section of the bridge which is 
already connected it will move any selected piece to that location as long 
as the contact points are of the same colour.  To reverse a move, the 
player first has to select the piece they would like to remove using the left 
key of the mouse and then press the right key to move it.  In this way the 
player is able to try a number of combinations until the bridge is complete.  
Once a bridge has been successfully completed a new bridge will appear 
as long as there is enough time remaining.   
 
2.11.1.4 Rainmaker  
 
Rainmaker is a game that focuses on attention.  Yellow comets can be 
seen by the player flying across the top of the computer screen from left to 
right.  They can be distinguished by their number (one, two or three) and 
by the colour (red, blue or black) of their spots.  In order for the player to 
achieve their objective, they must select the correct comet to burst using 
the fork.  For the purpose of this particular game it is the comet with only 
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two spots which needs to be targeted.  Once the player has worked this 
out they then continue only targeting these comets.  In order for the 
comets to burst the player must press the space bar at the appropriate 
time.  If the wrong comet is burst the computer will give you the relevant 
feedback.  Once the space bar is pressed it must be released otherwise 
the fork will remain in the air bursting other comets.   
 
Figure 2.7 – Rainmaker game screens from X-Cog®  
 
2.11.1.5 Parcel Service  
 
Parcel service is a game focusing on working memory, attention and 
visuo-motor skills.  In a system of pipes small yellow parcels are being 
delivered from four directions towards the middle of the screen (where 
there is a box) and they have to be collected by the player.  This is done 
by moving the box at the centre of the screen using the cursor keys on the 
keyboard.   
From the “expert” level and upwards some of the individual sections of the 
pipe are worn out and become blocked.  This then requires the player to 
replace these sections through the use of pre-made repair packages 
(which are blue) that can be seen on the right hand side of the screen.  
First the correct type of tube needs to be selected using the space bar and 
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then this pipe has to be inserted by pressing the up cursor key and shift 
key.  During this repair process the player is still expected to collect the 
yellow parcels.   
 
2.11.1.6 Yolk Hunt  
 
Yolk hunt is a game that focuses on working memory.  The game starts 
with hens of different colours moving around the field on the screen.  
Some of the hens then crouch behind bushes that are on the screen to lay 
eggs.  The player has to memorise the position and colour of the eggs 
(same as the hens colour).  After a 30 second delay the hens disappear 
and the player then has to find the eggs with minimum mistakes.  The 
player must first select an egg from a selection at the bottom of the screen 
using the left key of the mouse.  They must then select a bush where they 
think there is an egg of the selected colour.  If the player is correct in their 
choice the egg is carried away, if they are incorrect they have to try 
another bush to find the egg of the corresponding colour.  Six rounds have 
to be completed and in each round all of the eggs must be found.   
 
Figure 2.8 – Yolk hunt game screens from X-cog® 
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 2.12 Statistical Analysis  
 
The studies within this research thesis aimed to assess cognitive 
performance, wellbeing and remediation in first episode psychosis and 
chronic schizophrenia patients compared to healthy controls.   
Sample size calculations were based on power calculations, ‘expert’ 
advice from senior healthcare professionals and findings from previous 
studies which would provide an expected relevant difference in 
performance.  There have been numerous studies which have produced 
unequivocal findings on different types of cognitive dysfunction using 
varying methods of assessment.  The study sample size has therefore 
been based on previous study size, advice from statisticians and the 
realistic number of participants we could expect to recruit in the time frame 
available.    
Data was analysed using Statistical Package for Social Sciences Version 
16 (SPSS®, Chicago 2009).  Data were checked for normality using the 
Kolmogorov-Smirnov test and by examining the median and interquartile 
ranges.  In all three of the studies independent sample t-tests were 
conducted to compare the means of the two samples (control and patient) 
across all measures.  Linear regression analysis was carried out to 
forecast the effects of ethnicity, age, gender, years in education and IQ 
scores on cognition in all participants, with symptom expression being 
examined in the patient groups only.  Mann-Whitney U tests were used to 
evaluate the difference between the 2 treatment groups in the CRT study.
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3.1 Introduction  
 
Cognitive deficits are a core feature of schizophrenia and psychosis (Kurtz, 
2011, Bowins, 2011, Bozikas and Andreou, 2011, Kalkstein et al., 2010, 
Rund, 1998), with patients demonstrating significant impairments in most 
domains compared with both psychiatric and non-psychiatric populations, 
(Gopin et al., 2011, Anticevic et al., 2011, Daban et al., 2006, Altshuler et 
al., 2004, Heinrichs and Zakzanis, 1998). Specifically, patients with 
schizophrenia and psychosis have been shown to have impairments on 
neuropsychological measures of memory (Staring et al., 2011, Ragland et 
al., 2011 Saykin et al., 1991), executive function (Zandbelt et al., 2011, 
Kim et al., 2011, Addington and Addington, 2002), attention (Ferchiou et 
al., 2010, de Jong et al., 2010, Cornblatt and Keilp, 1994), information 
processing speed (Lencer et al., 2011, Bonner-Jackson et al., 2010, 
Nestor et al., 1992) and psychomotor processing (Brebion et al., 2009, 
Brebion et al., 2000, Hoff et al., 1992).   
It has been generally accepted that schizophrenia patients perform, on 
average, 1 - 1.75 standard deviations below healthy people in a wide 
variety of cognitive tests (Gold, 2004) and it has been suggested that the 
severity of the cognitive dysfunction is closely correlated with the 
functional outcome of the patient (Allott et al., 2011, Green et al., 2004, 
McGurk and Meltzer, 2000).  However cognitive dysfunction is largely left 
untreated by current antipsychotic medication and therefore poses a great 
unmet clinical need (Faber et al., 2011, Marder and Fenton, 2004).   
Chapter 3  First Episode 
84 
 
Historically studies have primarily focused on chronic schizophrenia 
patients, (Gopal and Variend, 2005, O’Carroll, 2000, Mohamed et al., 1999) 
and there have been relatively fewer studies investigating the important 
area of cognitive dysfunction in patients with first episode psychosis.  To 
date research has shown that first episode psychosis patients show 
significant cognitive impairments (Nuechterlein et al., 2011., Bilder et al., 
2000, Hoff et al., 1992), with further evidence demonstrating that cognitive 
dysfunction is present in some patients during the prodromal period 
(Frommann et al., 2011, Hawkins et al., 2008, Bartok et al., 2005) and in 
unaffected siblings (Montag et al., 2011, Weickert et al., 2010, Nam et al., 
2009).  
 The cognitive deficits reported at first episode are often comparable to 
those seen in chronic patients (Addington et al., 2003, Moritz et al., 2001, 
Addington and Addington, 2002). The understanding of the processes 
through which these neuropsychological deficits develop in patients with 
schizophrenia is still incomplete and an area of controversy (Pukrop et al., 
2006, Keefe et al., 2006, Bilder et al., 2000) however there is some 
evidence to suggest that these deficits may be a result of both early 
developmental abnormalities and subsequent deterioration following the 
onset of symptoms (Owen et al., 2011, Powell, 2010, Gonzalez and 
Blanch et al., 2010, Bilder et al., 1992). 
Research has consistently found that there is an increased rate of 
schizophrenia among migrant and black and minority ethnic (BME) groups, 
(Coid et al., 2008, Bresnahan et al., 2007, Cantor-Graae and Selten, 
2005).   Previous findings have shown that certain BME migrant groups 
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have an elevated risk of developing psychosis in comparison to other 
groups, (Coid et al., 2008, McGrath et al., 2004, Bhugra et al, 1997).  
Karlsen and Nazroo (2002) reported a significantly increased odds ratio for 
a range of health problems, including psychosis amongst BME groups.  
There are also a number of studies demonstrating higher rates of 
schizophrenia in the children of BME migrant groups.  This has been 
observed in many countries including; Greenland (Mortensen et al 1999), 
the USA (Malzberg, 1969) and the UK (Harrison et al 1988).  
Studies focussing on BME migrant groups in Bradford have reported a 
higher prevalence of psychosis amongst South Asian people compared to 
groups of other ethnic origins i.e. Black-Caribbean, Black Afircan, Chinese, 
Arab (Bradford Commissioning Strategy Support Document – Health 
Needs Analysis 2008-2011).  However despite this higher prevalence 
there is no reported research investigating cognitive function in first 
episode psychosis South Asian patients.  One possible explanation for this 
comes from recent studies which found that people of South Asian 
descent are less frequently found using mental health services compared 
to other ethnic groups and sometimes pursue alternative means of support 
to help deal with psychiatric conditions (Myers, 2011, Furnham et al., 2008, 
Patel, 2003).  
 
3.2 Study Aim 
 
The aim of the current study was to investigate cognitive function in first 
episode psychosis patients compared to healthy controls and examining 
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the relationship of ethnicity along with other demographic factors such as 
age, years in education and gender on cognitive function.  We also looked 
at the impact of pre-morbid IQ on neuropsychological functioning.  In 
patients the effects of medication, the effects of diagnoses and the effects 
of symptom expression and subsequent neuropsychological scores in first 
episode psychosis patients were also looked at.      
 
3.3 Methods 
 
See Chapter 2 for full description of methods used.     
 
3.4 Results  
 
3.4.1 Participant assessment schedule  
  
All participants took part in the same assessment procedures in relation to 
pre-morbid IQ testing and neuropsychological assessments, with the 
patient groups having an additional assessment for symptom expression 
(PANSS).  Each of the subjects completed all of their assigned tasks on 
one occasion.  The flow of participants through the study is represented by 
figure (3.1). 
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3.4.2 Participant Demographics  
 
All participants who took part in the study completed the Wechsler Test of 
Adult Reading (WTAR) on entry.  Following on from this subjects 
completed five subtests from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB®), with the first episode psychosis patients 
rated for symptom expression using the Positive and Negative Syndrome 
Scale (PANSS).  Age of participants ranged from 18 - 33 years for controls 
(South Asian 18 – 33 and Caucasian 19 – 33) and 18 – 39 for patients 
(South Asian 18 – 39 and Caucasian 20 – 32).  There were 20 males and 
10 females in the control group (21 South Asian and 9 White) and 26 
males and 9 females in the patient group (20 South Asian and 15 
Caucasian).  When participants were compared by ethnicity, mean age, 
years in education, gender and pre-morbid IQ scores, no significant 
differences were found (Table 3.1).  When patients were examined in 
relation to diagnoses and medication status no significant effects were 
found.  Throughout the study no undesirable effects were reported at any 
stage by any of the participants to the researcher (MS) or any other health 
care professional. 
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3.4.3 Patient Medication Status and Diagnoses  
 
The status of patient medication and diagnoses was considered.  Patients 
were divided into separate groups depending on the type of medication 
they were currently taking (see table 2.2) and the relationship between 
performance on the CANTAB® tests and medication was assessed.  No 
significant relationships were found between the types of medication that 
patients were on and subsequent scores on the neuropsychological tests.  
Similarly patients were divided into diagnostic categories (see table 2.1) 
and the relationship between performance on the CANTAB® tests and 
diagnostic status was examined.  There were also no significant 
relationships found between patient diagnoses and neuropsychological 
performance.   
 
3.4.5 Symptom Expression in Patients  
 
Symptom expression was assessed in the patients using the Positive and 
Negative Syndrome Scale (PANSS).  There are three main symptom 
groups that the PANSS assesses; positive symptoms (which include 
hallucinations and delusions), negative symptoms (which include social 
withdrawal and blunted affect) and general symptoms (which include 
anxiety and depression).  The graph below (fig 3.3), shows how there 
were no significant differences in positive symptoms between; South Asian 
(12.5 ± 2.4) and Caucasian (12.6 ± 3.1), t (33) = -0.12, p = 0.9 patients, 
negative symptoms between South Asian (17.1 ± 4.7) and Caucasian 
(14.7 ± 3.9), t (33) = 1.56, p = 0.12 patients and general symptoms 
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between South Asian (29.3 ± 5.9) and Caucasian (27.4± 4.5), t (33) = 0.98, 
p =0.33 patients.       
 
Positive, Negative and General symptoms mean scores for South  
Asian and Caucasian patients  
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Figure 3.2 – (P) Positive, (N) Negative and (G) General symptoms mean 
scores in (SA) South Asian patients (n=20) and (Ca) Caucasian patients 
(n=15).  Data are expressed as mean ± S.E.M.     
 
 
3.4.6 CANTAB® Neuropsychological Battery  
 
There were a total of 65 participants in the study with each participant 
being assessed only on the one occasion.  Mean group CANTAB® scores 
are presented for all 2 groups for each of the subtests used  and their 
respective outcome measures; Pattern Recognition Memory (PRM), 
Spatial Recognition Memory (SRM), Intra/extra Dimensional Shift (IED), 
Stocking of Cambridge (SOC) and Choice Reaction Time(CRT). 
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3.4.6.1 Pattern Recognition Memory (PRM) 
 
Visual memory was assessed using the Pattern Recognition Memory 
(PRM) task in a 2-choice forced discrimination paradigm.  This test is 
sensitive to dysfunction in medial temporal areas of the brain (Sahakian 
and Owen, 1992) and relatively insensitive to dysfunction in the frontal 
lobe.  The test takes approximately 5 minutes to administer depending on 
level of impairment.    
The outcome measures which were examined for this test were; number of 
correct responses and mean correct latency (speed of subject’s response).  
There were significant differences found between the patient group and 
the control group across both outcome measures with controls (22.26 ± 
1.5) performing better than patients (19.45 ± 2.7), t (63) = 4.93, p<0.001 
for number of correct responses (figure 3.4and 3.5) and controls (1680.95 
± 529.70) performing better than patients (2432.49 ± 948.15), t (63) = -
3.85, p< 0.001 for mean correct latency (figure 3.6).   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the two outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined no 
statistically significant effects were found.   
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Figure 3.3 – Pattern Recognition Memory mean number of correct 
responses score (out of 24).  Patients (n=35), Controls (n=30).  Data are 
expressed as mean ± S.E.M.  Controls vs. Patients, difference p<0.001***    
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Pattern Recognition Memory spread of data for number of correct 
responses  
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Figure 3.4 – Pattern Recognition Memory number of correct responses 
(out of 24) scores grouped by patient (n=35) and control (n=30).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001***  
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Figure 3.5 – Pattern Recognition Memory mean correct latency ms.  
Patients (n=35), Controls (n=30).  Data are expressed as mean S.E.M.   
Controls vs. Patients, difference p<0.001***   
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3.4.6.2 Spatial Recognition Memory (SRM) 
 
Spatial Recognition Memory (SRM) is a test of visuo-spatial recognition 
memory in a forced-choice paradigm.  This test is primarily sensitive to 
dysfunction in the frontal lobe, and relatively insensitive to temporal lobe 
damage (Sahakian and Owen, 1992).  The test takes approximately 5 
minutes to administer depending on level of impairment.   
The outcome measures which were examined for this test were; number of 
correct responses and mean correct latency (speed of subject’s response).  
There were significant differences found between the patient group and 
the control group across both outcome measures with controls (17.63 ± 
1.8) performing better than patients (15.22 ± 2.2), t (63) = 4.59, p<0.001 
for number of correct responses (figure 3.7and 3.8) and controls (1558.97 
± 754.9) performing better than patients (2123.45 ± 816.5), t (63) = -2.87, 
p< 0.001 for mean correct latency (figure3.9).   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the two outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined no 
statistically significant effects were found.   
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Figure 3.6 – Spatial Recognition Memory mean number of correct 
responses score (out of 20).  Patients (n=35), Controls (n=30).  Data are 
expressed as mean ± S.E.M.   Controls vs. Patients, difference p<0.001***  
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Figure 3.7 – Spatial Recognition Memory number of correct responses 
(out of 24) scores grouped by patient (n=35) and control (n=30).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.00***.   
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Figure 3.8 – Spatial Recognition Memory mean correct latency ms.  
Patients (n=35), Controls (n=30).  Data are expressed as mean S.E.M.   
Controls vs. Patients, difference p<0.001*** 
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3.4.6.3 Intra/extra Dimensional Shift (IED) 
 
IED Set Shift (IED) is a test of rule acquisition and reversal.  It features; 
visual discrimination, attentional set formation, maintenance, shifting and 
flexibility of attention.  This test is primarily sensitive to changes in the 
fronto-striatal areas of the brain (Sahakian and Owen, 1992).  The test 
takes approximately 7 minutes to administer depending on level of 
impairment.   
There outcome measures which were examined for this test were; total 
stages completed, total errors, pre extra dimensional shift errors and post 
extra dimensional shift errors.  There were significant differences found 
between the patient group and the control group across all of the outcome 
measures with controls (8.93 ± 0.3) performing better than patients (7.88 ± 
0.9), t (63) = 5.78, p<0.001 for total stages completed (figure 3.10), 
controls (13.16 ± 6.1) performing better than patients (30.05 ± 14.2), t (63) 
= -6.03, p< 0.001 for total errors (figure 3.11 and 3.12), controls (5.12 ± 1.3) 
performing better than patients (7.51 ± 7.7), t (63) = -1.11, p<0.05 for pre 
extra dimensional shift errors (figure 3.13 and 3.14) and controls (7.12 ± 
6.1) performing better than patients (17.85 ± 10.6), t (63) = -4.95, p<0.001 
for post extra dimensional shift errors (figure 3.15 and 3.16).     
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the four outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined 
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significant relationships were found between negative symptoms scores 
and all four outcome measures; [coef = -0.12, t (33) = -2.56, p<0.05] for 
total stages completed (figure 3.17), [coef = 1.86, t (33) = 2.60, p<0.05] for 
total errors (figure 3.18), [coef = 0.85, t (33) = 2.13, p<0.05] for pre extra 
dimensional shift errors (figure 3.19) and [coef = 1.42, t (33) = 2.69, 
p<0.05] for post extra dimensional shift errors (figure 3.20).  
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Figure 3.9 – Intra/extra Dimensional Shift total stages completed (total 9) 
Patients (n=35), Controls (n=30).  Data are expressed as mean S.E.M.   
Controls vs. Patients, difference p<0.001*** 
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Figure 3.10 – Intra/extra Dimensional Shift total errors.  Patients (n=35), 
Controls (n=30).  Data are expressed as mean S.E.M.   Controls vs. 
Patients, difference p<0.00*** 
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Figure 3.11 – Intra/extra Dimensional Shift total errors scores grouped by 
patient (n=35) and control (n=30).  Data are expressed as median (IQR), 
whiskers represent lowest and highest values.  Controls vs. patients, 
difference p<0.001*** 
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Intra/extra Dimensional Shift mean pre-extra dimensional shift errors 
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Figure 3.12 – Intra/extra Dimensional Shift pre-extra dimensional shift 
errors.  Patients (n=35), Controls (n=30).  Data are expressed as mean 
S.E.M.   Controls vs. Patients, difference p<0.05* 
 
 
Intra/extra Dimensional Shift spread of data for pre-extra dimensional 
shift errors 
Groups
IE
D
PE
D
Controls Patients
0
10
20
30
40 *
 
Figure 3.13 – Intra/extra Dimensional Shift pre-extra dimensional shift 
errors scores grouped by patient (n=35) and control (n=30).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.05*  
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Intra/extra Dimensional Shift mean post-extra dimensional shift 
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Figure 3.14 – Intra/extra Dimensional Shift post-extra dimensional shift 
errors.  Patients (n=35), Controls (n=30).  Data are expressed as mean 
S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 3.15 – Intra/extra Dimensional Shift post-extra dimensional shift 
errors scores grouped by patient (n=35) and control (n=30).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001*** 
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Intra/extra Dimensional Shift stages completed correlation to PANSS 
negative score 
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Figure 3.16 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift stages complete outcome measure in patients (n=35).  Y 
axis = IED stages complete and X axis = PANSS negative score, p<0.05*  
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Figure 3.17 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift total errors outcome measure in patients (n=35).  Y axis 
= IED total errors and X axis = PANSS negative scores, p<0.05*   
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Figure 3.18 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift pre-extra dimensional shift errors outcome measure in 
patients (n=35).  Y axis = IED pre-extra dimensional shift errors and X axis 
= PANSS negative scores, p<0.05* 
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Figure 3.19 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift post-extra dimensional shift errors outcome measure in 
patients (n=35).  Y axis = IED post-extra dimensional shift errors and X 
axis = PANSS negative scores, p<0.05*   
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3.4.6.4 Stockings of Cambridge  
 
Stockings of Cambridge (SOC) is a test of working memory and spatial 
planning, which give a measure of frontal lobe function (Sahakian and 
Owen, 1992).  The test takes approximately 10 minutes to administer 
depending on level of impairment.   
The outcome measures which were examined for this test were; mean 
moves (5 move problems), mean initial thinking time (5 move problems), 
mean subsequent thinking time (5 move problems) and problems solved in 
minimum moves.  There were significant differences found between the 
patient group and the control group in two of the outcome measures with 
controls (6.76 ± 1.1) performing better than patients (8.24 ± 2.1), t (63) = -
3.47, p<0.001 for mean moves (5 move problems) (figure 3.21and 3.22) 
and controls (8.53 ± 2.2) performing better than patients (6.57 ± 2.1), t (63) 
= 3.75, p< 0.001 for problems solved in minimum moves (figure 3.23 and 
3.24).  No statistically significant differences were found between controls 
(5056.23 ± 4472.26) and patients (4400.70 ± 5434.19), t (63) = 0.52, p = 
0.60 for mean initial thinking time (5 move problems) (figure 3.25) and 
between controls (1220.49 ± 2463.47) and patients (2295.59 ± 3368.06), t 
(63) = -1.44, p = 0.15 for mean subsequent thinking time (5 move 
problems) (figure 3.26).     
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the four outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
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performance on the outcome measures for patients was examined no 
statistically significant effects were found.   
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Figure 3.20 – Stockings of Cambridge mean number of moves made (5 
move problems).  Patients (n=35), Controls (n=30).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 3.21 – Stockings of Cambridge mean number of moves (5 move 
problems) grouped by patient (n=35) and control (n=30).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001*** 
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Figure 3.22 – Stockings of Cambridge mean number of problems solved 
in minimum moves.  Patients (n=35), Controls (n=30).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 3.23 – Stockings of Cambridge mean number of problems solved 
in minimum moves grouped by patient (n=35) and control (n=30).  Data 
are expressed as median (IQR), whiskers represent lowest and highest 
values.  Controls vs. patients, difference p<0.001*** 
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Figure 3.24 – Stockings of Cambridge mean initial thinking time ms (5 
move problems).  Patients (n=35), Controls (n=30).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference N/S. 
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Figure 3.25 – Stockings of Cambridge mean subsequent thinking time ms 
(5 move problems).  Patients (n=35), Controls (n=30).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference N/S. 
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3.4.6.5 Choice Reaction Time (CRT) 
 
Choice Reaction Time (CRT) is a 2-choice reaction time test which 
measures simple reaction time through the use of two possible stimuli and 
two possible responses.  It is useful for testing general alertness and 
motor speed and is often sensitive to medication effects (Sahakian and 
Owen, 1992).  The test takes approximately 7 minutes to administer 
depending on level of impairment.   
The outcome measures which were examined for this test were; total 
correct trials and mean correct latency (speed of subject’s response).  
There were significant differences found between the patient group and 
the control group in both of the outcome measures with controls (99.26 ± 
0.7) performing better than patients (97.65 ± 3.9) p<0.05 for total correct 
trials (figure 3.27and 3.28) and controls (335.46 ± 57.9) performing better 
than patients (399.26 ± 126.9) p< 0.05 for mean correct latency (figure 
3.29).   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the four outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined no 
statistically significant effects were found.   
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Figure 3.26 – Choice Reaction Time mean number of total trials correct 
(100 trails).  Patients (n=35), Controls (n=30).  Data are expressed as 
mean S.E.M.   Controls vs. Patients, difference p<0.05* 
 
 
Choice Reaction Time spread of data for number of total trials correct   
Groups
C
R
T 
TT
C
Controls Patients
70
80
90
100
110
*
 
Figure 3.27 – Choice Reaction Time number of total trials (100 trials) 
correct grouped by patient (n=35) and control (n=30).  Data are expressed 
as median (IQR), whiskers represent lowest and highest values.  Controls 
vs. patients, difference p<0.05*   
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Figure 3.28 – Choice Reaction Time mean correct latency ms.  Patients 
(n=35), Controls (n=30).  Data are expressed as mean S.E.M.   Controls 
vs. Patients, difference p<0.05* 
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3.5 Discussion  
 
In the current study deficits in cognitive performance were identified 
across a number of domains (visual memory, spatial memory, executive 
function, working memory, planning and attention) in both South Asian and 
Caucasian samples of first episode psychosis patients compared to 
healthy controls.  Patients were recruited from the Bradford District NHS 
Care Trust, Early Intervention Service along with the control group which 
was recruited from the same geographical area and matched as closely as 
possible in relation to demographics (ethnicity, age, years in education 
and gender) and IQ scores. The present study is among one of the first to 
examine cognitive functioning in first episode psychosis patients from a 
South Asian population as historically this community has been hard to 
access because of their lack of engagement with mental health services 
due to cultural insensitivities (Bowl 2007) compared to first episode 
patients from a Caucasian population who are commonly represented in 
first episode psychosis research studies.   
The current study demonstrates that first episode psychosis patients 
display the same cognitive deficits  as those  seen in individuals with 
chronic schizophrenia (Patel et al., 2006; Hughes et al., 2003; Elvevag 
and Goldberg, 2000)  and in other first episode psychosis studies 
(Rodriguez-Sanchez et al., 2007; Gonzalez-Blanch et al., 2007, Townsend 
and Norman 2004) regardless of ethnicity.     
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With respect to diagnostic sub groups we demonstrated that there were no 
significant differences observed in first episode psychosis patients across 
any of the domains tested, which is in agreement with the hypothesis that 
cognitive deficits are a core feature of all schizophrenia spectrum 
disorders (Holmen et al., 2010; Groom et al., 2008; Townsend, 2002).  
When comparisons were made between different medication regimes and 
neuropsychological performance in the first episode psychosis patients we 
found that there were no significant differences, thus supporting the 
argument that the impact of medication on improving cognition in patients 
is limited (Faber et al., 2011; Goldberg et al., 2007; Mishara and Goldberg 
et al., 2004).  However the groups were too small to investigate individual 
treatment regimes of patients with any real confidence.  There was also no 
significant correlation found between gender and performance on 
neuropsychological tests within and between groups, thus supporting 
previous findings (Torniainen et al., 2011; Albus et al., 1997; Goldberg et 
al 1995) however this again could be an effect of a small sample size.   
 
In the current study evidence was found to support the hypothesis that 
negative symptom expression in patients is associated with cognitive 
deficits in particular domains (Grant and Beck 2009; Ayres et al 2007; 
Harvey et al., 2006) suggesting that negative symptoms may predict the 
severity of cognitive function.  This would also suggest that an 
improvement in negative symptoms may potentially result in an 
improvement in cognitive performance in certain domains (Lincoln et al., 
2011; Greenwood et al., 2005; Addington et al., 1991).  We found no 
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significant differences between the South Asian and Caucasian patients in 
symptom expression across the positive, negative and general scales of 
the PANSS.     
When controlling for pre-morbid IQ scores between first episode patients 
and controls we found no significant differences in performance on the 
neuropsychological tests which is in agreement with previous findings (Hill 
et al., 2009; Goldberg et al., 2009; Huddy et al., 2007).  However some 
studies have shown that the level of pre-morbid IQ is a predictor of 
cognitive and functional outcome in first episode psychosis patients 
(Leeson et al., 2009; Woodberry et al., 2008; Kremen et al., 2008) 
however, the present study does not support this conclusion.  There have 
also been other studies where pre-morbid IQ between that patient and the 
control group has not been controlled for and this automatically leads to a 
bias in the results of the neuropsychological tests (Rodriguez-Sanchez et 
al., 2010; Jahshan et al., 2010; Zanello et al., 2009).  This evidence 
therefore suggests that cognitive deficits may be a core feature of the 
illness rather than early developmental abnormalities and subsequent 
deterioration following the onset of symptoms (Perez-Iglesias et al., 2010; 
Green et al., 2006; Bilder et al., 1992).   
Results from the present study have shown that first episode psychosis 
patients of both South Asian and Caucasian origin are significantly 
impaired in visual memory when compared to a healthy control group. 
Statistically significant differences were found in both of the outcome 
measures that were assessed; number of correct responses and mean 
correct latency.  However, we did not find any significant relationships 
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between demographics or pre morbid IQ and subsequent 
neuropsychological performance between and within groups and also no 
correlation between symptom expression and neuropsychological 
performance in patients for this particular domain.    
The deficits observed in visual memory suggest that first episode 
psychosis patients have a reduced ability to discriminate between familiar 
and novel stimuli and may also have difficulty in retaining visual 
information for short periods of time.  These results are in agreement with 
those found by Levaux et al., (2007) who evaluated the methodological 
strengths and weaknesses of CANTAB® as a neuro-cognitive battery for 
schizophrenia.  They showed how CANTAB® has been used successfully 
to highlight the range of visuo-spatial cognitive deficits in  psychosis and 
schizophrenia and that the validity of results produced are similar to those 
obtained with other more traditional neuropsychological tests.    
Research by Chen et al (2009) investigated visual processing of facial and 
non-facial information in schizophrenia.  They found that patients showed 
significantly reduced accuracy in visual detection of faces and non-faces 
and that the pattern of results in their research suggested that greater 
signal strength is required for visual and cognitive processing of facial and 
non-facial information in patients.   
Tan (2009) has shown how visual memory is less extensively studied than 
other cognitive domains in early psychosis and chronic schizophrenia, but 
appears to be equally affected by the illness.  He reported that the recall of 
visual objects in patients is significantly impaired when compared to a 
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healthy control population and that there may be a possibility that  further 
decline is associated with duration of the illness, thus proposing that 
cognitive remediation of this domain is necessary to prevent further 
deterioration.    
The present study found that there is a significant deficit in spatial memory 
in first episode psychosis patients when compared to healthy controls.  
Statistically significant differences between the two groups were observed 
in both outcome measures assessed; number of correct responses and 
mean correct latency.  However, we did not find any significant 
relationships between demographics or pre morbid IQ and subsequent 
neuropsychological performance between and within groups and also no 
correlation between symptom expression and neuropsychological 
performance of patients in this particular domain.   
The deficits found in spatial memory in our study are in agreement with 
previous findings by Pantelis et al., (1997) who in their study of fronto-
striatal cognitive deficits found that patients showed impairments on a 
visuo-spatial memory span task compared to other groups – normal 
controls and patients with other neurological disorders.  They reported that 
patients appeared to be unable to develop a systematic strategy to 
complete spatial memory tasks, relying instead on a limited visuo-spatial 
memory span.  Research by Badcock et al., (2005) has also shown how 
deficits in spatial memory exist in patients with psychosis and 
schizophrenia compared to healthy controls and bi-polar disorder patients.  
They found that in patients with psychosis and schizophrenia, poor spatial 
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memory was a significant predictor of planning impairments, consistent 
with failures in goal selection, evaluation and execution.   
In a meta-analysis by Stip et al., (2008) looking at visuo-spatial profiles of 
psychosis and schizophrenia patients, they found that there was a 
consistent trend for patients to perform below par compared to healthy 
controls in visuo-spatial tasks.  They concluded that the CANTAB® 
appears to be a useful and relevant neuropsychological tool to evaluate 
and describe the visuo-spatial profiles of schizophrenia and psychosis 
patients.   
In the present study results suggest that there was a significant deficit in 
executive function in first episode psychosis patients when compared to 
healthy controls.  Statistically significant differences between the two 
groups were observed in all of the outcome measures assessed; stages 
complete, total errors, pre-extra dimensional shift errors and post-extra 
dimensional shift errors.  However, we did not find any significant 
relationships between demographics or pre morbid IQ and subsequent 
neuropsychological performance between and within groups.  Although we 
did find a correlation between symptom expression and 
neuropsychological performance in patients in all four outcome measures 
of the test, with significant relationships between negative symptoms and 
subsequent neuropsychological performance on; stages complete, total 
errors, pre-extra dimensional shift errors and post-extra dimensional shift 
errors.     
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Deficits seen across executive function in the present study are typical of 
those seen in first episode and chronic schizophrenia patients.  The 
results suggest that patients have an inability to initiate appropriate actions 
and inhibit inappropriate actions when faced with a particular problem or 
situation.    Previous research has shown that there is a significant deficit 
in executive function in first episode psychosis and schizophrenia patients 
(Ceaser et al, 2008; Braw et al 2008, Almeida et al, 1995; Elliot et al, 
1995).  These findings may suggest that patients have difficulty in handling 
novel situations, decision making, troubleshooting and resisting temptation 
(Norman and Shallice 2000) which will all have an adverse effect on 
functional outcome.   
Research by McGurk et al., (2003) has shown how lack of problem solving 
abilities appears to be an important barrier to patients in choosing and 
maintaining employment.  They argue that deficits in executive function 
lead to patients settling for lower complexity jobs as these deficits cannot 
be compensated for through the use of aids and devices.  Problems 
solving skills cannot be easily learnt within a short time frame and require 
direct intervention by specialists (McGurk and Mueser 2006).  These 
findings suggest that deficits in executive function are a major barrier to 
good functional outcome in patients with psychosis and schizophrenia.   
The relationship found between negative symptoms and 
neuropsychological performance has been previously demonstrated.  
Addington et al., (1991) in their study exploring the relationship between 
symptoms of schizophrenia and cognitive performance found that 
cognitive deficits were more likely to be associated with high negative 
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symptoms ratings rather than positive symptoms.  In their study they 
assessed cognition using the Wechsler Adult Intelligence Scale (WAIS) 
and a battery of neuropsychological tests developed at the Montreal 
Neurological Institute and symptom expression was assessed with the 
Scale for the Assessment of Negative Symptoms (SANS) and Scale for 
the Assessment of Positive Symptoms (SAPS).  Both of the cognitive tests 
and the symptom rating scales were re-administered to the same sample 
at a 6 month follow-up period.  They found that at both time periods 
cognitive deficits were more likely to be associated with high negative 
symptoms.  Bassoo et al., (1998) in their research found that negative 
symptoms were associated with deficits involving intelligence, executive 
function and memory.  Psychotic symptoms were unrelated to deficits thus 
supporting the hypotheses that positive symptoms are less likely to be 
associated with neuropsychological performance and subsequent 
functional outcome.  The findings in the present study are in agreement 
with this previous research particularly in regards to the relationship 
between negative symptoms and performance in the test of executive 
function.   
Findings from the current study suggest that there is a significant deficit in 
working memory and planning in first episode psychosis patients when 
compared to healthy controls.  Statistically significant differences between 
the two groups were observed in two of the outcome measures assessed; 
mean moves (5move problems) and problems solved in minimum moves.  
However, we did not find any significant relationships between 
demographics or pre morbid IQ and subsequent neuropsychological 
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performance between and within groups and also no correlation between 
symptom expression and neuropsychological performance in this 
particular test in patients.   
Research by Tyson et al (2004) assessing planning ability in patients with 
schizophrenia and healthy controls found that patients were poorer than 
controls at baseline.  Our results are in agreement with these findings 
suggesting that patients have a reduced ability in forward planning when 
faced with problems of more complexity.  Other research by Wood et al 
(2003) has shown that spatial planning and working memory abilities are 
impaired in those at high risk for psychosis, thus suggesting that these 
deficits first occur at a prodromal phase. 
Zanello et al., (2009) in their study of working memory impairments in first 
episode psychosis and chronic schizophrenia patients found that reaction 
times were slower and accuracy was worse in both patient groups 
compared to healthy controls.  They also found that there were no 
differences in variables amongst the two patients groups thus suggesting 
that working memory deficits remain stable over time.    
Result from the current study report that there is a significant deficit in 
attention in first episode psychosis patients when compared to healthy 
controls.  Statistically significant differences between the two groups were 
observed in both of the outcome measures assessed; total trials correct 
and mean correct latency.  However, we did not find any significant 
relationships between demographics or pre morbid IQ and subsequent 
neuropsychological performance between and within groups and also no 
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correlation between symptom expression and neuropsychological 
performance in this particular test in patients.   
Deficits observed in the attention domain suggest that patients have 
problems in sustaining their attention over a period of time and also 
display slower reaction times compared to healthy controls. This lack of 
attention and slowness of reactions could potentially be caused by a 
number of different factors with medication side effects being one of the 
most important.  Previous research has shown how attentional deficits are 
a core feature of cognitive symptoms in schizophrenia and are usually 
apparent before the onset of the illness (Cornblatt and Keilp, 1994) again 
suggesting cognitive decline in the prodromal phase.   
Research by de Jong et al., (2010) in patients with psychosis and 
schizophrenia suggested that patients compared to healthy controls have 
modality-specific attention deficits when attempting to integrate information 
and Yun et al., (2011) in their research demonstrated how patients with 
psychosis displayed longer reaction times on the Choice Reaction Time 
test from CANTAB® compared to healthy controls.         
Limitations of the current study were that we were only able to recruit a 
relatively small number of patients due to patient availability and resources 
available to the recruitment team.  For future investigations it will be 
important to have a larger sample size with a more balanced male to 
female ratio.  We were unable to gain reliable information about duration 
of untreated psychosis or parental socio-economic status and educational 
achievement.  Furthermore, for future investigations the inclusion of a 
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group of long term schizophrenia patients from the same ethnic 
populations would allow for further comparisons to be made in regards to 
severity of cognitive decline and its association with longitudinal outcomes.  
It may also be of interest to recruit unaffected siblings of first episode 
psychosis patients to assess their neuropsychological functioning and to 
look for any prodromal signs in individuals at genetic risk for psychosis.   
In conclusion, first episode South Asian and Caucasian patients display 
significant cognitive deficits across a number of domains when tested on 
subtests of the CANTAB® when compared to a healthy control group.   
This study shows how cognitive deficits exist across all patient groups who 
have experienced a first episode of psychosis regardless of ethnicity, age, 
gender, cultural background, years of education and pre-morbid IQ.  We 
have also shown how negative symptoms in patients correlate with 
neuropsychological deficits on the task assessing executive function.  The 
results suggest that population based neuropsychological studies of first 
episode psychosis in minority populations are useful and allow for further 
investigations.  This study also consolidates the argument that more 
needs to be done with respect to helping patients improve their cognition 
through the use of pharmacological therapies and cognitive remediation 
therapy.   
The next chapter of this thesis will investigate the cognitive deficits in 
chronic schizophrenia patients (inpatients) compared to a matched healthy 
control group using the same methodology already described (chapter 2).   
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Chapter 4 
Investigation into the cognitive deficits of chronic schizophrenia 
patients as assessed by the Cambridge Neuropsychological Test 
Automated Battery (CANTAB®) 
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4.1 Introduction  
 
Although schizophrenia is an illness that has been historically 
characterized by the presence of positive symptomatology (Schneider, 
1959) decades of research highlight the importance of cognitive deficits in 
this disorder (Lesh et al., 2011; Trivedi, 2006; Aleman et al., 1999; 
Heinrichs and Zakzanis, 1998; Gold and Harvey, 1993; Saccuzzo and 
Braff, 1981).   
Cognitive dysfunction is now considered a primary characteristic of 
schizophrenia (Kurtz, 2005; O’Carroll 2000; Aleman et al., 1999) with 
recent investigations beginning to highlight when the dysfunction develops 
in the individual afflicted by the disorder (Hawkins et al., 2008; Cervellione 
et al 2007; Addington et al., 2005).  Research to date provides evidence 
for significant cognitive impairments prior to onset of psychosis in the 
prodromal phase (Woodberry et al., 2008; Caspi et al., 2003; Fuller et al., 
2002).  However, less is known about the course of cognitive dysfunction 
from initial onset to the chronic phase of schizophrenia, with some studies 
suggesting further deterioration at later stages of the illness (Kurtz 2005; 
Granholm et al., 2000; Gold et al., 1999).   
The cognitive domains which have been identified as the most affected in 
patients with schizophrenia are memory (Anticevic et al., 2011; Kalkstein 
et al., 2010; Badcock et al 2005), executive function (Yun et al., 2011; 
Ceaser et al., 2008; Tyson e al., 2004), spatial planning (Laroi et al., 2011; 
Badcock et al., 2005, Pantelis et al., 1997) and attention (Backes et al., 
2011; Luck and Gold, 2008; Sharma and Antonova, 2003).  The 
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relationship between symptomatology and cognitive deficits in 
schizophrenia has also been explored by a number of researchers with 
varied results (Grant and Beck, 2009; Addington et al., 2005; Walder et al., 
2000).  There is evidence to both support that there is, and is not, a causal 
relationship, with a significant emphasis on negative symptomatology and 
cognition (Bozikas et al., 2004; Basso et al., 1998; Goldberg 1993).  
Researchers have consistently shown that cognitive deficits associated 
with schizophrenia are directly related to functional outcome in patients 
and can be considered one of the biggest obstacles in patient recovery 
(Schmidt et al., 2011; Green, 2006; Green et al 2000).  The need for more 
effective treatment types to help remediate some of these deficits has 
been highlighted (Wykes and Spaulding, 2011; Wykes 2010; Wykes and 
van der Gaag, 2001).   
Current treatments of cognitive deficits in schizophrenia are limited with 
little or no evidence to suggest that any form of effective pharmacological 
treatment has yet been identified (Buchanan et al., 2011; Roesch-Ely et al., 
2010; Gold, 2004).  However, recently there have been advances in the 
field of psychological approaches in relation to cognitive remediation (see 
chapter 5) which appear to show more promise (Royer et al., 2011; 
Lewandowski et al., 2011; Grynszpan et al., 2011).  There have been 
suggestions that the most effective strategy would be a combined 
approach of add-on pharmacological agents and psychological therapies 
(Wykes et al., 2011; Barnett et al., 2010; Goldberg and Gold, 2009).   
Techniques used to assess cognitive deficits in patients with 
schizophrenia vary between studies (Barnett et al., 2010; Chianetta et al., 
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2008; Keefe et al., 2004).  Historically researchers have used pen and 
paper based tests to assess neuro-cognition (Carter and Barch, 2007; 
Malla et al., 2004; Amminger et al., 2002), however the use of batteries of 
tests which are computer based has become more common (Kertzman et 
al., 2008; Kraus et al 2007), as they can offer numerous advantages such 
as; accurate recordings of response times, no rater bias (as all recordings 
are automated), the exclusion of inter-rater reliability and test/retest validity 
(Barnett et al., 2010; Butcher et al., 2004; Schatz and Browndyke, 2002).   
The National Institute of Mental Health (NIMH) sponsored Measurement 
and Treatment Research to Improve Cognition in Schizophrenia 
(MATRICS) programme has, based on expert opinion (Kern et al., 2004) 
recommended the use of ten standardised neuropsychological tests – 
Matrics Consensus Cognitive Test Battery (MCCB) - which they believed 
will help researchers to identify key cognitive domains relevant to 
schizophrenia and related disorders and would standardise methodology 
and allow direct comparisons to be made between studies.  They 
proposed that standardisation of neuropsychological tests, both 
administration and scoring increases the quality of the data (Nuechterlein 
et al., 2008; Green and Nuechterlein, 2004; Green et al., 2004).  The use 
of this battery is not widespread as yet as it excludes numerous tests 
which have been developed to assess neuro-cognitive functioning in 
patients with various psychiatric illnesses.    
In the present study we have not used the MCCB, but have used the 
Cambridge Neuropsychological Test Automated Battery (CANTAB®) which 
has also been highly validated for the use of neuropsychological testing in 
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patients with schizophrenia (Stip et al., 2008 Levaux et al., 2007; Lowe 
and Rabbitt, 1998).   
 
4.2 Study Aim  
 
The aim of the current study was to investigate cognitive function in 
chronic schizophrenia patients in an inpatient setting compared to healthy 
controls and to examine the relationship of demographic factors such as 
age, years in education and gender on cognitive function.  The impact of 
pre-morbid IQ on neuropsychological functioning was also examined.  In 
patients the effects of medication, the relationship of diagnoses and finally 
the effects of symptom expression on subsequent neuropsychological 
scores were examined.     
 
4.3 Methods 
 
See Chapter 2 for full description of methods used.     
   
4.4 Results  
 
 
4.4.1 Participant assessment schedule   
 
All participants took part in the same assessment procedures in relation to 
pre-morbid IQ testing and neuropsychological assessments, with the 
patient groups having an additional assessment for symptom expression.  
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Each of the subjects completed all of their assigned tasks on one occasion.  
The flow of participants through the study is represented by figure (4.1).
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4.4.2 Participant Demographics  
 
All participants who took part in the study completed the Wechsler Test of 
Adult Reading (WTAR) on entry.  Following on from this, subjects 
completed five subtests from the Cambridge Neuropsychological Test 
Automated Battery (CANTAB®), with the chronic schizophrenia patients 
rated for symptom expression using the Positive and Negative Syndrome 
Scale (PANSS).  Age of participants ranged from 19 - 38 years for controls 
(male 19 – 38 and female 20 – 35) and 20 – 42 for patients (male 22 – 42 
and female 20 – 31).  There were 10 males and 7 females both in the 
control and patient groups.  When participants were compared by ethnicity, 
mean age, years in education, gender and pre-morbid IQ scores, there 
were no significant differences (Table 4.1).  When patients were examined 
in relation to diagnoses and medication status, no significant effects were 
found.  Throughout the study no undesirable effects were reported at any 
stage by any of the participants to the researcher (MS) or any other health 
care professional. 
Ch
ap
te
r 
4 
 
Ch
ro
ni
c 
Sc
hi
zo
ph
re
ni
a 
13
1 
  
M
ea
n 
 
Ag
e 
   
   
   
(Y
ea
rs
) 
G
en
de
r 
(m
/f)
 
M
ea
n 
 
Ed
uc
at
io
n 
 
(Y
ea
rs
) 
M
ea
n 
 
W
TA
R
   
   
   
 
(S
S)
 
M
ea
n 
To
ta
l 
PA
N
SS
   
   
(P
) 
M
ea
n 
To
ta
l 
PA
N
SS
   
   
(N
) 
M
ea
n 
 
To
ta
l  
PA
N
SS
  
(G
)  
   
   
 
C
on
tro
ls
  
(N
 =
 1
7)
 
26
.4
 
±1
.3
 
10
/7
 
12
.2
 
±0
.3
 
90
.8
 
±2
.7
 
N
/A
 
N
/A
 
 
 
N
/A
 
Pa
tie
nt
s 
 
(N
 =
 1
7)
  
29
.5
 
±1
.5
 
10
/7
 
12
.4
 
±0
.3
 
93
.7
 
±2
.9
 
13
.1
 
±0
.7
 
   
   
21
.7
 
   
   
±0
.9
 
  3
0.
1 
±1
.5
 
P 
va
lu
e 
 
0.
15
 
N
/A
 
0.
66
 
0.
48
 
N
/A
 
N
/A
 
N
/A
 
 Ta
bl
e 
4.
1 
– 
D
em
og
ra
ph
ic
 d
at
a 
an
d 
P
A
N
S
S
 s
co
re
s 
fo
r C
on
tro
ls
 a
nd
 P
at
ie
nt
s.
  (
N
), 
N
um
be
r o
f p
at
ie
nt
s 
in
 e
ac
h 
gr
ou
p.
  M
al
e 
(M
), 
Fe
m
al
e 
(F
). 
 W
ec
hs
le
r T
es
t o
f A
du
lt 
R
ea
di
ng
 (W
TA
R
). 
 S
ta
nd
ar
d 
S
co
re
 (S
S
). 
 P
os
iti
ve
 S
ym
pt
om
s 
(P
), 
N
eg
at
iv
e 
S
ym
pt
om
s 
(N
), 
G
en
er
al
 S
ym
pt
om
s 
(G
). 
D
at
a 
ar
e 
ex
pr
es
se
d 
as
 m
ea
n 
± 
S
.E
.M
Chapter 4  Chronic Schizophrenia 
132 
 
4.4.3 Patient Medication Status and Diagnoses  
 
The status of patient medication and diagnoses were considered.  Patients 
were divided into separate groups depending on the type of medication 
they were currently taking (see table 2.3) and the relationship between 
performance on the CANTAB® tests and medication was assessed.  No 
significant relationships were found between the types of medication that 
patients were on and subsequent scores on the neuropsychological tests.  
Similarly patients were divided into diagnostic categories (see table 2.1) 
and the relationship between performance on the CANTAB® tests and 
diagnostic status was examined.  There were also no significant 
relationships found between patient diagnoses and neuropsychological 
performance.  
 
4.4.4 Symptom Expression in Patients  
 
Symptom expression was assessed in the patients using the Positive and 
Negative Syndrome Scale (PANSS).  There are three main symptom 
groups that the PANSS assesses; positive symptoms (which include 
hallucinations and delusions), negative symptoms (which include social 
withdrawal and blunted affect) and general symptoms (which include 
anxiety and depression).   Figure 4.3 shows that there were no significant 
differences in positive symptoms between male (13.6 ± 3.7) and female 
(12.5 ± 2.5), t (15) = 0.63, p = 0.53 patients, negative symptoms between 
male (18.8 ± 1.8) and female (16.4 ± 1.4), t (15) = 0.92, p = 0.36 patients 
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and general symptoms between male (29 ± 1.8) and female (27.4 ± 2.2) t 
(15) = 0.55, p =0.59 patients.     
 
Positive, Negative and General symptoms mean scores for Male and 
Female patients  
PANSSP PANSSN PANSSG
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Figure 4.2 – (P) Positive, (N) Negative and (G) General symptoms mean 
scores in (M) Male patients (n=10) and (F) Female patients (n=7).  Data 
are expressed as mean ± S.E.M.     
 
 
4.4.5 CANTAB® Neuropsychological Battery  
 
There were a total of 34 participants in the study with each participant 
being assessed only on one occasion.  Mean group CANTAB® scores are 
presented for both groups for each of the subtests used  and their 
respective outcome measures; Pattern Recognition Memory (PRM), 
Spatial Recognition Memory (SRM), Intra/extra Dimensional Shift (IED), 
Stocking of Cambridge (SOC) and Choice Reaction Time(CRT). 
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4.4.5.1 Pattern Recognition Memory (PRM) 
 
The two outcome measures which were examined for this test were; 
number of correct responses and mean correct latency (speed of subject’s 
response).  There were significant differences found between the patient 
group and the control group across both outcome measures with controls 
(22.05 ± 1.6) performing significantly better than patients (17.47 ± 4.6), t 
(32) = 3.84, p<0.001 for number of correct responses (figure 4.3 and 4.4) 
and controls (1698. 89 ± 630.17) performing significantly better than 
patients (2955.47 ± 1480.76), t (32) = -3.21, p< 0.01 for mean correct 
latency (figure 4.5).   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the two outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined no 
statistically significant effects were found.   
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Figure 4.3 – Pattern Recognition Memory mean number of correct 
responses score (out of 24).  Patients (n=17), Controls (n=17).  Data are 
expressed as mean ± S.E.M.  Controls vs. Patients, difference p<0.001*** 
 
 
Pattern Recognition Memory spread of data for number of correct 
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Figure 4.4 – Pattern Recognition Memory number of correct 
responses(out of 24) scores grouped by patient (n=17) and control (n=17).  
Data are expressed as median (IQR), whiskers represent lowest and 
highest values.  Controls vs. patients, difference p<0.001*** 
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Pattern Recognition Memory mean correct latency  
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Figure 4.5 – Pattern Recognition Memory mean correct latency ms.  
Patients (n=17), Controls (n=17).  Data are expressed as mean S.E.M.   
Controls vs. Patients, difference p<0.01**   
 
4.4.5.2 Spatial Recognition Memory (SRM) 
 
The two outcome measures which were examined for this test were; 
number of correct responses and mean correct latency (speed of subject’s 
response).  Again there were significant differences found between the 
patient group and the control group across both outcome measures with 
controls (17.88 ± 1.2) performing better than patients (13.52 ± 2.5), t (32) = 
6.24, p<0.001 for number of correct responses (figure 4.6 and 4.7) and 
controls (1391±806.44) performing better than patients (2396.87 ± 
1192.63), t (32) = -2.87, p< 0.01 for mean correct latency (figure 4.8).   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the two outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
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performance on the outcome measures for patients was examined there 
were also no statistically significant effects found.   
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Figure 4.6 – Spatial Recognition Memory mean number of correct 
responses score (out of 20).  Patients (n=17), Controls (n=17).  Data are 
expressed as mean ± S.E.M.   Controls vs. Patients, difference p<0.001***   
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Figure 4.7 – Spatial Recognition Memory number of correct responses 
(out of 20) scores grouped by patient (n=17) and control (n=17).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001***  
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Figure 4.8 – Spatial Recognition Memory mean correct latency ms.  
Patients (n=17), Controls (n=17).  Data are expressed as mean S.E.M.   
Controls vs. Patients, difference p<0.01** 
 
4.4.5.3 Intra/extra Dimensional Shift (IED) 
 
The four outcome measures which were examined for this test were; total 
stages completed, total errors, pre extra dimensional shift errors and post 
extra dimensional shift errors.  There were significant differences found 
between the patient group and the control group across all of the outcome 
measures with controls (8.88 ± 0.4) performing better than patients (7.58 ± 
0.8), t (32) = 5.35, p<0.001 for total stages completed (figure 4.9), controls 
(15.52 ± 6.9) performing better than patients (21.82 ± 2.3), t (32) = -3.52, 
p< 0.001 for total errors (figure 4.10 and 4.11), controls (7.92 ± 4.3) 
performing better than patients (4.12 ± 1.3), t (32) = 1.11, p<0.05 for pre 
extra dimensional shift errors (figure 4.12 and 4.13) and controls (9.17 ± 
7.1) performing better than patients (20.82 ± 5.3), t (32) = -5.43, p<0.001 
for post extra dimensional shift errors (figure 4.14 and 4.15).     
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Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the four outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined 
significant relationships were found between negative symptoms scores 
and all four outcome measures; [coef = -0.14, t (15) = -2.12, p<0.05] for 
total stages completed (figure 4.16), [coef = 1.50, t (15) = 2.43, p<0.05] for 
total errors (figure 4.17), [coef = 0.79, t (15) = 1.95, p<0.05] for pre extra 
dimensional shift errors (figure 4.18) and [coef = 1.15, t (15) = 2.26, 
p<0.05] for post extra dimensional shift errors (figure 4.19). 
 
Intra/extra Dimensional Shift mean stages completed  
Controls Patients
0
2
4
6
8
10
Controls
M
ea
n 
sc
or
es
Patients
***
Intra/extra Dimensional Shift - Toal Stages Completed
 
Figure 4.9 – Intra/extra Dimensional Shift total stages completed (9 
stages).  Patients (n=17), Controls (n=17).  Data are expressed as mean 
S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 4.10 – Intra/extra Dimensional Shift total errors.  Patients (n=17), 
Controls (n=17).  Data are expressed as mean S.E.M.  Controls vs. 
Patients, difference p<0.001*** 
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Figure 4.11 – Intra/extra Dimensional Shift total errors scores grouped by 
patient (n=17) and control (n=17).  Data are expressed as median (IQR), 
whiskers represent lowest and highest values.  Controls vs. patients, 
difference p<0.001*** 
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Figure 4.12 – Intra/extra Dimensional Shift pre-extra dimensional shift 
errors.  Patients (n=17), Controls (n=17).  Data are expressed as mean 
S.E.M.   Controls vs. Patients, difference p<0.05* 
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Figure 4.13 – Intra/extra Dimensional Shift pre-extra dimensional shift 
errors scores grouped by patient (n=17) and control (n=17).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.05*   
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Intra/extra Dimensional Shift mean post-extra dimensional shift 
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Figure 4.14 – Intra/extra Dimensional Shift post-extra dimensional shift 
errors.  Patients (n=17), Controls (n=17).  Data are expressed as mean 
S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 4.15 – Intra/extra Dimensional Shift post-extra dimensional shift 
errors scores grouped by patient (n=17) and control (n=17).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001** 
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Intra/extra Dimensional Shift stages completed correlation to PANSS 
negative scores  
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Figure 4.16 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift stages complete outcome measure in patients (n=17).  Y 
axis = IED stages complete and X axis = PANSS negative score, p<0.05* 
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Figure 4.17 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift total errors outcome measure in patients (n=17).  Y axis 
= IED total errors and X axis = PANSS negative scores, p<0.05*   
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Figure 4.18 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift pre-extra dimensional shift errors outcome measure in 
patients (n=17).  Y axis = IED pre-extra dimensional shift errors and X axis 
= PANSS negative scores, p<0.05*   
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Figure 4.19 – Correlation of PANSS negative scores to Intra/extra 
dimensional shift post-extra dimensional shift errors outcome measure in 
patients (n=17).  Y axis = IED post-extra dimensional shift errors and X 
axis = PANSS negative scores, p<0.05*   
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4.4.5.4 Stockings of Cambridge  
 
The four outcome measures which were examined for this test were; mean 
moves (5 move problems), mean initial thinking time (5 move problems), 
mean subsequent thinking time (5 move problems) and problems solved in 
minimum moves.  There were significant differences found between the 
patient group and the control group in two of the outcome measures with 
controls (6.94 ± 1.2) performing better than patients (8.97 ±2.1), t (32) = -
3.56, p<0.001 for mean moves (5 move problems) (figure 4.20 and 4.21) 
and controls (8.41 ± 2.3) performing better than patients (5.76 ± 1.7), t (32) 
= 3.64, p< 0.001 for problems solved in minimum moves (figure 4.22 and 
4.23).  No statistically significant differences were found across mean 
initial thinking time (5 move problems) (figure 4.24) and mean subsequent 
thinking time (5 move problems) (figure 4.25) between controls and 
patients.   
Further analysis using multiple linear regression to investigate the effects 
of ethnicity, age, years in education, gender and pre-morbid IQ scores on 
the four outcome measures showed no statistical significance.  When the 
relationship between, positive, negative and general PANSS scores and 
performance on the outcome measures for patients was examined there 
were also no statistically significant effects found.   
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Stockings of Cambridge mean number of moves made (5 move 
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Figure 4.20 – Stockings of Cambridge mean number of moves made (5 
move problems).  Patients (n=17), Controls (n=17).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 4.21 – Stockings of Cambridge mean number of moves (5 move 
problems) grouped by patient (n=17) and control (n=17).  Data are 
expressed as median (IQR), whiskers represent lowest and highest values.  
Controls vs. patients, difference p<0.001*** 
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Stockings of Cambridge mean number of problems solved in 
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Figure 4.22 – Stockings of Cambridge mean number of problems solved 
in minimum moves.  Patients (n=17), Controls (n=17).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference p<0.001*** 
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Figure 4.23 – Stockings of Cambridge mean number of problems solved 
in minimum moves grouped by patient (n=17) and control (n=17).  Data 
are expressed as median (IQR), whiskers represent lowest and highest 
values.  Controls vs. patients, difference p<0.001*** 
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Stockings of Cambridge mean initial thinking time (5 move problems)  
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Figure 4.24 – Stockings of Cambridge mean initial thinking time ms (5 
move problems).  Patients (n=17), Controls (n=17).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference N/S. 
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Figure 4.25 – Stockings of Cambridge mean subsequent thinking time ms 
(5 move problems).  Patients (n=17), Controls (n=17).  Data are expressed 
as mean S.E.M.   Controls vs. Patients, difference N/S. 
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4.4.5.5 Choice Reaction Time (CRT) 
 
The two outcome measures which were examined for this test were; total 
correct trials and mean correct latency (speed of subject’s response).  
There were significant differences found between the patient group and 
the control group in both of the outcome measures with controls (99.29 ± 
0.6) performing better than patients (95.82 ± 4.4), t (32) = 3.17, p<0.05 for 
total correct trials (figure 4.26 and 4.27) and controls (342.72 ± 58.49) 
performing better than patients (489.98 ± 232.84), t (32) = -2.52, p< 0.05 
for mean correct latency (figure 4.28).   
Further analysis using the multiple linear regression model to investigate 
the effects of ethnicity, age, years in education, gender and pre-morbid IQ 
scores on the four outcome measures showed no statistical significance.  
When the relationship between, positive, negative and general PANSS 
scores and performance on the outcome measures for patients was 
examined there were also no statistically significant effects found. 
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Figure 4.26 – Choice Reaction Time mean number of total trials correct 
(100 trials).  Patients (n=17), Controls (n=17).  Data are expressed as 
mean S.E.M.   Controls vs. Patients, difference p<0.05* 
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Figure 4.27 – Choice Reaction Time number of total trials (100 trials) 
correct grouped by patient (n=17) and control (n=17).  Data are expressed 
as median (IQR), whiskers represent lowest and highest values.  Controls 
vs. patients, difference p<0.05*   
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Figure 4.28 – Choice Reaction Time mean correct latency ms.  Patients 
(n=17), Controls (n=17).  Data are expressed as mean S.E.M.   Controls 
vs. Patients, difference p<0.05* 
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4.5 Discussion  
 
In the current investigation cognitive deficits were identified in all of the 
domains examined (visual memory, spatial memory, executive function, 
working memory, planning and attention) in the chronic schizophrenia 
patients compared to healthy controls.  The deficits observed appear to be 
similar to those deficits which have been identified in first episode patients 
(chapter 3) thus supporting the argument that cognitive deficits remain 
relatively stable over the course of the illness (Addington and Addington, 
2002).  Patients in the current study were recruited from the Becklin 
Centre Inpatient Unit which is part of the Leeds Partnership NHS 
Foundation Trust (LPFT) and controls were recruited from similar 
geographical areas and were matched in terms of intelligence and 
demographics (age, gender, ethnicity, and years of education) to the 
patient group.   
The current study demonstrates that patients with chronic schizophrenia 
display similar cognitive deficits as those seen in patients with first episode 
psychosis and other chronic schizophrenia studies (Sponheim et al., 2010; 
Zanello et al., 2009; Ojeda et al., 2007) even when patients and controls 
are matched in terms of pre-morbid intelligence and other confounding 
demographic factors.   
The current study shows that when diagnostic sub-categories of the DSM-
IVTR were taken into consideration for the schizophrenia spectrum 
disorders no significant differences in cognitive performance were found 
between patients, thus supporting the findings in the previous first episode 
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study (chapter 3) and the proposed hypothesis that cognitive deficits are a 
core feature of the illness regardless of the individual diagnoses (Barbeito 
et al., 2011; Green, 2006; Lewis, 2004).  Furthermore when comparisons 
were made between different medication regimes and subsequent 
neuropsychological performance no significant differences were found 
between patients.  These results again support the findings in the previous 
first episode study (chapter 3) along with other research investigating the 
effects of medication on cognitive function (Faber et al., 2011; Goldberg et 
al., 2007; Mishara and Goldberg et al., 2004).  However, unlike the 
previous first episode study (chapter 3), the patients in the current study 
were not taking atypical antipsychotics (but rather typicals), had been on a 
variety of different antipsychotic medications over the years and some of 
them were currently on a combination of antipsychotic medications.  The 
ineffectiveness of conventional antipsychotics compared to atypical agents 
in improving cognitive deficits have been highlighted in numerous studies 
in the past (Harvey et al., 2004; Harvey and Keefe, 2001; Lee et al., 1999) 
with some research suggesting that conventional antipsychotics can 
potentially contribute to neuropsychological deficits (Sharma, 2002; 
Sweeney et al., 1991).  In addition, the use of poly-pharmacy and 
excessive dosing of antipsychotics has been shown to be detrimental to 
patients in symptom expression along with neuropsychological functioning 
(Hori et al., 2006; Turkington et al., 2004).  
However, Kontis et al., (2010) in their study between the association of 
antipsychotic poly-pharmacy and high dosage with cognition in 
schizophrenia reported that, they failed to find significant differences in 
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measures of cognitive function between patients that were on poly-
pharmacy or received high antipsychotic doses and those that were 
prescribed only one antipsychotic agent or they received a total 
antipsychotic dose that was inside the normal range (Kontis et al., 2010).  
This study opposes the widely regarded assumption that poly-pharmacy 
has a detrimental effect on neuropsychological functioning in patients with 
schizophrenia.   
In the current study there were also no significant differences found 
between gender and neuropsychological performance between the groups 
thus supporting findings from the previous study (chapter 3) and previous 
research investigating the effect of gender on cognitive performance in 
patients with schizophrenia (Torniainen et al., 2011; Albus et al., 1997; 
Goldberg et al 1995).  When looking at the findings described above, it 
would be useful to remember that the sample sizes in the study were small 
due to lack of patient availability and resources available so it would be 
difficult to make any conclusions with real confidence about the effects of 
diagnostic sub types, medication status and gender on neuropsychological 
performance in patients with schizophrenia.     
When the effects of symptomatology were examined in the current study, 
there were no significant associations found between positive and general 
symptoms and neuro-cognitive functioning.  However there was a 
significant association identified between negative symptoms and 
subsequent neuropsychological functioning.  This association was 
primarily found in the domain of executive function on the intra/extra 
dimensional shift (IED) test of CANTAB®.  Significant associations were 
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found between negative symptoms and all four outcome measures (stages 
completes, total errors, pre-extra dimensional shift errors, post-extra 
dimensional shift errors) of the test.  This association was also found in the 
previous first episode study (chapter 3), thus suggesting that higher 
negative symptoms lead to poorer neuropsychological performance in 
patients at all stages of the illness; from first episode schizophrenia to 
chronic schizophrenia.  This association between negative symptoms and 
cognitive performance has been highlighted in previous studies of 
cognitive deficits in first episode and chronic schizophrenia (Lincoln et al., 
2011; Grant and Beck 2009; Ayres et al 2007; Harvey et al., 2006; 
Greenwood et al., 2005; Addington et al., 1991).   
In the current study, when the differences in pre-morbid intelligence and 
relation to neuropsychological functioning were examined in patients and 
controls no significant differences were found between the two groups.  
These findings suggest that intelligence does not have an effect on 
cognitive functioning and that the deficits observed in patients are a result 
of the actual illness rather than any other associated factors (Perez-
Iglesias et al., 2010; Green et al., 2006).  Similar results have been 
reported in other studies where all participants have been matched in 
terms of pre-morbid intelligence (Hill et al., 2009; Huddy et al., 2007).  
However, there is some evidence to suggest the contrary and some 
studies have shown that intellectual functioning can have a direct effect on 
neuropsychological performance especially in early stages of the illness 
(Leeson et al., 2009; Woodberry et al., 2008), but these studies have a 
focus on current intelligence levels rather than on pre-morbid levels of 
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intellectual functioning.  The results reported in the current study in 
regards to pre-morbid intelligence support the results found in the first 
episode study (chapter 3) in that no differences were found between 
patients and controls.   
Deficits in visual memory have not been investigated as vigorously as 
other cognitive domains such as attention, working memory and executive 
function (Tan, 2009).  However perceptual functions are frequently 
disrupted in schizophrenia and thus this domain has been included in the 
Cognitive Neuroscience Treatment Research to Improve Cognition in 
Schizophrenia (CNTRICS) and the MCCB (Butler et al., 2008).    
Findings reported in the current study show that patients with chronic 
schizophrenia have deficits in visual memory.   The two outcome 
measures examined were; number of correct responses and mean correct 
latency.  The performance of patients on the pattern recognition memory 
(PRM) test from CANTAB® showed that their ability to remember visual 
stimuli, discriminate between a familiar and novel visual stimulus and 
respond correctly to a given problem were all impaired compared to 
healthy controls.  The results from the current study support the findings of 
the previous chapter, where similar deficits were found in first episode 
patients in visual memory and this supports the argument that cognitive 
deficits are relatively stable throughout the course of the illness and are 
neuro-developmental rather than neuro-degenerative in nature.   
Research by Fleming-Ficek et al., (2006) investigating visual memory 
deficits in schizophrenia reported that, patients demonstrated normal 
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range performance on basic measures of visual perceptual skills but a 
majority of patients demonstrated impaired free recall on the visual 
memory task.  Their findings suggested that patients with schizophrenia 
have core visual memory impairments that are not accounted for by basic 
deficits in visual perceptual functioning.    
However, Kalkstein et al., (2010) in their review of neuro-cognition in 
schizophrenia reported that learning and memory deficits have been 
demonstrated extensively, with some evidence that recall of verbal 
material is more affected than recall of visual information, and that 
recognition abilities are comparatively less impaired than recall for both 
modalities.  
In the current study patients with chronic schizophrenia were shown to 
have cognitive deficits in the domain of spatial memory when compared to 
healthy controls.  The deficits observed in the current study were similar to 
those reported in the previous first episode study (chapter 3).  The deficits 
were observed in both outcome measures (number correct and mean 
correct latency) of the spatial recognition memory (SRM) test from 
CANTAB®.  The results suggest that patients with chronic schizophrenia 
have difficulty in not only remembering visual stimuli as discussed above 
but also have a reduced ability in remembering the location of visual 
stimuli along with increased amount of thinking times in order to choose 
the correct answer.   
Levaux et al., (2007) in their study of the use of CANTAB® in assessing 
visuo-spatial cognitive deficits in patients with schizophrenia reported that, 
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the use of a computerized battery presents some methodological and 
practical advantages over traditional neuropsychological tests.  The main 
advantage of CANTAB® is the standardization of administration, the 
rigorous experimental heritage of the CANTAB® and the wide range of 
data already collected have allowed effects to be related to particular 
components of cognitive function and to potential underlying neural 
substrates.  
Deficits in spatial memory have been reported in other studies of 
schizophrenia, Piskulic et al., (2007) in their meta-analysis of 33 studies 
between the period of 1992-2005 on spatial working memory impairment 
reported that it is evident that patients with schizophrenia are consistently 
more impaired on spatial working memory measures than healthy controls.  
They speculated that these impairments may be related to social disability 
and may explain some cognitive deficits that characterise the clinical 
presentation of schizophrenia.  Research by Badcock et al., (2005) has 
also shown how deficits in spatial memory exist in patients with 
schizophrenia compared to healthy controls and bi-polar disorder patients.  
They found that in patients with schizophrenia, poor spatial memory was a 
significant predictor of planning impairments, consistent with failures in 
goal selection, evaluation and execution.  The results from the current 
study, the previous first episode study (chapter 3) and other available 
literature suggest that deficits in spatial memory remain stable throughout 
the course of the illness with little changes over illness progression.  
In the current study significant deficits were found in executive functioning 
in patients with chronic schizophrenia compared to healthy controls.  The 
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deficits found in the chronic schizophrenia patients were similar to the 
deficits found in the first episode patients in the previous study (chapter 3).  
Significant differences were found on all four outcome measures (total 
stages completed, total errors, total pre extra-dimensional errors and total 
post extra-dimensional errors) of the intra/extra dimensional shift test (IED) 
from CANTAB®.  Importantly a significant relationship was also found 
between outcome scores on the IED test and the PANSS negative 
symptoms scores.  This relationship suggests that the higher the negative 
symptomatology of a patient the worse the performance in the executive 
function domain.  This finding was also reported in the first episode 
patients in the previous study (chapter 3).   
Deficits in executive function have been widely reported in studies of 
neuropsychological functioning in patients with schizophrenia (Ceaser et al, 
2008; Braw et al 2008, Almeida et al, 1995; Elliot et al, 1995) and the 
relationship between negative symptomatology and neuropsychological 
functioning has also been identified (Perlick et al., 2008; Harvey et al., 
2006; Kirkpatrick et al., 2006).  These deficits in executive functioning 
have been attributed as one of the most important factors in patients 
having poorer functional outcome throughout the course of the illness 
(Tabares-Seisdedos et al., 2008; Kerns et al., 2008; Green et al., 2006).   
Freedman and Brown, (2011) in their review of the developmental course 
of executive function in patients with schizophrenia reported that, a review 
of the research points to a number of persistent debates about the course 
of executive functioning and its relation to illness course.  A better 
understanding of the neuro-cognitive trajectories of executive function in 
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schizophrenia could help identify the risk and modifying factors that 
influence the onset, severity and course of disease and the chance to re-
direct or re-shape the course and improve outcomes.     
Penades et al., (2010) in their study investigating the need for executive 
functioning to be targeted to improve social functioning reported that, it 
was improvements in executive function which predicted improved daily 
functioning.  Consequently, in order to improve daily functioning executive 
function needs to be targeted despite multiple deficits being present 
across different domains. 
Kurtz (2006) in his review of studies conducted between 2001-2005 
investigating the relationship of symptoms and neuro-cognitive skills to 
everyday functioning in patients with chronic schizophrenia reported that, 
negative symptoms, such as social withdrawal, psychomotor slowing, and 
blunted affect and neuro-cognitive measures of attention, executive 
function, working memory, verbal memory and psychomotor speed were 
most commonly linked to all three domains of everyday functioning.  
However no significant relationships were identified between positive 
symptoms such as, delusions and hallucinations, cognitive functioning and 
everyday function.  The results in the present study support the findings 
discussed above, however, no significant relationships were found 
between negative symptoms and cognitive domains with the exception of 
executive functioning.   
In the current study, significant deficits were found in working memory and 
planning in patients with chronic schizophrenia compared to healthy 
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controls.  Again the deficits found in the chronic schizophrenia patients 
were similar to the deficits that were found in the first episode patients in 
the previous study (chapter 3).  Significant differences were found in two 
of the outcome measures (mean number of moves and problems solved in 
minimum moves) with no significant differences found in two of the 
outcome measures (mean initial thinking time and mean subsequent 
thinking time) in the stockings of Cambridge (SOC) test from CANTAB®.  
The significant differences found suggest that patients have a reduced 
ability in planning and problem solving when faced with problems which 
require a higher level of processing.  The outcome measures which 
showed no significant differences suggest that patients and controls do not 
differ in the amount of time they spend thinking about a problem and 
subsequently executing the plan.  However the performance on the actual 
test itself suggests that maybe patients do need to spend longer on 
planning their moves in order for them to have a higher correct response 
rate.   
Previous studies have shown how patients with schizophrenia display 
deficits in working memory and planning.  Kebir and Tabbane (2008) in 
their review of working memory in schizophrenia reported that, deficits in 
working memory are present early in the course of schizophrenia and 
have been shown consistently to be associated with reduced levels of 
elementary social skills and learning capacity.  They also found that 
unaffected relatives of individuals with schizophrenia demonstrate deficits 
in tasks designed to measure working memory function, thus making 
working memory dysfunction suitable candidate markers for vulnerability.   
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Badcock et al., (2005) in their study of spatial working memory and 
planning ability using the SOC test from CANTAB® found that patients with 
schizophrenia were impaired on the spatial span task (which requires the 
maintenance and retrieval of stored information), between search errors 
(which requires the maintenance and manipulation of information) and 
showed poor spatial working memory.  All of these deficits observed were 
significant predictors of planning impairments consistent with failures in 
goal selection, evaluation and execution.   
Attention deficits have been previously identified as being a core feature of 
schizophrenia as some form of attention is required across all of the 
cognitive domains and like other deficits has been shown to begin pre-
illness onset (Cornblatt and Kleip, 1994).  In the current study, deficits in 
attention were found in patients with schizophrenia which were 
comparable to the deficits found in the previous first episode study 
(chapter 3).  Significant differences were found in both of the outcome 
measures assessed (number correct and mean correct latency) in the 
choice reaction time (CRT) test from CANTAB®.  The deficits observed in 
the outcome measures in the current study suggest that patients have 
difficulty in sustaining their attention for a prolonged period of time and that 
their speed of correctly responding to a visual stimuli is also impaired 
when compared to a healthy control population.   
Fibley et al., (2008) in their study of, selective attention deficits reported 
that, patients performed more poorly than healthy controls on most 
attentional measures.  Non-affected relative’s and siblings performance on 
several attention measures was intermediate to patients and controls thus 
Chapter 4  Chronic Schizophrenia 
163 
 
suggesting that these attention deficits are indeed present in relatives 
although to a less extent than patients with schizophrenia. 
Other research by Luck and Gold, (2008) investigating the construct of 
attention have shown that almost any task can be considered an attention 
task.  After reviewing the available evidence they suggested that rule 
selection and the control of selection are impaired in patients with 
schizophrenia, whereas input selection and the implementation of 
selection are relatively unimpaired, especially when contribution from rule 
selection and attentional control are minimised.  The results reported in 
the current study and in the previous first episode study support the 
available literature which shows that attentional deficits are a core feature 
of schizophrenia.   
Limitations of the current study were that we were only able to recruit a 
modest number of patients due to patient availability and resources 
available to the recruitment team.  For future investigations it will be 
important to have a larger sample size with a more balanced male to 
female ratio.  We were unable to gain reliable information about duration 
of untreated psychosis or parental socio-economic status and educational 
achievement.  Furthermore, for future investigations the inclusion of a 
group of first episode schizophrenia patients would allow for direct 
comparisons to be made in regards to severity of cognitive decline and its 
association with longitudinal outcomes.  It may also be of interest to recruit 
unaffected siblings of patients to assess their neuropsychological 
functioning and to look for any prodromal signs in individuals at genetic 
risk for psychosis.   
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In conclusion, patients with chronic schizophrenia display significant 
cognitive deficits across a number of domains when tested on subtests of 
the CANTAB® when compared to a healthy control group.   This study 
shows how cognitive deficits exist even when level of pre-morbid 
intelligence is controlled for between patients and controls.  We have also 
shown how negative symptoms in patients correlate with 
neuropsychological deficits on the task assessing executive function.  This 
study also consolidates previous research which suggests that more 
needs to be done with respect to helping patients improve their cognition 
through the use of pharmacological therapies and cognitive remediation 
therapy.   
 
The next section of this chapter will investigate the differences between 
first episode and chronic schizophrenia patients in relation to 
demographics, intelligence, symptom expression and neuropsychological 
performance.    
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4.6 First episode versus chronic schizophrenia 
 
4.6.1 Demographics and symptom expression  
 
Differences between first episode psychosis and chronic schizophrenia 
patients were examined in relation to demographic details i.e., age, gender, 
pre-morbid intelligence and years in education.  Comparisons of symptom 
expression were also made for the two patient groups.   
Age of participants ranged from 18 – 39 for the first episode patients and 
20 – 42 for the chronic schizophrenia patients.  There were 26 males and 
9 females in the first episode group and 10 males and 7 females in the 
chronic schizophrenia group.   
When patients were compared in relation to gender, pre-morbid 
intelligence, and years in education, there were no significant differences 
between the two groups.  However when patients were compared in 
relation to age a significant difference was found with chronic 
schizophrenia patients being older (see table 3.2). 
When patients were compared in relation to symptom expression, no 
significant differences were found in positive and general symptoms, 
however a significant difference was found in negative symptoms with 
chronic schizophrenia patients scoring higher (see table 3.2).
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4.6.2 Neuropsychological performance  
 
Performance on the neuropsychological tests was compared between first 
episode and chronic schizophrenia patients.   
Results show that there were no significant differences between first 
episode and chronic schizophrenia patients in any of the outcome 
measures of the tests (see table 4.3).   
Comparisons of performance on the test of visual memory (PRM) showed 
that patients with chronic schizophrenia made more mistakes on the 
number correct outcome measure (figure 4.29) but this effect was not 
statistically significant (see table 4.3).  Similarly, patients with chronic 
schizophrenia performed worse on the number correct outcome measure 
(figure 4.30) of the spatial memory test (SRM), however again this was not 
of statistical significance (See table 4.3).   
Patients with chronic schizophrenia performed worse on the test of 
executive function (IED).  In one of the outcome measures; total number of 
errors (figure 4.31); there was almost a significant difference found 
between both groups (see table 4.3) 
Measures of spatial planning, working memory (SOC) and attention (CRT) 
showed that there were no differences between both patient groups with 
all patients performing similarly (see table 4.3).  
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Figure 4.29 – Pattern Recognition Memory mean number of correct 
responses score.  First episode patients (n=35), chronic schizophrenia 
(n=17).  Data are expressed as mean ± S.E.M.  FE patients vs. CS 
patients p =0.059 N/S 
 
 
Spatial Recognition Memory mean number of correct responses  
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Figure 4.30 – Spatial Recognition Memory mean number of correct 
responses score.  First episode patients (n=35), chronic schizophrenia 
(n=17).  Data are expressed as mean ± S.E.M.  FE patients vs. CS 
patients p =0.052 N/S 
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Intra/extra Dimensional Shift mean total errors  
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Figure 4.31 – Intra/extra dimensional shift mean total errors score.  First 
episode patients (n=35), chronic schizophrenia (n=17).  Data are 
expressed as mean ± S.E.M.  FE patients vs. CS patients p =0.055 N/S 
 
 
4.6.3 Discussion of first episode versus chronic schizophrenia 
patients  
 
In the comparisons made in relation to first episode and chronic 
schizophrenia patients the results show that there was a significant 
difference in terms of age between both groups with patients from the first 
episode group being significantly younger.  This finding is to be expected 
in terms of chronology as the first episode patients are at the very 
beginning of their illness (thus being younger) whilst the chronic patients 
have a long history of the illness (thus being older) with multiple episodes 
of psychosis.  The average age of onset for a first episode psychosis has 
been shown to be different between males and females with males usually 
presenting at an earlier age (Baldwin et al., 2005; Welham et al., 2004; 
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Meltzer et al., 1997) therefore the average age of females with a chronic 
illness is usually higher than males.   
There were significant differences found in symptom expression between 
the two groups with the chronic patients having significantly higher 
negative symptoms than the first episode patients.  However, this 
difference in symptoms did not lead to a reduction in performance on the 
neuropsychological tests of the chronic patients.  Although in the present 
thesis it has already been shown that an increase in negative symptoms is 
correlated with deficits in executive function in both patient populations the 
level of severity does not appear to be also associated.  Hoff et al., (2005) 
in their ten year longitudinal study of neuropsychological functioning 
subsequent to a first episode of schizophrenia reported that, first episode 
patients have considerable cognitive decline by the time of their first 
hospitalisation and that it remains relatively stable through at least ten 
years of the illness.  Most cognitive changes take place early in the illness, 
prior to the first hospitalisation, but its exact timing still remains unknown.   
Addington and Addington,( 2002) in their investigation of cognitive 
functioning in first episode patients compared to multiple episode patients 
reported that first episode patients demonstrated cognitive impairments 
similar to those of patients with an established schizophrenia illness, even 
though first episode patients had generally superior scores on the 
neuropsychological tests, their performance was still impaired.   They also 
showed that negative symptoms were correlated with neuropsychological 
performance on the Wisconsin Card Sorting Test (WCST) which is a 
measure of executive function in both patient groups.  The findings 
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described in the above studies are in agreement with the present findings 
in that no significant differences were observed between the two patient 
groups in relation to neuropsychological performance.      
The reason that chronic patients had higher negative symptoms can 
perhaps be attributed to the fact that they were all residents in an in-
patient unit compared to the first episode patients who were all out-
patients living in their own homes and having a more ‘normal’ life.  The 
chronic patients had recently suffered a psychotic episode compared to 
the first episode patients who all had a minimum of 6 months since their 
last psychotic episode and this maybe a contributing factor to having a 
higher negative symptom score.  Another reason maybe that the chronic 
schizophrenia patients have been on a wide variety of medications and all 
of them were currently on typical antipsychotics compared to the first 
episode patients who were all on atypical antipsychotics.  Furthermore, 
another reason could be that chronic patients have had to live with their 
illness for a lot longer than the first episode patients and maybe a 
cumulative effect of having multiple episodes, polypharmacy and multiple 
in-patient admissions may lead to a general increase of negative 
symptoms (Barbeito et al., 2011; Faber et al., 2011; Hori et al., 2006; 
Harvey et al., 2004).  Regardless of these higher negative symptoms 
performance on the neuropsychological tests was not significantly different 
between the two patient groups, therefore supporting the hypothesis that 
cognitive deficits remain relatively stable over the course of the illness 
(Bozikas and Andreou, 2011; Gopal et al 2005; Albus et al., 2002; Albus et 
al., 1996).           
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The next chapter of this thesis will look at one possible way of remediating 
cognitive deficits in patients with first episode psychosis through the use of 
CRT.  
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Chapter 5 
Investigation into the effects of computerised cognitive remediation 
therapy (X-Cog®) in a first episode psychosis population  
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5.1 Introduction  
 
Cognitive deficits are now recognised as a core feature of schizophrenia 
(Goff et al., 2011; Allott et al., 2011; Bora et al., 2010).  A number of 
studies report profound deficits in cognitive function in both long term and 
first episode patients (Bozikas and Andreou, 2011; Hill et al., 2009; 
Addington and Addington, 2008).  Deficits have been reported in memory 
(Staring et al., 2011; Ragland et al 2011; Anticevic et al., 2011), attention 
(Ferchiou et al., 2010; Mayoral et al., 2008; Nestro et al., 1992) executive 
function (Yun et al., 2011; Liu et al 2011; Pena et al., 2011), and visuo-
spatial planning (Lencer et al., 2011; Huddy et al., 2007; Badcock et al., 
2005).  Research has shown that these deficits in cognition tend to persist 
even after conventional treatment and limit social and vocational 
functioning (Elie et al., 2010; Goldberg et al., 2007; Meltzer and McGurk 
1999).  Therefore there is a clear need for the development of alternative 
modes of treatment to help remediate these deficits which include not only 
pharmacological agents but also psychological approaches.   
One of these psychological approaches is referred to as cognitive 
remediation therapy which was developed to help treat cognitive deficits 
that affect everyday functioning in patients with psychosis and 
schizophrenia (Wykes et al., 2011; Holmen et al., 2010; McGurk et al 
2009).  Cognitive remediation therapy does not aim to address thought or 
belief content and emotions directly, but teaches basic thinking skills, 
using non-emotive material, which may help to facilitate more complex 
social behaviours and everyday living skills (Grynszpan et al., 2011; 
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Wexler and Bell, 2005; Bark et al., 2003).  The cognitive domains which 
are mainly targeted by cognitive remediation therapy are; memory, 
executive function and attention; as deficits in these domains have been 
shown to have a consistent relationship with progression of the illness in 
the long term (Tomas et al., 2010; Bell and Berson, 2001).   
Cognitive remediation therapy is based on three basic principles; errorless 
learning, repetition and positive reinforcement (Wykes and Reeder, 2005).  
Errorless learning is important because it avoids the implicit encoding of 
errors which cannot then be differentiated from correct information by 
explicit recall (Mullholland et al 2008; O’Carroll et al., 1999; Baddeley and 
Wilson, 1994).    Repetition is vital because it allows the patient to learn 
from previous experiences, it encourages the patient to monitor their own 
performance, and it helps to maintain the therapeutic alliance between 
patient and therapist (Wykes et al., 2007; Wexler, 2007; Kurtz et al., 2007).  
Positive reinforcement is required in order to encourage the desired 
behaviour, to ensure that the training is a positive experience and to 
provide tangible evidence to the patient of their success (Lindenmayer et 
al., 2008; Velligan et al., 2006; Wykes et al., 2003).   
The use of computers in cognitive remediation therapy has a relatively 
recent history (Medalia et al., 2002; Franco et al., 2000; Schufried, 1996).  
Research has demonstrated how computer aided training can help to 
improve patient performance in the following domains; memory, executive 
function, visual motor speed and attention (Surti et al., 2011; Poletti et al., 
2010; Cavallaro et al., 2009).  The advantages of using computer aided 
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training over more traditional pencil and paper methods are; they allow the 
degree of difficulty to be changed on an individual basis (Medalia and Choi, 
2009) they give immediate feedback to the patient (Ikezawa et al., 2011), 
they allow the use of varying reinforcement methods (Miller and Mason, 
2004), there is consistent monitoring of the learning process and finally 
computerised cognitive training has been proven to be more motivating 
than other training methods with the immediate feedback it provides (Choi 
and Medalia, 2010).  Some drawbacks of computer aided training are that 
there is little or no social interaction whilst the program is being 
administered and patients do not benefit from the social component that is 
afforded by working in groups (Tomas, 2010) and it is relatively expensive 
compared to other methods of Cognitive Remediation Therapy (Wykes 
and Reeder, 2005, O’Carroll, 2000).   
Studies using cognitive remediation therapy have shown inconsistent 
results with some authors reporting significant effects in patients across all 
the domains measured (Vita et al., 2011; Royer et al., 2011; Lewandowski 
et al., 2011; McGurk et al., 2007; Kurtz et al., 2007) and others reporting 
either minor or no effects and concluding that the treatment is ineffective 
(Silverstien et al., 2004; Piling et al., 2002; Hayes and McGrath, 2000).  
However after examining the available literature, it appears that the 
majority consensus is that cognitive remediation therapy can have a 
positive effect on cognition in combination with other psychosocial 
therapies and pharmacological agents and more needs to be done to 
develop these types of therapies.          
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5.2 Study Aim 
 
The aim of the current study was to investigate the effects of computerised 
cognitive remediation therapy on neuropsychological functioning in a 
sample of first episode psychosis patients.   
 
5.3 Methods  
 
For a full description of methods used see chapter 2 
 
 
5.3.1 Exclusion Criteria  
 
No patients were excluded from the study.   
 
5.3.2 Cognitive Remediation Intervention  
 
All patients in the cognitive remediation group underwent an 8 week 
Cognitive Remediation Therapy course (X-Cog®) in a group setting at the 
University of Bradford.  There were a total of 8 sessions (one a week) with 
each session lasting approximately 90 minutes.  The group was facilitated 
by the researcher (MS) with the support of an assistant psychologist from 
the Early Intervention Service and an undergraduate student from the 
University of Bradford.  For full details of the Cognitive Remediation 
Therapy intervention please see chapter 2 section 2.11.  The control group 
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in the study received treatment as normal (no intervention) with no 
cognitive remediation therapy.   
 
5.3.3 Participants  
 
Patients who participated in the cognitive remediation trial were recruited 
from the First Episode Psychosis investigation – see chapter 3.  Patients 
from the First Episode study were invited to take part in the current study 
through letters of invitation (Appendix 12).  A total of 35 invitations were 
sent out and a response was received from 11 patients who were willing to 
take part in the study.  Group allocation was subject to self selection bias 
with patients selecting themselves into a group due to patient availability 
and resources available. Neither cognitive deficits, symptoms or treatment 
were taken into account when patients assigned themselves to a group.  
 
5.3.4 Assessment Schedule 
 
The study patients were evaluated once for pre-morbid IQ (WTAR). 
Neuropsychological functioning was assessed twice using the CANTAB® - 
once before the cognitive remediation therapy and once after therapy. For 
the control group, the first and second evaluations were separated by an 
interval equal to the cognitive remediation therapy intervention of 8 weeks. 
The neuropsychological test battery was the same for both of the groups.  
Symptom expression was assessed using the Positive and Negative 
Syndrome Scale (PANSS) on both occasions in both groups.   All training 
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and assessments were undertaken by the researcher (MS).  The flow of 
participants through the study is shown in figure (5.1).   
 
5.3.5 Statistical Analysis  
 
For full description of analysis used see chapter 2 section 2.12.
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5.4 Results 
 
 
5.4.1 Patient demographics  
 
The study population consisted of 11 patients (8 male 3 female). 
Demographic data and clinical information on age, gender, ethnicity, 
educational level, pre-morbid intellectual quotient (Wechsler Test of Adult 
Reading) and symptom expression (Positive and Negative Syndrome 
Scale) was collected (table 5.1).  Each patient was being treated with 
antipsychotic medication (figure 2.2).  Diagnostic classifications are 
described in (figure 2.1).    
Throughout the study, no undesirable effects were reported at any stage 
by any of the participants to the researcher (MS) or any other health care 
professional.  
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5.4.2 Symptom Expression in Patients 
 
5.4.2.1 Symptom expression at baseline between groups 
 
Symptom expression was assessed in all of the patients using the Positive 
and Negative Syndrome Scale (PANSS).  There are three main symptom 
groups that the PANSS assesses; positive symptoms (which include, 
hallucinations and delusions), negative symptoms (which include, social 
withdrawal and blunted affect) and general symptoms (which include, 
anxiety and depression).  A one way Anova showed that there were no 
significant differences in symptom expression at baseline between the X-
cog patients, control patients and non participating patients [F (2, 32) = 
0.25, p = 0.78], in positive symptoms, [F (2, 32) = 0.06, p = 0.93] in 
negative symptoms and [F (2, 32) = 0.66, p = 0.52]  in general symptoms.   
Positive, Negative and General symptoms mean scores for patient 
controls, patients and non-participants at baseline  
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Figure 5.2 – (P) Positive, (N) Negative and (G) General symptoms mean 
scores in patient controls (n=6), patients (n=5) and non participants (n=24).  
Data are expressed as mean ± S.E.M.   
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5.4.2.2 Symptom expression at follow up between groups  
 
After the cognitive remediation therapy, symptom expression was 
reassessed in both groups before neuropsychological testing and results 
show that there were no significant differences in symptom expression in 
positive symptoms between the patient group (11.6 ± 3.8) and patient 
control patient group (11.8 ± 3.8) t (9) = -0.10, p = 0.92 or in general 
symptoms between the patient group (22 ± 3.7) and patient control group 
(24.8 ± 6.1) t (9) = -0.90, p = 0.39.  However, there was a significant 
difference found in negative symptoms between the patient group (10.6 ± 
2.7) and patient control group (15.8 ± 4.3) t (9) = -2.32, p<0.05 (figure 5.4) 
with patients scoring lower in negative symptoms than patient controls.   
 
Positive, Negative and General symptoms mean scores for patient 
controls and patients at follow-up 
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Figure 5.3 – (P) Positive, (N) Negative and (G) General symptoms mean 
scores in patient controls (n=6) and patients (n=5).  Data are expressed as 
mean ± S.E.M. p<0.05* 
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5.4.2.3 Symptom expression at baseline and follow-up within groups 
 
When changes in symptom expression were compared within groups at 
baseline and at follow- up (i.e. after CRT) results showed that there were 
no significant differences in the patient control group for positive 
symptoms at baseline (12.5 ± 2.5) and follow-up (11.8 ± 3.6) t (10) = 0.36, 
p =0.72, negative symptoms at baseline (16.6 ± 2.7) and follow-up (15.8 ± 
4.3), t (10) = 0.39, p = 0.70 and general symptoms at baseline (26.1 ± 2.7) 
and follow-up (24.8 ± 6.1), t (10) = 0.48, p = 0.63. 
 In the patient group we found that there were no significant differences in 
positive symptoms from baseline (13.8 ± 3.1) and follow-up (11.6 ± 3.8) t 
(8) = 0.99, p = 0.34. However, we did find significant reductions in 
negative symptoms at baseline (16.6 ± 2.7) and follow up (10.6 ± 2.7) t (8) 
= 3.45, p<0.01 and general symptoms at baseline (29.8 ± 3.8) and follow-
up (22 ± 3.7), t (8) = 3.22, p<0.05 (figure 5.5).   
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Positive, Negative and General symptoms mean scores for patient 
controls and patients at baseline and follow-up 
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Figure 5.4 – (P) Positive, (N) Negative and (G) General symptoms mean 
scores in (C) patient controls (n=6) and (P) patients (n=5).  (B) baseline, (F) 
follow up.  Data are expressed as mean ± S.E.M.  p<0.01**, p<0.05*   
 
5.4.3 Neuropsychological Test Performance  
 
5.4.3.1 Pattern Recognition Memory (PRM) 
 
Visual memory was assessed using the Pattern Recognition Memory 
(PRM) test.   
The two outcome measures examined for this test were; number of correct 
responses and mean correct latency (speed of subject’s response).  The 
results indicate no significant difference between the two groups on both 
outcome measures.   
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Number of correct responses, U = 9.50, p = 0.32, with the mean rank 
equal to 5.08 for the control group and 7.10 for the patient group.  Mean 
correct latency, U = 11.00, p = 0.53, with the mean rank equal to 6.67 for 
the control group and 5.20 for the patient group.  See table (5.2)   
Table showing median, min/max and significance scores in both 
groups on the PRM test post intervention 
  
PATIENT CONTROL 
(N=6) 
 
PATIENT (N=5) 
 
PRM Median Min/Max Median Min/Max P value 
 
MNC 
 
 
0.00 
 
(-3, 2) 
 
0.00 
 
(0, 1) 
 
p = 0.32 
 
MCL 
 
 
-147.36 
 
(-478.9, 
658.6) 
 
-215.35 
 
(-834.2, 
474) 
 
p = 0.53 
Table 5.2 – Pattern Recognition Memory (PRM).  Mean number correct 
(MNC), Mean correct latency (MCL).  Number of participants in group (N).  
Data are expressed as median and min/max scores 
 
5.4.3.2 Spatial Recognition Memory (SRM) 
 
Spatial memory was assessed using the Spatial Recognition Memory 
(SRM) test.   
The two outcome measures examined for this test were; number of correct 
responses and mean correct latency (speed of subject’s response).  The 
results indicate no significant difference between the two groups on both 
outcome measures.  
 Number of correct responses, U = 15.00, p = 1.00, with the mean rank 
equal to 6.00 for the control group and 6.00 for the patient group.  Mean 
correct latency, U = 11.00, p = 0.53, with the mean rank equal to 5.33 for 
the control group and 6.80 for the patient group.  See table (5.3).  
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Table showing median, min/max and significance scores in both 
groups on the SRM test post intervention 
  
PATIENT CONTROL 
(N=6) 
 
PATIENT (N=5) 
 
SRM Median Min/Max Median Min/Max P value 
 
MNC 
 
 
0.50 
 
(-4, 2) 
 
1.00 
 
(-1, 1) 
 
p = 1.00 
 
MCL 
 
 
-257.18 
 
(-547.42, 
74.03) 
 
-192.93 
 
(-531.62, 
1787.38) 
 
p = 0.53 
Table 5.3 – Spatial Recognition Memory (SRM).  Mean number correct 
(MNC), Mean correct latency (MCL).  Number of participants in group (N).  
Data are expressed as median and min/max scores.   
 
 
5.4.3.3 Intra/extra Dimensional Shift (IED) 
 
Executive function was measured using the Intra/extra Dimensional Shift 
(IED) test.  
The four outcome measures examined for this test were; total stages 
completed, total errors, pre extra dimensional shift errors and post extra 
dimensional shift errors.  The results indicate that there were significant 
differences between the two groups across all four of the outcome 
measures assessed, with the patient group performing better than the 
control group.   
Total stages completed, greater for patients U = 3.00, p <0.05, with the 
mean rank equal to 4.00 for the control group and 8.40 for the patient 
group (figure 5.6).  Total errors, less for patients U = 3.00, p = <0.05, with 
the mean rank equal to 8.00 for the control group and 3.6 for the patient 
group (figure 5.7).  Pre extra-dimensional shift errors, less for patients U = 
1.00, p<0.05, with the mean rank equal to 8.33 for the control group and 
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3.20 for the patient group (figure 5.8).  Post extra-dimensional shift errors, 
less for patients U = 1.00, p<0.001, with the mean rank equal to 8.33 for 
the control group and 3.20 for the patient group (figure 5.9).   See table 
(5.4).  
Table showing median, min/max and significance scores in both 
groups on the IED test post intervention 
  
PATIENT CONTROL 
(N=6) 
 
PATIENT (N=5) 
 
IED Median Min/Max Median Min/Max P value 
 
SC 
 
 
0.00 
 
(0, 0) 
 
2.00 
 
    (0, 2) 
 
p<0.05* 
 
TE 
 
 
2.00 
 
(0, 14) 
 
-12.00 
 
(-18, 2) 
 
p<0.05* 
 
PED 
 
2.50 
 
(0, 3) 
 
 
-1.00 
 
 
    (-3, 0) 
 
 p<0.05* 
 
EDS 
 
1.00 
 
(-4, 3) 
 
 
-18.00 
  
(-26, -1) 
 
 p<0.001** 
Table 5.4 – Intra/extra Dimensional Shift (IED).  Stages completed (SC), 
Total errors (TE), Pre extra-dimensional shift errors (PED), Post extra-
dimensional shift errors (EDS).  Number of participants in group (N).  Data 
are expressed as median and min/max scores.  Significance p<0.001***, 
p<0.01**, p<0.05*   
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Intra/extra Dimensional Shift mean stages completed 
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Figure 5.5 – Intra/extra Dimensional Shift total stages completed pre and 
post Xcog.  (P) patients.  Control patients (n=6), Xcog patients (n=5).  Data 
are expressed as mean S.E.M.   Patient control vs. Xcog patients, difference 
p<0.05* 
 
 
 
 
Intra/extra Dimensional Shift mean total errors  
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Figure 5.6 – Intra/extra Dimensional Shift total errors pre and post Xcog.  (P) 
patients.   Control patients (n=6), Xcog patients (n=5).  Data are expressed as 
mean S.E.M.   Patient control vs. Xcog patients, difference p<0.05* 
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Intra/extra Dimensional Shift mean pre-extra dimensional shift errors 
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Figure 5.7 – Intra/extra Dimensional Shift pre extra dimensional shift errors.  
(P) patients.  Control patients (n=6), Xcog patients (n=5).  Data are expressed 
as mean S.E.M.   Patient control vs. Xcog patients, difference p<0.05* 
 
 
Intra/extra Dimensional Shift mean post-extra dimensional shift errors 
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Figure 5.8 – Intra/extra Dimensional Shift post extra dimensional shift errors.  
(P) patients.  Control patients (n=6), Xcog patients (n=5).  Data are expressed 
as mean S.E.M.   Patient control vs. Xcog patients, difference p<0.001*** 
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5.4.3.4 Stockings of Cambridge  
 
Spatial planning and working memory was assessed using the Stockings of 
Cambridge test (SOC) test.   
The four outcome measures examined for this test were; mean moves (5 
move problems), mean initial thinking time (5 move problems), mean 
subsequent thinking time (5 move problems) and problems solved in 
minimum moves.  The results indicate no significant difference between the 
two groups on any of the outcome measures assessed.  
 Mean moves (5 move problems), U = 6.50, p = 0.12, with the mean rank 
equal to 4.58 for the control group and 7.70 for the patient group.  Mean initial 
thinking time (5 move problems), U = 9.00, p = 0.32, with the mean rank 
equal to 5.00 for the control group and 7.20 for the patient group.  Mean 
subsequent thinking time (5 move problems), U = 6.50, p = 0.12, with the 
mean rank equal to 4.58 for the control group and 7.70 for the patient group.  
Problems solved in minimum moves, U = 13.50, p = 0.79, with the mean rank 
equal to 5.75 for the control group and 6.30 for the patient group.  See table 
(5.5).   
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Table showing median, min/max and significance scores in both groups 
on the SOC test post intervention 
  
PATIENT CONTROL 
(N=6) 
 
PATIENT (N=5) 
 
SOC Median Min/Max Median Min/Max P value 
 
MM5 
 
 
-2.37 
 
(-5.25, 
0.50) 
 
-1.25 
 
    (-2, 1) 
 
p = 0.12 
 
MITT5 
 
 
-813.37 
 
(-3763.25, 
10520) 
 
6335.25 
 
(-4485.75, 
11330.50) 
 
p = 0.32 
 
MSTT5 
 
-1216.39 
 
(-4683.16, 
633.08) 
 
 
0.00 
 
 
 (-902.44,      
766.91) 
 
p = 0.12 
 
PSMM 
 
0.00 
 
(-1, 4) 
 
 
1.00 
  
(-1, 4) 
 
p = 0.79 
 
Table 5.5 – Stockings of Cambridge (SOC).  Mean moves – 5 move problems 
(MM5), Mean initial thinking time – 5 move problems (MITT5), Mean 
subsequent thinking time – 5 move problems (MSTT5), Problems solved in 
minimum moves (PSMM).  Number of participants in group (N).  Data are 
expressed as median and min/max scores.   
 
5.4.3.5 Choice Reaction Time (CRT) 
 
Attention was assessed using the Choice Reaction Time (CRT) test.   
There were two outcome measures which were examined for this test which 
were; total correct trials and mean correct latency (speed of subject’s 
response).  The results indicate no significant difference between the two 
groups on any of the outcome measures assessed.  
Total correct trials, U = 14.50, p = 0.93, with the mean rank equal to 6.08 for 
the control group and 5.90 for the patient group.  Mean correct latency, U = 
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13.00, p = 0.79, with the mean rank equal to 6.33 for the control group and 
5.60 for the patient group.  See table (5.6).   
 
Table showing median, min/max and significance scores in both groups 
on the CRT test post intervention 
  
PATIENT CONTROL 
(N=6) 
 
PATIENT (N=5) 
 
CRT Median Min/Max Median Min/Max P value 
 
TC 
 
 
0.50 
 
(0, 3) 
 
1.00 
 
(-1, 3) 
 
p = 0.93 
 
MCL 
 
 
24.96 
 
(-171.88, 
189.65) 
 
2.72 
 
(-8.89, 
133.44) 
 
p = 0.79 
 
Table 5.6 – Choice Reaction Time (CRT).  Total correct (TC), Mean correct 
latency (MCL).  Number of participants in group (N).  Data are expressed as 
median and min/max scores.   
 
 
5.5 Discussion  
 
 
There is a broad consensus that cognitive ability influences the patient’s 
quality of daily life.   There is also evidence to suggest that cognitive deficits 
are more persistent over time than positive symptoms, more resistant to 
conventional treatment and are a better indicator and predictor of functional 
outcome (Wykes and Spaulding, 2011; Hodge et al., 2010; Kern et al., 2009). 
In the present study we found significant improvements in executive function 
and negative symptoms in first episode psychosis patients following cognitive 
remediation therapy.  However we did not find any significant improvements 
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in visual memory, spatial memory, working memory, planning or attention.  
Although there were slight improvements in these cognitive domains, nothing 
was of statistical significance.   
There has been recent research looking at the different techniques, uses and 
effects of cognitive remediation in patients with schizophrenia.   In Medalia 
and Choi’s (2009) meta-analysis of cognitive remediation in schizophrenia 
they found that cognitive remediation programs vary in the extent to which 
they reflect neuro-cognitive learning activities.  They reported a moderate 
range effect size following cognitive remediation on cognitive test 
performance and daily functioning.  They also reported that reciprocal 
interactions between baseline ability, the type of instructional techniques used, 
and motivation may provide some explanations for the differences in patient 
response to cognitive remediation.  Other research by Medalia et al (2009) 
suggested that differences in response to cognitive remediation might depend 
on instructional techniques, intellectual ability, and intrinsic motivation.  In the 
present study, these principles were closely followed by attaching great 
importance to instructional approach along with providing lots of positive 
reinforcement for the patients.   
The results from the current investigation showed that improvements in 
executive function were the most significant following cognitive remediation.  
Significant reductions in deficits across all of the outcome measures 
assessed on the IED test from CANTAB® were found in the patient group.   
Interestingly, the deficits in executive function were the most profound 
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compared to the other cognitive domains at baseline.  These findings are in 
agreement with other studies, where significant improvements in executive 
function have been observed post cognitive remediation (Penades et al., 
2010; Stratta and Rossi, 2004; Reeder et al., 2004).   
Research by Penades et al., (2010) concluded that cognitive remediation 
should target executive functioning in order to achieve social functioning 
improvements in patients.  McGurk et al., (2007) also suggested that some 
aspects of executive functioning need to be targeted if some improvement in 
functionality is expected.  
Although no statistically significant improvements were found in the other 
cognitive domains tested; visual memory, spatial memory, working memory, 
planning and attention; there was an improvement in performance on the 
neuropsychological tests in the patient group in all of these areas.  With these 
improvements only being subtle in nature, one could hypothesise that, a 
larger group of patients and a longer, more intensive intervention may have 
given more statistical power.   
Previous research by Wykes et al., (2007) showed how cognitive remediation, 
given as an adjunct to treatment as usual, moderately improves working 
memory compared with treatment as usual, and these improvements are 
maintained six months after treatment. Cognitive remediation therapy also 
improved cognitive flexibility six months after treatment, but did not improve 
planning.  Recent research by Deppen et al., (2011) reported how a greater 
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improvement was found in the cognitive functions which were specifically 
trained through the use of individual cognitive remediation compared to the 
cognitive functions which were not targeted with any course of therapy.  
Suggesting that cognitive remediation is effective across all domains as long 
as they are specifically targeted with an appropriate technique.    
Research investigating the effectiveness of cognitive remediation has shown 
that it is an effective intervention across various domains of cognition, as long 
as it is used in an appropriate way and is not the sole method of remediation 
(Surti et al., 2011; d’Amato et al., 2011; Laroi et al., 2010; Cochet et al., 2006; 
Fiszdon et al., 2004; Bellack et al., 1990).       
In the current study a significant reduction of negative symptoms was 
observed in the patient group compared to the control group after the 
cognitive remediation intervention.  In the two previous chapters of this thesis 
it has been demonstrated that there is a significant relationship between 
negative symptoms and outcome measures on the IED test of executive 
function on CANTAB® (see chapter 3 and 4).  So the finding that there was a 
reduction in negative symptoms and an improvement in the executive 
function domain may not be all that surprising and begs the question, which 
factor is the cause and which is the effect?  Does the cognitive remediation 
cause a reduction in negative symptomatology? Or does the reduction in 
negative symptoms affect performance on the neuropsychological tests?  
One possible explanation may be that the participants in the cognitive 
remediation group were involved in a ‘group therapy’ situation which meant 
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having regular interactions with other people and the therapist, thus having a 
causal effect on their symptomatology, which the participants in the control 
group did not have access to.  Also, the fact that the patient and control 
groups was self selecting, suggests that the patient group were more 
motivated to take part in the therapy and affect some form of change to help 
improve their cognition.     
Previous research by Greenwood et al., (2005) focusing on the relationship 
between negative symptoms, cognitive deficits and functional outcome 
reported that, poor community function may be predicted both by specific 
cognitive impairments that are prominent in people with negative symptoms 
and through the moderating effect of negative symptoms on cognition. They 
suggested that this may reflect an association between symptoms and 
cognition, where negative symptoms arise from cognitive impairment but also 
impact detrimentally on cognitive functioning.  Thus both cognitive processes 
and negative symptoms should be targeted in cognitive remediation to effect 
the greatest change in functional outcome.   
Other research by Bark et al (2003) looking at the impact of cognitive 
remediation on psychiatric symptoms of schizophrenia reported that a 10-
session course of cognitive remediation therapy is sufficient to benefit 
cognition in patients and has some positive effects on psychopathology as 
measured by the PANSS.  The number of sessions (10) offered by Bark and 
colleagues, were similar to the number of sessions that were offered to 
patients in the current study.  However, the length of the sessions was 
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significantly different with sessions in their study lasting 25 minutes and 90 
minutes in the present study.  Although both of these studies were quite short 
in duration positive effects were still found, thus suggesting that prolonged 
interventions may have more significant and lasting effects on cognition than 
what was currently observed.   Bark et al (2003) concluded that, psychiatric 
symptom profile may not be predictive of the degree to which cognitive 
symptoms respond to cognitive remediation and that significant improvements 
can be made regardless of the severity of the symptoms.    
Research by Bellucci et al., (2003) investigating the effects of cognitive 
remediation therapy on negative symptoms reported that patients showed 
greater improvement in cognitive functioning and negative symptoms 
following cognitive remediation therapy, than patients who did not receive any 
form of cognitive remediation.  The effects on negative symptoms were 
similar in magnitude to the effects on cognitive functioning.   
Through the use of computerised cognitive remediation over more traditional 
pen and paper tasks we were able to record accurate information from all 
participants as no rater subjectivity was involved.  It also increased the 
enjoyment levels for the participants as the remediation package is designed 
in a ‘computer game’ format thus not feeling like a traditional therapeutic 
intervention as such and patients reported enjoying ‘playing’ the games.  The 
constant feedback provided by the computer software increased the amount 
of positive reinforcement that the patients were receiving which could 
potentially have a direct impact on patient motivation.  Levels of motivation 
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have been shown to be vital in the success of any form of psychosocial 
therapy as patients with schizophrenia have diminished experiences of 
external reward and reinforcement in their daily interactions and activities.  
Choi and Medalia, (2010) reported that in cognitive remediation in patients 
with schizophrenia, incorporating intrinsically motivating instructional 
techniques into a difficult cognitive task promoted greater learning of the 
material, higher levels of intrinsic motivation to attempt the demanding task 
and feelings of self efficacy and achievement to learn.  The levels of difficulty 
were also easy to adjust with patients moving on to the next degree of 
difficulty automatically thus allowing for a sense of achievement.   
Vita et al., (2011) looked at the effects of two different modalities of cognitive 
remediation (computerised versus non-computerised) on symptomatological, 
neuropsychological and functional outcomes in patients with schizophrenia 
and reported that both of the cognitive remediation programs had a 
significantly larger effect on negative, positive and total symptom severity 
than standard care.  The computerised program showed a significantly better 
effect on processing speed, working memory and executive function variables, 
on which the non-computerised intervention had a smaller but still significant 
effect, with both cognitive treatments having a larger effect on some 
functional outcome measures as assessed by the Health of the Nation 
Outcome Scales (HoNOS).  The HoNOS is a multidimensional scale that 
includes behaviour, social, relational items and also an item specifically 
relative to cognitive functioning.  The different effects on functional outcome 
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detected through the use of the HoNOS raises the question of possible 
differential effects of different cognitive remediation interventions on the 
heterogeneous outcome domains of schizophrenia.     
However in a recent Meta –analysis Wykes et al (2011) found that no 
treatment element (remediation approach, duration, computer use, etc.) was 
associated with cognitive outcome and that significantly stronger effects on 
functioning were found when cognitive remediation therapy was provided 
together with other psychiatric rehabilitation such as psychopharmacological 
agents and psychological therapies.  It is therefore possible to conclude that 
there is a mild to moderate durable effect of cognitive remediation on 
cognition and functioning, that is not affected by study methodology and 
design.  If the target is to improve function, then adjunctive therapy is 
essential, with the best effects being shown when a more strategic cognitive 
remediation approach is adopted. 
There are several limitations of the present study. Firstly, the number of the 
patients in the study was very small.  Secondly, subjects were not randomly 
assigned to either of the groups.  Thirdly, we were not able to provide 
cognitive remediation on an individual basis and had to opt for a group setting.  
It would have been ideal to have had a longer more intensive intervention and 
to be able to provide the control group with an alternative therapy thus not 
neglecting them of any benefit of having regular contact with either a group or 
therapist.  For future studies it would be ideal to include an alternative 
intervention group along with the cognitive remediation group and treatment 
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as usual group.  In addition to reassessing patients six months post cognitive 
remediation to see if the changes are robust and enduring.     
In conclusion, it is evident that there is considerable interest in gaining a more 
detailed insight into the cognitive impairments accompanying schizophrenia, 
the impact of these impairments on social functioning and possible 
techniques of remediating them.  As a logical consequence, various 
intervention programs are being designed, employed and evaluated, albeit 
from different theoretical starting points, with the objective of improving 
cognition in schizophrenia and social functioning. However, many programs 
still have important unresolved issues where more research is needed.  For 
example, evaluation of effectiveness in global terms and specific evaluation of 
each component of cognitive function.   
At the same time it is worth remembering recommendations such as those 
from Medalia and Richardson (2005), and those of Velligan et al., (2006) that 
point out a series of factors contributing to cognitive improvement when it 
comes to commencing an intervention such as patient baseline impairment, 
intrinsic motivation, working style, factors related with the illness, the 
symptom profile, medication type, treatment intensity, therapist training and 
the relationship between training and the patient’s characteristics.  The need 
for effective cognitive remediation is paramount if patients with schizophrenia 
are to return to some form of normality in their daily lives and the earlier these 
interventions are offered the greater the impact they may potentially have on 
functional outcome.    
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6.1 Introduction  
 
The aims of this thesis were to investigate cognitive deficits in first episode 
psychosis/schizophrenia patients compared to demographically matched 
healthy controls whilst examining the effect of ethnicity (South Asian versus 
Caucasian). Secondly, to investigate cognitive deficits in chronic 
schizophrenia patients compared to demographically matched healthy 
controls.  Finally, to investigate the effects of cognitive remediation therapy on 
cognitive function in first episode psychosis patients.   
The results presented in this thesis show that cognitive deficits are evident in 
patients with schizophrenia at all stages of the illness, from the first episode 
through to the chronic phase. The effects of ethnicity (South Asian and 
Caucasian), pre morbid IQ and demographics such as age, gender and years 
in education do not appear to affect cognitive function.  The results also 
indicate that there is a relationship between negative symptoms and 
performance on the executive function task on CANTAB® (IED), with higher 
negative symptoms leading to more impaired performance.  Results also 
show that chronic patients have higher negative symptoms than first episode 
patients but their level of cognitive impairment is the same.  The use of 
cognitive remediation has been shown to have a positive effect on cognition 
with significant improvements found in the domain of executive function along 
with a reduction in negative symptoms.  Other results from the research have 
indicated that schizophrenia spectrum diagnoses and medication do not have 
a significant effect on cognitive function.  
Chapter 6  General Discussion 
206 
 
Although there is an increasing amount of knowledge about cognitive deficits 
in schizophrenia there is less known about the course of these deficits and 
how early they begin to develop.  There is evidence to suggest that cognitive 
deficits begin to become noticeable at a prodromal stage of the illness at a 
very early age and then become progressively worse throughout the illness; 
however no firm conclusions have yet been reached with researchers 
currently focusing on this area (Frommann et al., 2011, Hawkins et al., 2008, 
Bartok et al., 2005).    
Our understanding of schizophrenia is still fairly limited even though the 
illness has been extensively researched over the last 100 years, with an 
increase in research on cognition in schizophrenia over the last 20 years.  
There is still no real conclusive evidence to suggest the causes of the illness 
although a variety of risk factors have been identified.  Clinical research is 
sometimes hindered due to the lack of availability of patients willing to take 
part in trials, particularly in population based studies and for studies 
investigating the prodromal stages of the illness.     
 
6.2 Demographics, pre-morbid IQ, symptomatology and cognitive 
deficits  
 
The cognitive deficits found in first episode psychosis patients and chronic 
schizophrenia patient’s highlighted the fact that these deficits are a core 
feature of the illness.  In the first episode study (chapter 3) the deficits in 
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patients were found to be similar across both of the ethnic groups that were 
examined (South Asian and Caucasian) when compared to matched healthy 
controls, thus leading to the conclusion that ethnicity does not play a 
significant role in the severity of cognitive deficits in patients.  Other research 
which has looked at the effect of ethnicity on neuro-cognitive outcomes has 
also found similar findings.  However all of this research has usually 
separated patients into two separate groups; Caucasian and all other 
ethnicities.  The present study is the first (as far as I am aware) to look 
specifically at South Asian versus Caucasian patients therefore there is 
limited other data available to which any direct comparisons can be made.  
Hughes et al., (2003) in their longitudinal study of symptoms and cognitive 
function in chronic schizophrenia reported that there were no significant 
relationship between ethnicity and cognitive function.  Heaton et al., (2001) in 
their study of stability and course of neuropsychological deficits in 
schizophrenia reported that they found no significant relationship between 
ethnicity and cognitive function in their patient groups.  The literature does 
suggest that ethnicity does not have a significant effect on 
neuropsychological functioning which is in agreement with the findings in the 
present study.       
The results from the chronic schizophrenia study (chapter 4) showed similar 
deficits to those found in the first episode study, with patients performing 
worse across all of the subtests compared to the healthy controls.  Analysis of 
neuropsychological performance between first episode and chronic 
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schizophrenia patients showed that there were no significant differences in 
the level of impairment in any of the cognitive domains tested.  These results 
confirm that cognitive deficits are evident throughout all stages of the illness.  
Similar research by Sponheim et al., (2010) investigating the disparity of 
cognitive function in recent onset and chronic schizophrenia patients yielded 
evidence for similar cognitive deficits from shortly after onset to chronic phase 
of the disorder.  The results from their study are consistent with cognitive 
deficits being comparable from early in the course of schizophrenia until the 
chronic phase of the disorder and not progressing beyond what is expected 
with normal aging and subsequent decline in cognition in later life.   
In the present first episode and chronic schizophrenia studies, all participants 
were matched as closely as possible in terms of demographics (i.e. age, 
gender, ethnicity and years in education).  Participants were also matched for 
pre morbid intellectual quotient (IQ) functioning.  No significant differences 
were found between ethnic groups in pre morbid IQ or years in education.  
However, significant differences were still found between patients and 
controls in cognitive function.  This suggests that level of education and pre-
morbid IQ does not have a significant effect on cognitive performance and 
that ethnicity does not affect IQ levels.  Therefore, suggesting that the actual 
illness itself is a far greater contributor to the level of deficits observed than 
any of these variables controlled for in the studies.  Given that estimated pre-
morbid IQ failed to account for cognitive deficits observed in the patients, 
findings in the present study are consistent with the course of the illness 
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theory which is discussed above.  Research by Leeson et al., (2010) 
investigating the relationship between pre morbid IQ and cognition in recent 
onset psychosis reported that patients had higher pre morbid IQ scores than 
the healthy controls.  However, patients had undergone an intellectual decline 
as a consequence of the illness and therefore showed significant deficits in 
their cognitive function.  These findings highlight how pre morbid IQ does not 
affect the performance of patients on cognitive tasks.  The findings in the 
current studies support these findings with the exception of patients having 
higher pre morbid IQ than the healthy controls.   
The differences in cognitive function between male and female patients were 
also examined and no significant differences were found.  There has been 
some research which suggests that female patients have superior cognitive 
function in certain domains compared to male patients.  Longenecker et al., 
(2010) in their investigation of cognitive differences between men and women 
with schizophrenia and healthy controls found that women patients performed 
better than male patients in most domains, with significant advantages in 
verbal memory, processing speed, visual memory, and card sorting/executive 
function.  These findings are consistent with the hypothesis that female 
patients show less cognitive impairment than males.  However, the present 
research does not support this hypothesis as no significant effects were 
identified.  Although this could be a result of small numbers of females 
participating in the research (see patient demographics) and for any 
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conclusions to be made with real confidence more participants would need to 
be included.    
When the effects of medication were examined on cognitive deficits no 
significant relationships were found.  Patients on a variety of atypical and 
typical antipsychotics all performed at a similar level.  However, there is 
evidence to suggest that certain antipsychotics have a remediating effect on 
cognition.  Research by Goldberg et al., (2007) investigating the effects of 
atypical antipsychotics (olanzapine and risperidone) on cognition in first 
episode schizophrenia patients observed highly significant improvements in 
cognitive performance following 16 weeks of pharmacological treatment.  The 
most significant improvements were found in speed of processing that 
required psychomotor function, in visual and verbal tests of episodic memory 
and in executive function related to set shifting.  The results from their 
research indicated that the differential medication effects on cognition were 
small and their findings are consistent with several other studies of direct 
comparisons of olanzapine and risperidone that did not observe differential 
effects in the long term (Harvey et al., 2003; Bilder et al., 2002).  Other 
research by Keefe et al., (2007) investigating the neuro-cognitive effects of 
antipsychotic medication in patients with chronic schizophrenia in the CATIE 
trial found that after 2 months of treatment (olanzapine, risperidone, 
quetiapine, perphenazine and ziprasidone) all patients had a small but 
significant improvement in their cognitive function.  There were no differences 
between any of the medications including the typical antipsychotic 
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perphenazine.  The results in this study differ from others which suggest that 
atypical antipsychotics have neuro-cognitive advantages compared to typical 
antipsychotics.  The authors speculated that this may be a result of 
methodological differences between the studies, with the most pertinent 
difference being the number of patients involved in the CATIE trial which was 
twice as many as the largest previous trial conducted.  However, none of 
these previous findings were replicated in the present study and this may be 
due to the small sample sizes.  The findings reported in the present study are 
not in agreement with these findings, with no significant differences found 
between medications.   
Similarly, when patients were divided up into diagnostic sub categories of 
DSM-IV-TR of the schizophrenia spectrum no significant differences were 
found between the patients in cognitive function.  Addington et al (2003) in 
their study of initial presentation of first episode patients reported that 
cognitive deficits are seen across the different schizophrenia spectrum 
disorders, suggesting that cognitive deficits are a core feature not just of 
schizophrenia but also other spectrum disorders.  Holmen et al., (2010) 
investigating neuropsychological profile in early onset schizophrenia 
spectrum disorders using the MATRICS battery reported that there were no 
differences in the level of impairment between patients with a narrow 
schizophrenia diagnosis and patients with psychotic disorders.  The findings 
above were replicated in the present study with no differences found between 
patients in different diagnostic sub categories. 
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Interestingly, when symptom expression was examined in patients, no 
significant relationship was found between positive and general 
symptomatology and cognitive functioning.  However, there was a significant 
relationship between negative symptom expression and performance on the 
intra/extra dimensional shift test from the CANTAB®.  Results showed that 
higher levels of negative symptoms were indicative of worse scores across all 
outcome measures of the IED test.  This finding was true for both sets of 
patients; first episode and chronic regardless of ethnicity.  These findings 
support previous research which has found that increased levels of negative 
symptoms leads to an increase in cognitive deficits in certain cognitive 
domains.  Addington and Addington (2002) in a study looking at cognitive 
deficits in first episode and multiple episode schizophrenia patients found that 
there were several significant associations between negative symptoms and 
cognition in both sets of patient groups, but no association between positive 
symptoms and cognition in either group.   
There has been extensive research looking at the relationship between 
negative symptoms and cognition and it is widely agreed that reduced 
performance in both of these domains are directly linked to poorer functional 
outcome in patients.  Deficits in cognition can lead to lack of social skills and 
social withdrawal in patients as they feel that they do not possess the 
necessary skills for social situations and interactions.  Therefore a 
relationship between negative symptoms and executive function (which has 
been identified as one of the most important domains involved in social 
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situations) may not be surprising.  Research by Sponheim et al., (2010) has 
shown that deficits in executive function may be a contributor to the marked 
impairment in community and vocational function often noted in the chronic 
phase of the disorder.  Therefore, functional decline may not only be due to 
the social effects of the disorder but also difficulties with efficiently solving 
problems of everyday living.   
There were significant differences found in symptom expression between the 
two patient groups with the chronic patients having significantly higher 
negative symptoms than the first episode patients.  However, this difference 
in symptoms did not lead to a reduction in performance on the 
neuropsychological tests of the chronic patients.  Although in the present 
thesis it has already been shown that an increase in negative symptoms is 
correlated with increases in deficits in executive function in both patient 
populations, the higher negative symptoms in chronic patients compared to 
first episode patients do not appear to be associated with increases in 
performance on tasks of executive function.  The first episode patients did 
show slightly improved performance compared to the chronic patients in 
certain outcome measure of the neuropsychological tests however none of 
these were statistically significant.  These findings suggest that cognitive 
deficits remain relatively stable over the course of the illness regardless of 
symptomatology.  
Harvey et al., (2006) investigated the relationship between negative 
symptoms and cognitive deficits and reported that negative symptoms and 
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cognitive deficits in schizophrenia share many features and are correlated in 
their severity on a cross-sectional basis.  However they concluded that 
negative symptoms and cognitive deficits may be separable, if not 
conceptually independent domains of the illness and that it may be possible 
to develop treatments that target negative symptoms and cognitive deficits 
independently.    
The findings in the cognitive remediation therapy (CRT) study (chapter 5) 
showed how there is a relationship between improvements in executive 
function and a decrease in negative symptoms in patients.  In chapters 3 and 
4, the relationship between negative symptoms and performance on the IED 
test has already been discussed.  The fact that there was a reduction in 
negative symptoms following the CRT and an improvement in performance 
on the IED test is a very interesting finding and postulates the following 
questions; does the cognitive remediation cause a reduction in negative 
symptomatology? Or does the reduction in negative symptoms affect 
performance on the neuropsychological tests?  As alluded to in chapter 5 one 
possible explanation may be that the participants in the cognitive remediation 
group were involved in a ‘group therapy’ situation which meant having regular 
interaction with other people. Along with a regular structured routine and 
interactions with the therapist, thus having a causal effect on their negative 
symptoms. 
Previous research by Bellucci et al., (2003) investigating the effects of 
computer aided cognitive remediation on severely mentally ill populations 
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found that cognitive rehabilitation reduces the severity of negative symptoms 
in patients with schizophrenia.  Their study was one of the first to show that 
cognitive rehabilitation can influence negative symptoms among people with 
schizophrenia and other related disorders.  They reported that the effect of 
cognitive rehabilitation on negative symptoms was similar in magnitude to the 
effects on cognitive functioning. Therefore implying that the influence of 
cognitive rehabilitation on negative symptoms was not simply mediated 
through cognitive improvement.  One possibility being the stimulation of brain 
reward systems by the feedback and successful experiences that cognitive 
rehabilitation provides.     
McGurk et al., (2007) in their meta-analysis of 26 studies of cognitive 
remediation in schizophrenia found that the overall effect size of cognitive 
remediation on improving negative symptoms was significant.  They reported 
that cognitive remediation may have some beneficial effects on negative 
symptoms by providing positive learning experiences that serve to bolster 
self-esteem and self-efficacy for achieving personal goals.  The findings of 
the present study are in agreement with these previous findings in that there 
was a reduction in negative symptoms following CRT and an improvement in 
cognition and as far as I am aware this study is one of the first to use X-cog® 
where this relationship has been identified.       
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6.3 Cognitive deficits assessed by CANTAB® 
 
Performance on all of the subtests from the CANTAB® showed that first 
episode psychosis and chronic schizophrenia patients have significant 
cognitive deficits when compared to healthy controls.  Both sets of patients 
appeared to have similar deficits thus supporting the theory of cognitive 
deficits remaining stable over the course of the illness.  The group of first 
episode patients who participated in the cognitive remediation study showed 
improvements in cognitive function following the course of therapy when 
reassessed by CANTAB®.   
Deficits in both outcome measures of the Pattern Recognition Memory (PRM) 
test (number correct and mean correct latency) in the present study showed 
that patients have deficits in visual memory.  Difficulty in remembering visual 
information for short periods of time and a reduced ability to discriminate 
between familiar and unfamiliar stimuli have been shown to be problematic for 
patients when involved in social, educational or employment situations.  Kim 
et al., (2008) in their study on the effects of organisational strategy on visual 
memory in patients with schizophrenia reported that patients appear to have 
a visual memory deficit which could be related to their organisational deficits 
and poor planning ability.  They also found that patients appeared to have 
deficits in the retention and retrieval of information.  Chen et al., (2009) in 
their research of visual and cognitive processing of face/non-face information 
in schizophrenia reported that the patients ability to detect faces and non-face 
objects was deficient.  Their ability to discriminate individual identities based 
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on similar face/non-face images was deficient.  Their ability to discriminate a 
current face/non-face image from those seen recently (3 seconds earlier) was 
also impaired.   The findings in the present study are in agreement with these 
previous studies as significant deficits were observed in short-term visual 
memory in patients with first episode psychosis and schizophrenia.   
Results in the present study from the PRM test also showed that patients take 
longer to correctly respond to a given problem, thus having longer periods of 
thinking time, planning and hesitation.  Krieger and Gallhofer (2001) in their 
study of cognitive sub-processes and schizophrenia reported that in first-
onset patients, if stimulus discrimination is required, latency of movements 
but not time necessary to execute these movements is lengthened. However, 
if patients had to choose between response alternatives, then only the speed 
of movements, but not their latency, is influenced.  They concluded that 
healthy controls are better able to decide which target to touch after the 
initiation of movements and that doing so requires high confidence in the 
correctness of perception.  The findings in the present research are in 
agreement with these findings as patients had significant delays in their mean 
correct latency times.   
Similar to the PRM test, significant deficits were identified in patients in both 
outcome measures of the Spatial Recognition Memory (SRM) test.  Patients 
showed reduced ability in being able to remember the location of visual 
stimuli and displayed a deficit in mean correct latency.  This suggests that 
these deficits are not exclusive to one domain and that there appears to be 
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some cross over with other cognitive functions.  Piskulic et al., (2007) in their 
meta-analysis of 33 studies (conducted between1992-2005) investigating 
behavioural studies of spatial memory dysfunction in schizophrenia, reported 
that patients with schizophrenia are consistently more impaired on the spatial 
memory measures than healthy controls.  These impairments may be related 
to social disability and explain some cognitive deficits that characterise the 
clinical presentation of schizophrenia.  The findings from this meta-analysis 
are in agreement with the current research.   
Stip et al., (2008) in their meta-analysis of 49 studies (conducted between 
1987-2006) investigating computerised assessment of visuo-spatial cognition 
in schizophrenia using CANTAB® reported that, patients with schizophrenia 
differed in maintenance and retrieval of simple spatial information.  This 
finding is in agreement with that of Lee and Park (2005) who in their meta-
analysis of working memory reported that patients with schizophrenia display 
working memory deficits independent of the specific modality of the task 
(spatial or verbal).   
According to the results of Stip et al., (2008) recognition of visual stimuli is 
impaired in patients with schizophrenia.  This deficit is non-verbal stimuli 
could be of interest because it appeared to be more impaired than recognition 
of verbal stimuli which goes against other research which has shown that 
verbal recognition is equally as impaired in schizophrenia (Aleman et al 1999; 
Heinrichs and Zakzanis 1998).  The findings from the present study are in 
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agreement with the literature that has been reviewed above in relation to 
deficits in spatial memory.  
Results from the present research showed how patients have significant 
deficits in their executive function compared to healthy controls.  Patients 
displayed deficits on all outcome measures (total stages completed, total 
errors, pre extra dimensional shift errors and post extra dimensional shift 
errors) of the Intra/extra dimensional shift (IED) test from CANTAB®.  These 
deficits were also found to be correlated with negative symptomatology in 
patients.  Furthermore, results from the cognitive remediation study showed 
that improvements in cognitive function (in particular the domain of executive 
function) are directly related to changes in negative symptomatology.  
Interestingly the domain of executive function appeared to be one of the most 
significantly affected domains in patients and subsequently it was also the 
domain which was most significantly improved after completion of the 
cognitive remediation therapy.   
Freedman and Brown (2011) in their review of the developmental course of 
executive functioning in schizophrenia reported that, a better understanding 
of the neuro-cognition trajectories of executive functioning is required.  This is 
to help identify the risk and modifying factors that influence the onset and 
severity of the disease and to re-direct the course and improve outcomes.  
They concluded that assessment of the diverse and integrated nature of 
these abilities and changes in these abilities over time is required.   
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Bozikas and Andreou (2011) in their systematic review of 26 longitudinal 
studies of cognition in first episode psychosis reported that significant deficits 
in executive function have been reported in all studies examined.  However, 
more detailed research is required regarding the time course of decline in 
specific executive functions.  This is especially important since some of these 
functions have been proposed as endophenotypes for use in genetic studies 
in schizophrenia.  They also reported that improvements in psychopathology 
appear to positively influence the course of cognitive deficits, hence sufficient 
and comprehensive treatment of these symptoms is of utmost importance.    
The findings in the present study are in agreement with these previous 
findings, that deficits in executive function have a direct effect on 
symptomatology.  
Since deficits in executive function have been shown to be critical in 
functional outcome in patients with schizophrenia, remediation of these 
deficits has become vitally important.  Findings in the present study have 
shown how cognitive remediation can lead to improvements not only in 
executive function but also in negative symptomatology in patients.  Stratta 
and Rossi (2004) in their review of the research examining remediation of 
executive function reported that patients with schizophrenia have some 
degree of cognitive deficit that often precedes the clinical onset of the illness, 
persisting even when the positive symptoms have been resolved.  They 
concluded that neuro-cognitive deficits in executive function can be modified 
by psychological remediation with the effects not exclusively confined to the 
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cognitive domain but also social and working abilities, symptomatology and 
self esteem.  These findings are in agreement with the results reported in the 
present research.   
Deficits in planning were identified in all patients in the present research.  
These deficits were evident on the Stockings of Cambridge (SOC) test of the 
CANTAB®.  Patients performed significantly worse than controls on two of the 
outcome measures; mean moves (5 move problems) and problems solved in 
minimum moves.  No significant differences were found in the mean initial 
thinking time (planning measure) and mean subsequent thinking time 
(execution measure) outcome measures between patients and controls.   
These findings suggest that, although there were differences in the problem 
solving measures of the task, there were no differences in speed of 
processing.   
Greenwood et al (2011) compared the planning performance of patients with 
schizophrenia on the Tower of London task versus real life analogue 
performance in the form of a board-game style diary planning task.  They 
reported that the patient group demonstrated inefficient planning across both 
tasks but did not display any difference in initial and subsequent planning 
times.     
Grootens et al (2009) reported in their study of psychomotor planning in 
recent onset schizophrenia that patients were significantly slower than 
healthy controls in the initiation of motor actions however the same slowing 
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was absent in the execution phase.  They concluded that the cognitive 
processes that support motor control such as goal selection, planning, 
sequencing and response inhibition are already deficient in patients with 
recent onset schizophrenia.  The findings in the present study support these 
findings in that patients have shown similar deficits in the domains of planning 
and problem solving.   
Significant deficits in attention were found in patients when compared to 
healthy controls on the Choice Reaction Time (CRT) test from CANTAB®.  
Statistically significant differences between the two groups were observed in 
both of the outcome measures assessed; total trials correct and mean correct 
latency.  Deficits observed in the attention domain suggest that patients have 
problems in sustaining their attention over long periods of time compared to 
healthy controls.  This lack of attention could potentially be caused by a 
number of different factors.  Previous research has shown how attentional 
deficits are a core feature of cognitive symptoms in schizophrenia and are 
usually apparent before the onset of the illness (Cornblatt and Keilp, 1994).   
The present research also showed how patients had slower reaction times in 
comparison to healthy controls.  The amount of time it took the patients to 
press the correct key after seeing the visual stimuli was significantly longer 
than in healthy controls.  One possible explanation for this difference may be 
that the antipsychotic medication side effects slow patient’s reaction times 
down (Filbey et al., 2008).   
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Research by de Jong et al., (2010) in patients with psychosis and 
schizophrenia suggested that patients compared to healthy controls have 
modality-specific attention deficits when attempting to integrate information. 
Yun et al., (2011) in their research demonstrated how patients with psychosis 
displayed longer reaction times on the Choice Reaction Time test from 
CANTAB® compared to healthy controls.  The findings in the present study 
are in agreement with the previous research mentioned in relation to deficits 
in attention.   
 
6.4 Strengths and limitations of this work 
 
6.4.1 Strengths  
 
The patient group in the first episode study (chapter 3) included a significant 
sample of patients and controls from the South Asian community.  To my 
knowledge this is the first study to include a large number of participants from 
this ethnic group.  The control groups in the first episode study and chronic 
schizophrenia study (chapter 4) were matched for intelligence and all other 
demographics to the patient groups thus eliminating any confounding factors.  
All participants were assessed under identical conditions and were recruited 
from the same geographical location.   
The use of CANTAB® as a neuropsychological assessment battery allowed 
for results to be recorded accurately.  There was no rater subjectivity or bias 
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involved.  The subtests of the CANTAB® were all language independent.  The 
format of the subtests (computer-game like) decreased the chances of 
boredom and kept participants engaged.  Recruitment of patients at first 
episode and the comparison with chronic schizophrenia patients showed how 
cognitive deficits remain relatively stable over the course of the illness 
regardless of length of illness and medication status.  For the cognitive 
remediation study, the use of a longitudinal, repeated measures methodology 
allowed each participant to act as their own control; in this way individual 
change in outcomes were revealed across time.   
 
6.4.2 Limitations   
 
Limitations of the current study were that there were only a modest number of 
patients recruited due to patient availability and resources available to the 
recruitment team.  For future investigations it will be important to have a 
larger sample size with a more balanced male to female ratio.  We were 
unable to gain reliable information about duration of untreated psychosis or 
parental socio-economic status and educational achievement for patients and 
controls.   Patients were on a variety of anti-psychotic medications for 
different periods of times.    
There were several limitations of the cognitive remediation study; the number 
of the patients in the study was very small, the patient and control groups 
were self selecting, subjects were not randomly assigned to either of the 
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groups, there was no alternative intervention for the control group and the 
researcher was not able to provide cognitive remediation on an individual 
basis and had to opt for a group setting instead.   
 
6.5 Future study  
 
For future investigations the inclusion of a group of long term schizophrenia 
patients in the first episode study from the same ethnic background would 
allow for further comparisons to be made in regards to severity of cognitive 
decline and its association with longitudinal outcomes.  It may also be of 
interest to recruit unaffected siblings of first episode psychosis and 
schizophrenia patients to assess their neuropsychological function and to 
investigate for any prodromal signs in individuals at genetic risk for 
psychosis/schizophrenia.  The use of other neuropsychological tests both 
from the CANTAB® and the MCCB would be useful.  It would also be of 
interest to recruit a sample of patients who are medication naive, to assess 
the level of their cognitive deficits pre-treatment.   
For the cognitive remediation study there are several improvements that 
could be made for future studies.  It would be ideal to have a longer more 
intensive intervention for patients and controls.  To provide the control group 
with an alternative therapy, thus not neglecting them of any benefit of having 
regular contact with either a group or therapist.  For future studies, it would be 
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ideal to include an alternative intervention group along with the cognitive 
remediation group and treatment as usual group.  Along with reassessing 
patients six months post cognitive remediation to see if the changes remain 
constant over time and if the improvement made a real change to patients 
lives.   It may also be of interest to provide cognitive remediation to the 
chronic schizophrenia patients to investigate if similar improvements can be 
found in their cognition post therapy.   
 
6.6 Conclusions 
 
The aims of the studies in this thesis were; to assess cognitive function in first 
episode psychosis patients and to investigate the effects of ethnicity, to 
investigate the cognitive function of chronic schizophrenia patients and to 
investigate the effects of cognitive remediation therapy on cognitive function 
in first episode psychosis patients.  The aims were achieved and the 
knowledge gained will add to published data and will also inform the design of 
future studies.  Future studies will provide a more comprehensive picture of 
how cognitive deficits can be remediated and how these improvements can 
be consolidated in patients with psychosis/schizophrenia through the use of 
pharmacotherapy combined with cognitive remediation.  
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Chairman:  Professor Alan C Roberts 
  OBE TD DL MPhil PhD DSc DTech LLD FLS FlBiol  
Administrator:  Susan Jude 
 
Tel: 01274 365508   Email: susan.jude@bradfordhospitals.nhs.uk 
Fax: 01274 365509   Email: alan.roberts@bradfordhositals.nhs.uk 
 
29 June 2009 
 
Mr Majid M Saleem 
PhD Research student  
University of Bradford  
School of Pharmacy  
Richmond Road  
Bradford  
BD7 1DP 
 
Dear Mr Saleem 
 
Study Title: Investigation into the cognitive deficits experienced by 
patients in first episode psychosis and schizophrenia.     
REC reference number: 09/H1302/61 
Protocol number: 1 
 
Thank you for your letter of 24 June 2009, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chairman.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below). 
Bradford Research Ethics Committee 
Top Floor 
Extension Block 
St Lukes Hospital 
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Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
For NHS research sites only, management permission for research (“R&D approval”) should be 
obtained from the relevant care organisation(s) in accordance with NHS research governance 
arrangements.  Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.  Where the only involvement of the 
NHS organisation is as a Participant Identification Centre, management permission for research is not 
required but the R&D office should be notified of the study. Guidance should be sought from the R&D 
office where necessary. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date      
Response to Request for Further Information    24 June 2009    
Participant Consent Form: Control Group  1  24 June 2009    
Participant Information Sheet: Control Group  1  24 June 2009    
Participant Consent Form  2  24 June 2009    
Participant Information Sheet  2  24 June 2009    
Application  1  29 May 2009    
Peer Review         
Protocol  1  29 May 2009    
Supervisors CV  2  29 May 2009    
Compensation Arrangements    21 July 2008    
Investigator CV  2  29 May 2009    
 
Statement of compliance 
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The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
? Notifying substantial amendments 
? Adding new sites and investigators 
? Progress and safety reports 
? Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
 
09/H1302/61 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Professor A Roberts 
Chairman – Bradford Research Ethics Committee 
 
 
Enclosures: “After ethical review – guidance for researchers”   
 
Copy to: Professor Jo Neill 
Professor of Psychopharmacology 
University of Bradford 
School of Pharmacy 
Bradford 
BD7  1DP 
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? You must comply with the guidelines laid out in the Research Governance 
Framework for Health and Social Care1(RGF).  Failure to do this could lead 
to permission to carry out this research being withdrawn. 
? You must comply with any other relevant guidelines including the Data 
Protection Act, The Health and Safety Act and local Trust Policies and 
Guidelines. 
? If you encounter any problems during your research you must inform your 
Sponsor and us immediately to seek appropriate advice or assistance. 
? Research projects will be added to any formal Department of Health 
research register. 
Please note that suspected misconduct or fraud should be reported, in the first 
instance, to local Counter Fraud Specialists for your Trust.  Consortium R&D staff 
are also mandated to do this in line with requirements of the RGF. 
 
Adverse incidents relating to the research procedures and/or SUSARs (suspected 
unexpected serious adverse reactions) should be reported using Trust incident 
reporting procedures in the first instance and to the chief investigator2.   
They should also be reported to: 
? The Consortium R&D Department 
? the Research Ethics Committee that gave approval for the study 
? other related regulatory bodies as appropriate. 
 
You are required to ensure that all information regarding patients or staff remains 
secure and strictly confidential at all times. You must ensure that you understand 
and comply with the requirements of the NHS Confidentiality Code of Practice 
(http://www.dh.gov.uk/assetRoot/04/06/92/54/04069254.pdf ) and the Data Protection 
Act 1998. Furthermore you should be aware that under the Act, unauthorised 
disclosure of information is an offence and such disclosures may lead to prosecution. 
 
 
Changes to the agreed protocol MUST be approved by both the Trust/s and 
Research ethics Committee granting initial approval, before any changes in 
protocol can be implemented.  Copies of revised documents must be provided 
to the R&D Office.  Advice on how to undertake this process can be obtained 
from R&D. 
 
 
Projects sponsored by organisations other than the Consortium Trusts are reminded 
of those organisations obligations as defined in the Research Governance 
Framework, and the requirements to inform all organisations of any non-compliance 
with that framework or other relevant regulations discovered during the course of the 
research project. 
                                                          
1 Details from: 
http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/Publica
tionsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4108962&chk=Wde1Tv  
2 SUSARS – this must be within 24 hours of the discovery of the SUSAR incident 
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Once you have finished your research you will be required to complete a Project 
Outcome form. This will be sent to you nearer the end date of your project 
(Please inform us if the expected end date of your project changes for any 
reason).  
We will require a copy of your final report/peer reviewed papers or any other 
publications relating to this research. Finally we may also request that you 
provide us with written information relating to your work for dissemination to a 
variety of audiences including service users and carers, members of staff and 
members of the general public. You must provide this information on request. 
 
If you have any queries during your research please contact us at any time.  May 
I take this opportunity to wish you well with the project. 
 
Yours sincerely 
John Hiley 
Research Governance & Programme Manager 
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Hi Jo and Majid 
  
Ethics Application E48 
Title “Investigation into the Cognitive Deficits experienced by patients in first 
episode psychosis and schizophrenia” 
  
Thank you for sending me a copy of the ethics approval letter from the Bradford 
Research Ethics Committee which I have forwarded to the Chair of the BNP Research 
Ethics Panel.   
  
I can now confirm that Dr Martin Brinkworth, Chair of the Biomedical, Natural and 
Physical Sciences Research Ethics Panel at the University has given  Chair’s approval 
for the research study to go ahead.   
  
Regards 
Lynda 
  
__________________________________ 
Lynda Nuttall 
Ethics Administrator 
Research and Knowledge Transfer Support 
University of Bradford 
Tel: 3170 
l.d.nuttall@bradford.ac.uk 
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Investigation into cognitive (memory) function 
in first episode psychosis 
  
This is a study being carried out by a research group at the University of Bradford 
working with the Bradford and Airedale Early Intervention Service and Bradford 
District Care Trust.   
Before you decide whether you want to be part of our investigation we would 
like to explain exactly why the study is being undertaken and what being a 
volunteer would involve. 
 
BEING INVOLVED IN THIS STUDY WILL NOT HARM YOU IN ANY WAY 
 
Please take time to read the following information carefully. If there is anything 
that is not clear or if you would like more information please contact us either 
through the details given below or through your health care professionals.  
 
Aims of the study 
The term "cognition" is used to describe processes carried out in the brain such 
as memory, planning and problem-solving. In this study we will look at these 
aspects of memory using a computer based programme. You do not need 
computer experience to be involved. If you decide to volunteer we will need to 
meet you three times over the next six months. 
 
Your participation is completely voluntary; it is up to you to decide whether or 
not to take part.  If you do decide to help us you will be given this information 
sheet to keep and you will be asked to sign a consent form. You are free to 
withdraw at any time from the study without giving a reason and this will not 
affect the standard of care you receive. 
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What you will be asked to do if you take part? 
We will arrange three meetings with you at your convenience.  These will take 
place at one of the following locations: University of Bradford; Horton Park 
Centre; other NHS premises; home visit. 
The meeting location will be decided by you. Transport costs to and from the first 
three locations will be provided. 
 
1st Meeting: 
At this meeting you will be told all about the study and can ask any questions you 
may have. You will be given a consent form to take away and decide whether 
you want to take part in the study. We will make arrangements to contact you to 
see if you wish to take part in the study.  
 
2nd and 3rd Meetings 
At one of the meetings we will ask you if you would be willing to give a small 
sample of saliva, we would like this so that we can look at the genes that might 
be related to memory. No names will be attached to any samples and complete 
anonymity will be assured (any unused saliva will be stored and may be used in future 
research related to this study only).                                               
At both meetings: 
The researcher will ask you a number of questions about your mood and feelings 
in general.  This will be in the form of a discussion and will last around 45 
minutes.   
We will ask to weigh you and measure your height.   If you would prefer not to 
give these measurements you are free to refuse.  Again, all information will be 
confidential.  
 
You will be asked to do a non-invasive computer-based task that lasts about 45 
minutes.  There are no words or numbers only patterns.  All you need to do is 
touch the computer screen to move objects, no computer skills are needed to 
complete any of the tasks. 
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EVERYTHING WILL BE EXPLAINED TO YOU AS YOU GO THROUGH THE MEETINGS, FEEL 
FREE TO ASK ANY QUESTIONS AT ANY TIME. BOTH MEETINGS WILL LAST 
APPROXIMATELY 2 HOURS. 
 
You will not be required to change any of your personal habits, medication, 
diet or lifestyle choices. You will not be put at any risk as a result of the 
research.   
 
If you do have any complaints about the research you are free to discuss these 
with the researcher or a member of NHS staff.  All complaints will be treated very 
seriously and rectified accordingly. 
  
The tests selected are designed to be interesting rather than off-putting.  It is 
hoped your time in the study will be rewarding and enjoyable to you. 
Participation will allow you to experience a number of different tasks and to find 
out which type of task you prefer, e.g. you may like planning tasks more than 
memory tasks; information which may be useful when making life choices.  
 
You will also have the satisfaction of being part of some important research, the 
results of which will be useful to health care professionals and patients.  After 
the study is completed we will be happy to send you a summary of the results. 
 
Confidentiality 
All results and discussions will be treated with total confidentiality.  Your name 
and contact details will not be stored with the results.   Any information 
collected during the meetings will NOT contain your name or address so that you 
cannot be recognised from it.   
 
Funding and ethics  
The study is being funded by the University of Bradford.  Transport costs to and 
from the meeting locations will be provided. The person carrying out the study is 
a postgraduate student called Majid Saleem who is working under the 
supervision of experienced researchers and healthcare professionals. Both the 
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University of Bradford and the NHS ethics committee have reviewed and 
approved this study. 
 
Contact information 
Please contact Majid Saleem at The University of Bradford. Email: 
m.m.saleem@bradford.ac.uk  
Alternatively, contact Prof. Jo Neill at the University of Bradford. Email: 
j.c.neill@bradford.ac.uk  
 
If you decide to take part in the study you will be given a copy of this information 
sheet and your consent form. 
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Investigation into cognitive (memory) 
function in first episode psychosis 
 
This is a study being carried out by a research group at the University of Bradford 
working with the Bradford and Airedale Early Intervention Service and Bradford District 
Care Trust.   
Before you decide whether you want to be part of our investigation we would like to 
explain exactly why the study is being undertaken and what being a volunteer would 
involve. 
 
BEING INVOLVED IN THIS STUDY WILL NOT HARM YOU IN ANY WAY 
 
Please take time to read the following information carefully. If there is anything that is 
not clear or if you would like more information please contact us either through the 
details given below.  
 
Aims of the study 
The term "cognition" is used to describe processes carried out in the brain such as 
memory, planning and problem-solving. In this study we will look at these aspects of 
memory using a computer based programme. You do not need computer experience to 
be involved. If you decide to volunteer we will need to meet you three times over the 
next six months. 
 
Your participation is completely voluntary; it is up to you to decide whether or not to 
take part.  If you do decide to help us you will be given this information sheet to keep 
and you will be asked to sign a consent form. You are free to withdraw at any time 
from the study without giving a reason. 
 
What you will be asked to do if you take part? 
We will arrange three meetings with you at your convenience.  These will take place at 
one of the following locations: University of Bradford or home visit. 
The meeting location will be decided by you. 
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1st Meeting: 
At this meeting you will be told all about the study and can ask any questions you may 
have. You will be given a consent form to take away and decide whether you want to 
take part in the study. We will make arrangements to contact you to see if you wish to 
take part in the study.  
 
2nd and 3rd Meetings 
At one of the meetings we will ask you if you would be willing to give a small sample of 
saliva, we would like this so that we can look at the genes that might be related to 
memory. No names will be attached to any samples and complete anonymity will be 
assured (any unused saliva will be stored and may be used in future research related to 
this study).                                               
At both meetings:   
we will ask to weigh you and measure your height.   If you would prefer not to give 
these measurements you are free to refuse.  Again, all information will be confidential.  
you will be asked to do a non-invasive computer-based task that lasts about 45 minutes.  
There are no words or numbers only patterns.  All you need to do is touch the 
computer screen to move objects, no computer skills are needed to complete any of 
the tasks. 
 
EVERYTHING WILL BE EXPLAINED TO YOU AS YOU GO THROUGH THE MEETINGS, FEEL 
FREE TO ASK ANY QUESTIONS AT ANY TIME. BOTH MEETINGS WILL LAST 
APPROXIMATELY 1 HOUR. 
 
You will not be required to change any of your personal habits, medication, diet or 
lifestyle choices. You will not be put at any risk as a result of the research.   
 
If you do have any complaints about the research you are free to discuss these with the 
researcher.  All complaints will be treated very seriously and rectified accordingly. 
 
The tests selected are designed to be interesting rather than off-putting.  It is hoped 
your time in the study will be rewarding and enjoyable to you. Participation will allow 
you to experience a number of different tasks and to find out which type of task you 
prefer, e.g. you may like planning tasks more than memory tasks; information which 
may be useful when making life choices.  
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You will also have the satisfaction of being part of some important research, the results 
of which will be useful to health care professionals and patients.  After the study is 
completed we will be happy to send you a summary of the results. 
 
Confidentiality 
All results and discussions will be treated with total confidentiality.  Your name and 
contact details will not be stored with the results.   Any information collected during 
the meetings will NOT contain your name or address so that you cannot be recognised 
from it.   
 
Funding and ethics  
The study is being funded by the University of Bradford.  The person carrying out the 
study is a postgraduate student called Majid Saleem who is working under the 
supervision of experienced researchers and healthcare professionals. Both the 
University of Bradford and the NHS ethics committee have reviewed and approved this 
study. 
 
Contact information 
Please contact Majid Saleem at The University of Bradford. Email: 
m.m.saleem@bradford.ac.uk  
Alternatively, contact Prof. Jo Neill at the University of Bradford. Email: 
j.c.neill@bradford.ac.uk  
 
If you decide to take part in the study you will be given a copy of this information sheet 
and your consent form. 
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Wechsler Test of Adult Reading 
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Appendix X 
Positive and Negative Syndrome Scale  
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Xcog Information Sheets  
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Magic Carpet 
 
Task description 
The box at the bottom of the screen has one missing shape.  Use BOB to pick up the 
shape you think  
is correct from the choices at the top.  Use the mouse to drop it into the empty space.   
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Bridgework 
Task description  
BOB has to get over the river to pick a flower.  Place the shapes together to make a 
bridge, making  
sure the edges are the same colour.   
2 or 3 shapes can be seen on the left of the screen.    
Select the shape you want by moving the mouse to its centre and clicking the left mouse 
button.  
 When selected the centre of the shape turns red.  If the shape has a yellow square in its 
centre, it  
can be turned to change the colour at the top.  Right click the mouse until you get the 
colour you  
want.   
To move your chosen shape to make the bridge, left click on the shape you want it to 
connect to 
 making sure the colours are the same.   
To remove the last shape connected select it by clicking the left button and then remove 
it by a right  
button click.  
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Rainmaker  
 
Task description  
Yellow comets fly from left to right at the top of the screen.  They have 1,2 or 3 spots in 
different  
colours.   
To water the flowers target only the comets with 2 spots (of the right colour).  Burst 2 
spot comets by pressing the space  
bar (on keyboard) which makes the fork move upwards.   
If a 2 spot comet is burst, a downpour of rain reaches the flowers, which causes the 
flowers to grow. 
  If you burst 1 or 3 spot comets, a layer of thick dust will shrink the flowers.  If you don’t 
burst  
enough 2 spot comets, this will also shrink the flowers.   
The fork stays in the air as long as the space bar is held down.  So remember to let go of 
it in time 
 otherwise the next comet may fly into the raised fork.   
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Parcel Service  
 
Task description  
BOB waits in the middle circle to collect parcels.  Small yellow parcels travel along tubes 
from 4  
directions towards BOB.  Use the cursor keys to move the black hole so BOB can get the 
parcels.   
Parcels colliding with a closed gap are destroyed.    
When you move up a level sometimes pipes can become damaged, stopping parcels 
from reaching 
 the middle.  Damaged pipes can be replaced by repair packs (blue parcels).  First the 
type of tubing  
matching the blocked pipe has to be selected (on the right of the screen) by pressing the 
space bar.   
Then the blue repair package has to be put into the damaged pipe.  This is done by 
pressing the  
arrow up and shift key together.  Yellow parcels must not be destroyed during the repair 
process.   
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Yolk Hunt  
 
Task description  
Hens of different colours move around the screen.  Some of these hens crouch behind a 
bush to lay  
an egg.  Your job is to remember the position and colour of these eggs (same as the hens 
colour).   
The eggs behind these bushes then need to be collected by BOB.  Choose the egg colour 
you want by  
clicking on an egg at the bottom of the screen.  The egg will then be marked with a red 
frame.  Click  
on the bush behind which you think there is an egg of the selected colour.  If your choice 
is correct 
 BOB carries the egg away.  If there is no egg there, or the colour does not match try 
another bush or  
another colour.   
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9th February 2011. 
 
Dear Client Name,  
 
Thank you for taking part in the CANTAB® assessment with me.  Following on from this 
memory task we are setting up a group to look at how we can support people in 
improving their memory & attention.  This would be a short computer-based course 
where we would use computer games to help you develop skills around problem-solving, 
memory & attention.   
 
The group will be taking place at The University of Bradford, in March 2011.  It will run 
for about 8 weeks on a Wednesday afternoon from 2pm.  There will be time for the 
computer games and a break with tea, coffee & biscuits.  I hope the group will be fun as 
well as helpful to you.  At the end of the group you will be given a certificate of 
attendance from The University of Bradford.   
 
I will be running the group with Alexandra Gill from the EI team.  Myself or Alexandra 
will be giving you a phone call to let you know more about it and discuss whether you’d 
be interested in attending the course.  Please let me or your key worker know before 
then if you do not wish to be contacted.   
 
I’d like to take this chance to thank you for taking part in my research so far, and hope 
you will take up the opportunity to join our group. 
 
Yours Sincerely,  
 
Majid Saleem 
PhD Researcher 
University of Bradford 
Cc [name], Care Coordinator. 
 
 
